

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/73444 A2

(51) International Patent Classification: **G01N 33/68**,
C07K 14/00, G06F 19/00

Colin [GB/US]; The Burnham Institute, 10901 North
Torrey Pines Road, La Jolla, CA 92037 (US).

(21) International Application Number: PCT/GB01/01358

(74) Agents: **WALTON, Sean, M.** et al.; Mewburn Ellis, York
House, 23 Kingsway, London, Greater London WC2B 6HP
(GB).

(22) International Filing Date: 27 March 2001 (27.03.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/192,180

28 March 2000 (28.03.2000)

US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): **CAM-
BRIDGE UNIVERSITY TECHNICAL SERVICES
LIMITED** [GB/GB]; The Old Schools, Cambridge,
Cambridgeshire CB2 1TS (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FARNDALE,**
Richard, William [GB/GB]; 21 Hawthorne Road, Sta-
pleford, Cambridge, Cambridgeshire CB2 5DU (GB). **EMSLEY,**
Jonas [GB/GB]; Flat 1, 169A London Road,
Leicester, Leicestershire LE2 1EG (GB). **KNIGHT, Clive,**
Graham [GB/GB]; 238 Queen Edith's Way, Cambridge,
Cambridgeshire CB1 8NL (GB). **BARNES, Michael,**
John [GB/GB]; 229 Chesterton Road, Cambridge, Cam-
bridgeshire CB4 1AN (GB). **LIDDINGTON, Robert,**

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 01/73444 A2

AA

(54) Title: RECEPTOR/PEPTIDE CRYSTAL STRUCTURE FOR IDENTIFICATION OF INHIBITORS

(57) Abstract: The crystal structure of a collagen peptide in complex with integrin $\alpha 2$ I-domain is provided. Coordinates for the crystal structure are useful in designing novel molecules that can be tested for binding to the receptor and other I-domains and preferably ability to inhibit I-domain binding to ligand, and I-domain function. Regions of I-domains that undergo conformation change upon ligand binding are also identified and provided as targets for binding molecules such as antibodies. Molecules that inhibit the function of polypeptides comprising I-domains are of therapeutic potential in a number of diseases and disorders.

RECEPTOR/PEPTIDE CRYSTAL STRUCTURE
FOR IDENTIFICATION OF INHIBITORS

Technical Field

5

The present invention relates to use of coordinates of peptide/receptor crystal structure in designing and obtaining molecules that inhibit protein I-domain interactions and function, especially collagen/receptor interaction, and are of therapeutic potential. The present invention relates to
10 modulating platelet aggregation, adhesion and activation, as well as the adhesion, migration and phenotypic expression of many other cells, and inhibitors of collagen interaction with collagen receptors.

15

Background Art

Collagens and collagen-related peptides

The collagens provide the vertebrate organism with tensile
20 strength; they are the major protein component of skin, bone, cartilage and other connective tissue. Collagens, for example Type IV, provide a network of protein known as the basal lamina to which cells can attach and over which cells can migrate. Such structures are found beneath endothelial and
25 epithelial cell layers in many locations. Deeper into tissues such as the epidermis or the intimal layer of the blood vessels, fibrous collagens such as Types I and III are found [2]. The structure and precise amino acid composition of the collagens varies with type. Each type is the product of a
30 distinct gene or genes. What characterises a protein as a collagen is that it contains, substantially or in some part, a triple-helical structure in which three polypeptide chains, each helical in its own right, are wound around one another to

form a superhelix. A specific amino acid sequence, Gly-Pro-Hyp, (GPO in single-letter nomenclature) when repeated sufficiently can support triple-helical conformation. A related sequence, GPP, also adopts a triple-helical
5 conformation.

The properties of these sequences which support triple-helical structure are:

- (i) the tight bends associated with the strained ring
10 structure of the iminoacids proline and hydroxyproline,
- (ii) the presence of glycine at every third residue whose side chain, simply a hydrogen atom, positioned in the interior of the cylinder defined by the triple helix, is so small as to present no obstacle to the protein chains associating in this
15 conformation, and
- (iii) the capacity of the hydroxyproline residues in particular to support intra- or inter-chain hydrogen bonding, thus stabilising the helix.

20 In long peptides, where such effects may be additive over many triplets of amino acids, substantial deviation from the GPO prototypic sequence still allows triple-helical structure. Thus, in Type I collagen, where the explicit triplet GPO comprises only around 10% of the primary sequence of the
25 molecule, which is over three hundred triplets in length, the structure exhibits a melting temperature, i.e. the temperature at which the helix will unwind, in excess of 40°C, significantly higher than physiological temperatures. In nature, the helix and its higher order assembly, the collagen
30 fibril, is further stabilised by cross-linking.

Synthetic peptides are known where, utilising a sequence of repeating GPP triplets or repeating GPO triplets,

significantly higher melting temperatures can be achieved. For example, peptides comprising [GPO]₁₀ melt at about 60°C [3], but [GPO]₅ melts at below 20°C [4-6].

5 Such synthetic peptides have found increasing application in biomedical research, since they may have biological activity. For example, in cross-linked form the sequence [GPO]₁₀ will bind to a specific platelet receptor population, known as glycoprotein VI, on human platelets and activate them, most
10 likely by stabilising these receptors in close proximity, allowing proteins associated with their intracellular domains to interact [7-10]. Clustering of receptors in this way may be one mechanism by which signals, such as a change in phosphorylation state of intracellular proteins, may propagate
15 within the platelet [10, 11]. This mechanism is thought to be a key activatory step in haemostatic events leading to platelet aggregation, and in pathological events including thrombosis [12-14]. Thus the peptide containing the GPO motif, known as collagen-related peptide or CRP, provides a
20 receptor-specific peptide useful in the study of platelet activation [8].

Peptide motifs which support triple helical structure, i.e. GPO or GPP, can be used as flanking sequences which confer
25 triple-helical structure upon other sequences from collagen, or indeed from other proteins, which would not otherwise adopt this conformation [15-18]. Such peptides allow the researcher to investigate the properties of small sequences from the primary structure of the collagen alpha chains, such as the
30 alpha 1 chain from type I collagen, or the alpha 2 chain from type I collagen or the alpha 1 chains of type III collagen, whilst retaining the triple-helical structure which is crucial for cell-reactivity. Such investigations have allowed other

specific receptor-binding sequences to be identified.

One such is the sequence GFOGER, which binds to a further class of receptors, the integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ [18].

5

The integrins

The integrins are expressed on the surface of cells, being widespread throughout the different tissues of the body, and their functions are manifold. Integrins are heterodimeric structures, comprising two subunits, designated α and β [19]. Certain combinations of the 20 or so known α subunits with the 10 or so known β subunits are allowed, whilst many are excluded and do not occur in nature. Thus, at present, about 30 different integrins are known in man. Their selectivity for particular ligands derives primarily from the combination of subunits, but may be dependent also upon the activation state of the integrin [20, 21].

Some integrins mediate direct cell-cell contact, as between leukocytes, or between the cells forming a cell layer or epithelium. Often, counter-receptors such as the cellular adhesion molecules (CAMs) may bind to such integrins [22]. This represents the model by which the $\beta 2$ integrins found upon the leukocyte surface mediate cell-cell contact. Commonly, integrins are found to bind to extracellular proteins of the plasma (such as fibrinogen) or of the matrix (such as collagen or fibronectin). Very often, the amino acid sequences supporting interaction with integrins include an acidic residue such as D or E. Thus the sequence RGD can bind to the fibrinogen receptor, $\alpha IIb\beta 3$, the vitronectin receptor $\alpha v\beta 3$, to the fibronectin receptor, $\alpha 5\beta 1$ and to certain other integrins [20]. Sequences elsewhere within the ligand may enhance and

provide further selectivity to this primary interaction.

Integrin α subunits can be described as having a modular structure, with seven consensus repeats in their extracellular domains [23]. Some of these, known as EF-hands, bind cations, Ca^{2+} , for example, (although other divalent cations such as Zn^{2+} , Co^{2+} or Mn^{2+} may serve the same purpose) which support the activity of the receptor. One property of the αIIb subunit of the fibrinogen receptor known to depend upon the presence of these divalent cations is the ability to associate with the $\beta 3$ subunit, essential for receptor function [24].

Integrin α subunits fall into two classes, those as described above and those which possess an additional protein module, the inserted domain or I-domain, which is sometimes known as the A-domain because it adopts the same fold and may share other properties with the A-domains of the protein, von Willebrand factor.

The collagen-binding integrins, $\alpha 1\beta 1$ and $\alpha 2\beta 1$ contain I-domains [25]. These I-domains are crucial for the capacity of the integrin to bind collagen, which resides in a characteristic structure at one end of the domain which binds a divalent cation. Several species of cation can occupy this site, for example Mg^{2+} or Co^{2+} or Mn^{2+} [26]. In physiology it is likely that Mg^{2+} may be the ion present in this specialised binding structure, known as the metal ion dependent adhesion site or MIDAS. Because of its crucial role in mediating collagen binding, the I-domain MIDAS is the subject of close scrutiny in the field.

Protein domains are defined as stretches of sequence which

fold independently into the native conformation of the peptide, i.e. when separated from other regions of the parent protein. The I-domain, in suitably pure form, expressed, for example as a recombinant protein, can re-fold [26] into a structure which has the same capacity to bind cations in its MIDAS and the same capacity to bind ligands as the parent integrin [27]. For this reason, the $\alpha 2$ I-domain provides a ready model for studying the interaction of collagen with $\alpha 2\beta 1$.

10

A key question has been how the binding of ligand to the I-domain may alter its structure, which various techniques have been applied to address. For example, suitable computer algorithms allow fold prediction to be made, based upon the known primary sequence and by analogy with other I-domains or A-domains, which may provide an important input to this process. Such algorithms might allow a proposed ligand-binding cleft to be visualised in 3-dimensions, and to be compared with the known shape of the ligand. Often, suitable algorithms provide an analysis of the charge density on the surface of both the ligand and the proposed binding cleft, to establish complementary sites which might provide the basis for their interaction.

15

20

25

30

Previous work has elucidated the structure of the $\alpha 2$ I-domain in its free, unligated form [26]. The key feature of I domains and vWf A-domains is that they contain a characteristic assembly of five parallel and one anti-parallel beta-strands which form the stable platform of the structure. This conformation, known as the dinucleotide-binding fold (or Rossman fold) is found in other proteins such as NAD hydrolase, guanine nucleotide-binding proteins and protein kinases. Common to all of these structures is that ligand

binding occurs at the C-terminal surface formed by these beta-strands, although this has not hitherto been formally demonstrated. So it is with the integrin I-domains. This structure is linked by a series of peptide loops, several of which elaborate α -helices and at least one anti-parallel beta strand which substantially enclose the beta-sheet as they return to the base of the beta-sheet structure.

Another crucial feature of I-domains is that they possess an amino acid motif regarded as diagnostic of I-domains, having the sequence D_xS_xS, where x may represent any amino acid. These three amino acids, D151, S153 and S155, are present in the N-terminal loop arising from the first beta strand of the α 2 I-domain. These, along with other oxygen-containing residues in nearby peptide loops, co-ordinate the metal ion and constitute the MIDAS.

In the case of α 2 I-domain, beta-strand 5 elaborates above it a single turn of α -helix, known as the C-helix. A C-helix is known to exist in the α 1 I-domain, and might be predicted in other, less well-characterised I-domains. This appears to obstruct the MIDAS in its un-ligated state. It seems very likely that similar structures may occur in other I-domains.

25 *Structure determination*

Structure prediction, based upon the primary sequence of a protein domain, although a useful adjunct to the research endeavour, needs to be confirmed by measurement. The procedures used for such purposes include nuclear magnetic resonance and X-ray crystallography. Each approach offers its own advantage: nuclear magnetic resonance allows the examination of proteins in aqueous media, and at temperatures

close to physiological. However, nuclear magnetic resonance requires that the proteins be synthesised during their expression from amino acids comprising atomic nuclei with unpaired spin, such as ^{15}N or ^{13}C , in their peptide or other
5 bonds. Protons within the structure may need to be replaced by deuterons which do not resonate. This may present a significant difficulty, especially given that quite high protein concentration, such as 1 millimolar, and volume, such as 1 millilitre, may be needed to allow the analysis to
10 proceed. Further, the magnetic resonance are critically-dependent upon the size of the target protein, so that structures larger than about 100 amino acids are difficult to obtain, because of limitations of the field strength and frequency of the instrument.

15 X-ray diffraction also suffers from practical constraints, the major drawback being that the protein under examination must crystallise under laboratory conditions to provide a crystal of sufficient size and homogeneity as to be useful for
20 subsequent analysis. Suitable instruments include quite widespread laboratory-scale X-ray diffraction units, useful in the initial examination of the crystal, or the much larger-scale synchrotron devices. The choice of instrument is governed by the size of the crystal available and the spatial
25 resolution required of the analysis.

In the crystallisation of two structures as a complex, further constraints emerge. Firstly, the complex must adopt an appropriate, presumably physiological, conformation.
30 Secondly, the association between the two species must be stable at solution temperatures. Thirdly, the dimensions of the complex must be such as to allow unit cells, i.e. the most fundamental level of organisation of the complex, to align in

an array which can form a crystal. Where the two species are of grossly different shapes or sizes, this may be a meaningful constraint. For example, the tropocollagen molecule, the triple helical structure comprising the intact α -chains of the collagen in question, may approximate to a rod about 300nm in length, whereas the I-domain of the integrin $\alpha 2\beta 1$ approximates to a sphere about 3nm diameter. It is unlikely that a complex formed from single copies of such disparate structures will crystallise, although complex formation might very well occur.

Disclosure of the Invention

The present invention is based on work in which a collagen peptide was produced as a trimer, and a crystal structure obtained for the complex formed by binding of the peptide to integrin $\alpha 2$ I-domain. Coordinates for the crystal structure are useful in designing novel molecules that can be tested for binding to the receptor and other I-domains, and preferably ability to inhibit I-domain binding to ligand (e.g. collagen) and function. Regions of I-domains that undergo conformational change upon ligand binding are also identified and provided as targets for binding molecules such as antibodies. Molecules that inhibit the function of polypeptides comprising I-domains are of therapeutic potential in a number of diseases and disorders. The coordinates of the crystal structure for use in aspects and embodiments of the present invention are shown in Table 1. Specific contacts of additional interest are shown in Table 2. Details of interaction between peptide and receptor are shown in the Figures, described below.

The coordinates of Table 1 provide a measure of atomic location in Angstroms. The coordinates are a relative set of

positions that define a shape in three dimensions. The skilled person would recognise that it is possible that an entirely different set of coordinates having a different origin and/or axes could define a similar or identical shape.

5 Furthermore, he would recognise that varying the relative atomic positions of the atoms of the structure so that the root mean square deviation of residue backbone atoms (i.e. the nitrogen-carbon-carbon backbone atoms of protein amino acid residues) is less than 1.5 Å (preferably less than 1.0 Å and
10 more preferably less than 0.5 Å) when superimposed on the coordinates provided in Table 1 for the residue backbone atoms, will generally result in a structure which is substantially the same as the structure of Table 1 in terms of both its structural characteristics and potency for structure-
15 based drug design. Likewise he would recognise that changing the number and/or positions of the water molecules of Table 1 will not generally affect the potency of the structure for structure-based drug design of I-domain inhibitors. Thus for the purposes described herein as being aspects of the present
20 invention, it is optionally within the scope of the invention if: the Table 1 coordinates are transposed to a different origin and/or axes; the relative atomic positions of the atoms of the structure are varied so that the root mean square deviation of residue backbone atoms is less than 1.5 Å
25 (preferably less than 1.0 Å and more preferably less than 0.5 Å) when superimposed on the coordinates provided in Table 1 for the residue backbone atoms; and/or the number and/or positions of water molecules is varied. Reference herein to the coordinates of Table 1 thus optionally includes the
30 coordinates in which one or more individual values of Table 1 are varied in this way.

Also, the skilled person would recognise that modifications in

the $\alpha 2$ I-domain crystal structure due to e.g. mutations, additions, substitutions, and/or deletions of amino acid residues could account for variations in the atomic coordinates of the complex. Therefore, atomic coordinate data of the $\alpha 2$ I-domain modified so that a ligand that bound to the $\alpha 2$ I-domain would also be expected to bind to the modified $\alpha 2$ I-domain are, for the purposes described herein as being aspects of the present invention, optionally also within the scope of the invention. Reference herein to the coordinates of Table 1 thus optionally includes the coordinates modified in this way.

Furthermore, the Table 2 coordinates being derived from Table 1, reference herein to the coordinates of Table 2 optionally includes the coordinates in which one or more individual values of Table 2 are changed as a result of the above-mentioned variation and/or modification of the coordinates of Table 1.

The crystal structure defined by the co-ordinates may be visualised and rendered by many molecular graphics programmes, suitable examples of which include MolView (T.J. Smith, Dept. Biology, Purdue University, In47907, USA), RasMol Molecular Graphics (Roger Sayle, Biomolecular Structures Group, Glaxo Wellcome Research & Development, Stevenage, Hertfordshire, UK), Swiss PDB Viewer (Glaxo Wellcome Experimental Research) or XtalView (D.J. McRee, (1992) J. Mol. Graphics, 10, 44-47).

Many other software suites are available to the skilled researcher.

Modelling and refinement of crystallographic data can be performed using AMORE [30] and XtalView, or other suitable software, as noted in the Methods section below.

The use in rational drug design of both the co-ordinates produced by these algorithms and the identity and chemical nature of the atoms involved in the interaction between I-domain and ligand, presented in Table 2, may involve use of interpretive software such as MCSS (Miranker, A. and Karplus, M., "Functionality Maps of Binding Sites: a Multiple Copy Simultaneous Search Method," Proteins: Structure, Function, and Genetics, 11 29-34 (1991)).

10

Use of these data in identification of chemical compounds which may be potential ligands or inhibitors of the I-domain:collagen interaction may utilise database searching software such as HOOK: A Program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site, (Eisen, M. B., et al., Proteins, 19 199-221 (1994)) or DOCK (Meng, E.C. et al., J. Comput. Chem. 13, 505-524 (1992)). Suitable databases of candidate ligands may include the ACD (Available Chemicals Directory; Molecular Design Limited Information Systems, San Leandro, CA, USA) or the NCI Drug Information System 3D Database (National Cancer Institute, USA).

20

A binding motif within collagen was previously identified, the sequence GFOGER [17, 18]. As for the parent molecule, this amino acid sequence adopts a triple helical conformation, when flanked by suitable repeats of GPO or GPP triplets, and binds to the integrin. Evidence for this is provided by the observation that the sequence is inactive when flanked by repetitive GAP motifs [18], so that non-helical structure is adopted, rather than the GPP or GPO motifs described above which support triple-helical conformation.

30

The structure of the candidate peptide is determined by the various requirements for co-crystallisation. If the flanking sequences of GPP or GPO are too long, then the dimensions of the triple-helix no longer match those of the I-domain, and
5 crystallisation will be increasingly less likely, as outlined above. But it remains important that sufficiently long flanking sequences are present to maintain triple-helical structure even at the cold-room temperature (0-8EC, typically 4EC) used for crystallisation. Hence the extent of the
10 flanking triplets is likely to be critical, being long enough to support triple-helical structure but not so long as to impede crystallisation.

A further consideration is that the peptide should be located
15 centrally upon the I-domain, so that the complex is approximately symmetric, a property which favours crystallisation.

In accordance with the present invention, a peptide has been
20 synthesized comprising [GPO]₂GFOGER[GPO]₂, which has a melting temperature of about 22°C and allows co- crystallisation to proceed at cold-room temperatures, where 95% or more of the peptide is in triple-helical form (see Figure 1). This peptide forms a single turn of the triple-helix after assembly
25 in trimer. Further, the disposition of two GPO triplets at the N-terminus of the peptide and three at the C-terminus allows the crucial glutamate (E) residue to be centrally located within the resultant triple-helix, favouring a symmetrical complex with the $\alpha 2$ I-domain.

30

An important consideration in the design of this peptide is the chemical modification of charged groups at its amino-

terminus and carboxy-terminus. This has the effect of rendering the ends of the peptide neutral at physiological pH, so that electrostatic repulsion between adjacent chains within a triple-helix is minimised. This permits the peptide to
5 assemble as a triple-helix at higher temperature, so facilitating the use of shorter peptide ligands, consistent with the dimensions of the receptor, in the crystallisation process. Several chemistries may be suitable. In the present case, acetylation of the N-terminal amino group and
10 incorporation of a C-terminal amide achieved this purpose.

Methods useful in attempts to induce crystallisation are known in the art [28]. Crucial factors may be the inclusion of suitable buffers to maintain the appropriate charge of the
15 protein and the peptide ligand; suitable detergents to maintain the conformation of the receptor; suitable polymers to increase the effective concentration of both receptor and ligand; suitable concentration of divalent cation to saturate the MIDAS; suitable concentration of peptide; precipitants to
20 induce the gradual precipitation/crystallisation of the complex; that the crystallisation be performed at temperatures at which the peptide is triple-helical; glycerol to stabilize the I domain and act as a cryo-protectant during the flash freezing prior to data collection.

25

Once the crystallisation and X-ray diffraction data have been obtained, then the 3-dimensional co-ordinates of the atoms within the crystal may be deduced by the use of suitable computer algorithms. The resultant data set allows the
30 construction of 3-dimensional models of the ligand in complex with the receptor, which offers to the researcher a fundamental understanding of the interaction between the two.

Knowledge of the structure of the ligand-I domain complex allows key processes to be established, such as a change in conformation in the receptor or ligand as the complex forms. Such information allows for the design of materials which
5 interact with the receptor, most likely at the site of interaction, the MIDAS, but possibly elsewhere in the structure, for example in the C-Helix or near Helix $\alpha 7$. Such materials may be used to impede the activation process of the integrin, preventing collagen from binding to the receptor.
10 In therapeutic use, such materials may be used to prevent cell contact with collagen, so impeding disease processes such as thrombosis, atherogenesis and metastasis.

In general aspects, the present invention is concerned with
15 identifying or obtaining potential inhibitors of Integrin I-domain interaction with ligand (e.g. collagen) and/or function, and in preferred embodiments identifying or obtaining actual inhibitors of such interaction and/or function. Crystal structure information presented herein is
20 useful in designing potential inhibitors and modelling them or their potential interaction with the I-domain of Integrin $\alpha 2\beta 1$ or other I-domain. Potential inhibitors may be synthesized and brought into contact with the relevant I-domain to test for ability to interact with the I-domain, ability to inhibit
25 interaction of the I-domain with collagen or other ligand, or with a collagen peptide that binds the I-domain, and/or ability to affect I-domain or Integrin function. Actual inhibitors may be identified from among potential inhibitors synthesized following design and model work performed *in*
30 *silico*. An inhibitor identified using the present invention may be formulated into a composition, for instance a composition comprising a pharmaceutically acceptable excipient, and may be used in manufacture of a medicament for

use in a method of treatment. These and other aspects and embodiments of the present invention are discussed below.

Table 2 provides details of contacts between the peptides and I-domain in the crystal structure. These too may be used in design of molecules that make similar contacts with the I-domain. Such molecules may be synthesised and tested for ability to interact with the I-domain, ability to inhibit interaction of the I-domain with collagen or with a collagen peptide that binds the I-domain, and/or ability to affect I-domain or Integrin function.

Comparison of the structure of the I-domain crystallised with the triple-helical peptide and the I-domain crystal structure without the peptide identifies a number of changes in conformation in the I-domain on peptide binding, and consequently parts of the I-domain which may be targeted for inhibition. This is discussed further below.

In accordance with a first aspect of the present invention there is provided a method of identifying a potential inhibitor of an I-domain-containing polypeptide, especially an integrin I-domain, e.g. selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 10$, $\alpha 11$, αD , αE , αL , αM and αX , preferably $\alpha 2$ or $\alpha 1$ and most preferably $\alpha 2$, the method comprising either (i) employing a three-dimensional structure of the Integrin $\alpha 2$ I-domain as shown in Table 1 to design or select a potential inhibitor, (ii) designing or selecting a potential inhibitor that interacts with one or more points in the I-domain crystal structure shown for the I-domain in Table 2, or (iii) designing or selecting a potential inhibitor that mimics one or more (and preferably three or more) points in the peptide structure shown for the peptide structure in Table 2.

In accordance with a further aspect of the present invention there is provided a method of identifying a potential inhibitor of an I-domain-containing polypeptide, especially an integrin I-domain, e.g. selected from the group consisting of
5 $\alpha 1$, $\alpha 2$, $\alpha 10$, $\alpha 11$, αD , αE , αL , αM and αX , preferably $\alpha 2$ or $\alpha 1$ and most preferably $\alpha 2$, the method comprising the steps of:

(a) employing a three-dimensional structure of the Integrin $\alpha 2$ I-domain as shown in Table 1 to design or select a
10 potential inhibitor;

(b) synthesizing or providing said potential inhibitor;
and

(c) testing said potential inhibitor for ability to interact with an I-domain-containing polypeptide.

15

A potential inhibitor of an integrin or other I-domain containing polypeptide may be designed by modelling points of interaction between the trimerized collagen peptide and the $\alpha 2\beta 1$ I-domain, for example as shown in Table 2. One or more
20 electrostatic interactions and/or one or more hydrogen bonds and/or one or more hydrophobic interactions may be used in the modelling. In a preferred embodiment, all the I-domain points identified in Table 2 are employed in the design, and/or all the peptide points identified in Table 2.

25

Thus, in a further aspect the present invention provides a method of identifying a potential inhibitor of an I-domain-containing polypeptide, especially an integrin I-domain, e.g. selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 10$, $\alpha 11$, αD , αE ,
30 αL , αM and αX , preferably $\alpha 2$ or $\alpha 1$ and most preferably $\alpha 2$, the method comprising the steps of:

(a) designing or selecting a potential inhibitor that

interacts with one or more points in the I-domain crystal structure shown for the I-domain in Table 2;

(b) synthesizing or providing said potential inhibitor;
and

5 (c) testing said potential inhibitor for ability to interact with an I-domain-containing polypeptide.

In a further aspect the present invention provides a method of identifying a potential inhibitor of an I-domain-containing
10 polypeptide, especially an integrin I-domain, e.g. selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 10$, $\alpha 11$, αD , αE , αL , αM and αX , preferably $\alpha 2$ or $\alpha 1$ and most preferably $\alpha 2$, the method comprising the steps of:

(a) designing or selecting a potential inhibitor that
15 mimics one or more points in the peptide structure shown for the peptide structure in Table 2;

(b) synthesizing or providing said potential inhibitor;
and

(c) testing said potential inhibitor for ability to
20 interact with an I-domain-containing polypeptide. Preferably, in step (a) the potential inhibitor mimics three or more spaced points in the peptide structure.

Step (c) of each of the above aspects may comprise bringing said
25 potential inhibitor into contact with the I-domain-containing polypeptide to determine ability of said potential inhibitor to inhibit (i) ability of the I-domain to interact with collagen or a collagen peptide or other ligand which binds the I-domain, and/or (ii) I-domain or I-domain-containing polypeptide function.
30 The I-domain-containing polypeptide may be an integrin (e.g. $\alpha 2\beta 1$).

Integrin function may be measured in a number of different

ways.

For instance, cells which express the integrin may be allowed to come into contact with a surface coated with a substrate known to bind the integrin. By illustration with reference to $\alpha 2\beta 1$ Integrin as a preferred embodiment without limitation to the ability to employ other integrins and I-domains in embodiments of the present invention, cells, such as human or other platelets, or any cell type utilising $\alpha 2\beta 1$ as an adhesive receptor, or cells such as HT1080 cells which use only $\alpha 2\beta 1$ as a receptor for collagen, may be allowed to settle upon the surface, and after suitable incubation time, e.g. from 10 minutes to 1 hour, or to 3 hours or longer, be washed from the surface [18]. Cells removed by this washing procedure may be quantitated, for example using an electronic particle counter [18], a haemocytometer, or other suitable procedure, allowing the proportion of cells that is not removed by washing to be defined as adherent. Alternatively, such cells as remain, constituting adherent cells, may be quantitated directly, either by microscopical counting, or if radiolabelled cells were used, then the amount of radioactivity remaining may be measured, or the cells may be stained using histochemical dyes and the amount of stain retained may be quantitated colorimetrically, or cells may be lysed using suitable detergent or other procedure, and the enzymes released from the cells may then be quantitated colorimetrically as a measure of the adherent cell numbers [18]. Each of these, or other suitable procedure, allows the adhesion of cells via $\alpha 2\beta 1$ to be measured, which defines the function of the integrin. Such procedures are well-known to those skilled in the art [refs 3,7,16,17,18,25,27].

In another variant of the procedure, similar surfaces coated

with substrate, such as peptide or collagen as defined above, may be used to support the adhesion of the purified integrin $\alpha 2 \beta 1$ or of the recombinant $\alpha 2$ I-domain. In these variants, the receptor or I-domain is suitably labelled, for example with
5 biotin [18], or, if expressed as recombinant fusion protein, with a poly-His tag, or glutathione-S-transferase, or with a fluorescent dye or with any other suitable means of identification, each of which may readily be detected by routine methodology. Alternatively, the protein may be
10 allowed to interact directly with a specific antibody, and its presence may then be detected immunologically. Such assays allow the extent to which the integrin or I-domain adheres to the substrate to be determined, which is a measure of integrin function.

15

Alternatively or additionally, step (c) of the above aspects may comprise the sub-steps of:

- (i) forming a complex of the I-domain-containing polypeptide and said potential inhibitor ; and
- 20 (ii) analysing said complex by X-ray crystallography or NMR spectroscopy to determine the ability of said potential inhibitor to interact with the I-domain-containing polypeptide. Detailed structural information can then be obtained about the binding of the potential inhibitor to the
25 I-domain-containing polypeptide, and in the light of this information adjustments can be made to the structure or functionality of the potential inhibitor, e.g. to improve binding to the polypeptide.

- 30 A further aspect of the present invention (which may be used in the above-mentioned analysis sub-step (ii)) provides a method of analysing an I-domain-containing polypeptide complex comprising employing (i) X-ray crystallographic diffraction

data from the I-domain-containing polypeptide complex and (ii) atomic coordinate data according to Table 1 to generate a difference Fourier electron density map of the complex.

- 5 Therefore, an I-domain-containing polypeptide complex can be crystallised and analysed using X-ray diffraction methods, and a difference Fourier electron density map can be calculated based on the X-ray diffraction pattern of the complex and the solved structure for the I-domain of Table 1. Such a map can
10 be used to determine whether and where a particular ligand binds to the I-domain and/or changes to the conformation of the I-domain.

Electron density maps can be calculated using programs such as
15 those from the CCP4 computing package (Collaborative Computational Project 4. The CCP4 Suite: Programs for Protein Crystallography, Acta Crystallographica, D50 760-763, (1994)).

For map visualisation and model building programs such as O (Jones et al., Acta Crystallographica, A47 110-119 (1991)).
20 Structure factor data, which are derivable from atomic coordinate data (see e.g. Blundell et al., in *Protein Crystallography*, Academic Press, New York, London and San Francisco, (1976)), are particularly useful for calculating difference Fourier electron density maps.

25

Analysis of the changes in conformation of the $\alpha 2$ I-domain allows certain residues to be identified as becoming exposed upon ligand binding: residues E318 (at the N-terminal end of Helix $\alpha 7$) and D292 (close to the N-terminal end of Helix $\alpha 6$).

- 30 Inhibitors of the I-domain and integrin function may be identified by targeting a binding molecule to the regions of the I-domain including these amino acids, for example by generating antibodies or other binding molecules to sequences

comprising, for instance residues 315 to 320, or 288 to 295. Certain parts of the I-domain, for example the C-helix, residues 284 to 288, also dramatically alter their conformation upon binding. These similarly provide a target
5 to inhibit conformational change, with therapeutic potential.

Thus, in a further aspect the present invention provides a method of obtaining a potential inhibitor of an Integrin, the method comprising the steps of:

- 10 (a) providing a peptide fragment of Integrin $\alpha 2$ I-domain, which peptide fragment contains the E318 residue (e.g. comprises residues 315-320), the D292 residue (e.g. comprises residues 288-295) or the residues 284-288;
- (b) bringing the peptide fragment into contact with a
15 test substance, such as an antibody molecule; and
- (c) determining the ability of the peptide fragment to bind with the test substance.

A substance which binds the peptide, e.g. an antibody
20 molecule, is a potential inhibitor of integrin function, e.g. Integrin $\alpha 2 \beta 1$ function. Ability of a potential inhibitor actually to inhibit may be determined as discussed elsewhere herein.

25 Similarly, the present invention provides for identifying a molecule that interacts with any part of the integrin I-domain identified by means of the crystal structure disclosed herein as making a contact with another part of the I-domain or the peptide in the crystal, or as altering in conformation on
30 binding of the peptide.

Data presented in Table 1 allows identification of those residues and their corresponding co-ordinates within the

resting I-domain (Brookhaven Protein Database number 1aox, reference 26) which are critically involved in both its conformational change and ligand binding cleft. Thus, in the light of data presented in Table 1 and the additional
5 disclosure herein, the resting I-domain co-ordinates [26] becomes a useful reference point for rational drug design. This allows certain surfaces, defined by the residues presented in Table 1, but whose resting co-ordinates are contained in 1aox, to be identified unambiguously as
10 contributing to the latent ligand binding cleft. Hence an inhibitor may be designed to bind to the resting I-domain and so prevent it from binding ligand.

For other I-domains, regions corresponding to those identified
15 for $\alpha 2$ I-domain as targets for antibody molecules are identified in accordance with the present invention as:

αM : residues 301-304 (N-terminal end of Helix $\alpha 7$),
residues 272-284 (N-terminal end of Helix $\alpha 6$);
 αL : residues 290-295 (N-terminal end of Helix $\alpha 7$),
20 residues 258-272 (N-terminal end of Helix $\alpha 6$);
 $\alpha 1$: residues 318-324 (N-terminal end of Helix $\alpha 7$),
residues 292-298 (N-terminal end of Helix $\alpha 6$).

Thus, an antibody molecule or other binding molecule may be
25 obtained, e.g. by making a peptide comprising or consisting of the above residues of any of the above regions and bringing the peptide into contact with a mixture containing potential binding molecules, determining binding to the peptide and selecting a binding molecule that binds. A binding molecule
30 such as an antibody molecule may be tested for ability to bind and inhibit an I-domain, and may be employed as an inhibitor of a polypeptide comprising an I-domain for one or more

purposes as disclosed herein.

Specific residues can also be identified, such as T221 in $\alpha 2$ I-domain, linked to metal ion in the resting I-domain

5 indirectly via a water molecule. Suitable inhibitors may be designed to bind T221 and prevent the metal ion from moving closer to become co-ordinated directly. Such inhibitors may be used to prevent subsequent ligand binding.

10 Comparison of the crystal structure of the integrin $\alpha 2$ I-domain in complex with the triple-helical collagen-like peptide with that of the free, uncomplexed, I-domain [26] allows regions of the I-domain to be identified which may be exposed in the free state, but which become hidden in the
15 complexed state. An example will be those areas of the surface of the I-domain which are obscured by the binding of the triple-helical peptide. These specific residues are identified in Table 2. Other such sites are remote from the binding cleft, and are revealed by conformational changes
20 which occur during the transition from the free to the complexed state. Such sites may also represent therapeutic targets: agents such as inhibitors or antibodies which bind to these critical exposed regions of the complexed integrin may block the transition to the resting conformation, so
25 maintaining the integrin in its active conformation.

The present invention allows such residues to be identified, and the co-ordinates of the I-domain surface in these regions to be used for rational drug design, as described above.

30

Alternatively, as noted, knowledge of these critical regions of the I-domain allows peptide sequences to be used to raise antibodies or other binding molecules by appropriate

methodology, for example against short peptide sequences derived from the I-domain or by DNA vaccination of nucleotide sequences corresponding to these regions of the I-domain. The utility of such inhibitors may be tested as described above,
5 in suitable adhesion or other assays.

Reference to an Antibody molecule describes an immunoglobulin whether natural or partly or wholly synthetically produced. The term also covers any polypeptide
10 or protein having a binding domain which is, or is substantially homologous to, an antibody binding domain. Thus, antibody molecules for use in the present invention include fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd and diabodies, all of which are
15 well known in the art.

Comparison of the two forms of the integrin I-domain allows sites to be identified upon its surface which are hidden in the free integrin, and which are exposed only after complex
20 with suitable ligand, for example the triple-helical peptide described above, Ac-(GPO)₂GFOGER(GPO)₃-NH₂. Such sites, when targeted by inhibitors may have two possible effects: if sufficiently close or within the binding cleft, they may inhibit ligand binding, but if sufficiently remote so as not
25 to impede ligand binding, they may stabilise the integrin in its active conformation and so enhance ligand binding. Such activity may be identified by binding assays as described herein, and each class of agent, whether inhibitory or activatory towards integrin function, may have its own
30 therapeutic use or other application.

Regions of interest within the $\alpha 2$ I-domain binding cleft are identified in Table 2, which also lists residues of the I-

domain (E318 and D292) which are exposed upon ligand binding and are not obscured by the triple-helical peptide.

A collagen peptide employed in testing for ability of a
5 potential inhibitor to inhibit binding of the I-domain to the
peptide may be a triple-helical peptide, of sequence GFOGER
known to bind the $\alpha 2$ I-domain [18], or other sequence which
binds to the I-domain, flanked by suitable repeats of GPO or
GPP triplets to ensure triple-helical structure.
10 Alternatively, physiological substrates such as collagens, for
example type I or type III or type IV or type VI or other
collagens, readily coat and adhere to the surface of tissue
culture dishes or 96-well plates, and are known to bind to
 $\alpha 2\beta 1$. Alternatively, other substrates such as the
15 extracellular protein laminin, also known to bind the I-domain
of $\alpha 2\beta 1$, may be used for the same purpose. Specificity of
interaction in this and other assays may be verified by using
antibodies against either the immobilised substrate or the
receptor on the surface of cells under test.

20

In any aspect of the present invention a potential inhibitor
that tests positive when brought into contact with the I-
domain, that is fulfils one or more of the specified criteria,
is considered an actual inhibitor.

25

Thus further aspects of the present invention provide methods
of identifying and/or obtaining inhibitors of a polypeptide
which contains an I-domain, especially an Integrin, which may
be selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 10$, $\alpha 11$, αD ,
30 αE , αL , αM and αX , especially $\alpha 2$ or $\alpha 1$, most preferably $\alpha 2$.

Another aspect of the present invention provides a crystal of

$\alpha 2$ I-domain complex having a space group $P2_12_12_1$, and unit cell dimensions of $a = 42.0 \text{ \AA}$, $b = 48.4 \text{ \AA}$, and $c = 114.5 \text{ \AA}$. Or more generally $a = 42.0 \pm 0.2 \text{ \AA}$, $b = 48.4 \pm 0.2 \text{ \AA}$, and $c = 114.5 \pm 0.2 \text{ \AA}$.

5

Alternatively or additionally, the present invention provides a crystal of $\alpha 2$ I-domain complex having the three dimensional atomic coordinates of Table 1.

- 10 Further aspects of the present invention provide (i) a computer system, intended to generate structures and/or perform rational drug design for I-domain-containing polypeptides or I-domain-containing polypeptide complexes, the system containing atomic coordinate data according to Table 1
- 15 or Table 2, and (ii) computer readable media for use in the computer system, having atomic coordinate data according to Table 1 or Table 2 recorded thereon.

By a "computer system" we mean the hardware means, software means and data storage means used to analyse atomic coordinate data. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means and data storage means. Desirably a monitor is provided to visualise

20 structure data. The data storage means may be RAM or means for accessing computer readable media of the invention. Examples of such systems are microcomputer workstations available from Silicon Graphics Incorporated and Sun Microsystems running Unix based, Windows NT or IBM OS/2

25 operating systems.

30

By "computer readable media" we mean any media which can be read and accessed directly by a computer e.g. so that the

media is suitable for use in the above-mentioned computer system. Such media include, but are not limited to: magnetic storage media such as floppy discs, hard disc storage medium and magnetic tape; optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media.

By providing such a system or such computer readable media, the atomic coordinate data can be routinely accessed to model I-domain-containing polypeptides and complexes thereof, e.g. using the molecular graphics programs discussed above.

Another aspect of the present invention provides an inhibitor of an I-domain identified or obtained by any method disclosed herein.

An inhibitor may be formulated into a composition comprising at least one additional component.

Following identification of an inhibitor it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.

Thus, the present invention extends in various aspects not only to an inhibitor as provided by the invention, but also a pharmaceutical composition, medicament, drug or other composition comprising such an inhibitor, a method comprising administration of such a composition to a patient, e.g. for treatment (which may include preventative treatment) of a disorder or disease, use of such an inhibitor in manufacture

of a composition for administration, e.g. for treatment of a disorder or disease, and a method of making a pharmaceutical composition comprising admixing such an inhibitor with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.

Disorders and diseases which may be treated in accordance with aspects of the present invention include the thrombotic disorders, myocardial infarction and stroke, acute thrombosis associated with angioplasty and with coronary bypass grafting, and with liver fibrosis or thrombotic complication of liver necrosis each of which is prone to occur after hepatitis infection. Inhibition of platelet $\alpha 2\beta 1$ may be used to treat longer-term occlusion of arteries, restenosis which commonly occurs after angioplasty as well as atherogenesis as a consequence of arterial vascular smooth muscle cell migration from the medial to the intimal space. Collagen receptor antagonism may be used to provide a novel means of anti-platelet therapy, and to be of benefit in clinical situations where conventional anti-platelet therapy is also effective.

The integrin $\alpha 2\beta 1$, and the closely-related $\alpha 1\beta 1$, for which GFOGER-containing triple-helical peptide is also a ligand, are widely expressed in mammalian cells. These integrins each provide a means of adhesion and migration of cells over the underlying collagen-containing extracellular matrix, and as such, may be essential for the metastasis of tumour cells. Inhibitors of $\alpha 2$ and $\alpha 1$ I-domain function may be used to inhibit metastasis.

As discussed herein, the present invention will also apply to other I-domains, such as those of αL and αM , inhibition of which will lead to down-regulation of those aspects of

leukocyte function which depend upon cell adhesion.

Therapeutically, such aspects of the present invention may be used to prevent excessive leukocyte (both monocyte and neutrophil) infiltration across vascular endothelia which may result in excessive tissue necrosis in sepsis; inhibition may be valuable in controlling inflammation.

An inhibitor of a polypeptide (e.g. Integrin $\alpha 2\beta 1$) may be used in treatment of a disease or disorder in which the polypeptide has a role, and may be administered to any individual, human or non-human, in need thereof.

When an inhibitor according to the present invention is to be given to an individual, administration is preferably in a prophylactically effective amount or a "therapeutically effective amount" as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc., is within the responsibility of general practitioners and other medical doctors.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may include, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in

the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by
5 injection, e.g. cutaneous, subcutaneous or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid
10 pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be
15 included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous
20 solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
25 Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Examples of techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition,
30 Osol, A. (ed), 1980.

The basis for considering that the principles established here for $\alpha 2$ I-domain will be applicable to other receptors is two-

fold. Firstly, the surface of the several I-domains under consideration is very similar. On these grounds alone it is anticipated that antagonists of $\alpha 2$ I-domain will also inhibit other I-domains. Secondly, experiment has demonstrated that this principle does extends to the $\alpha 1$ I-domain, since the triple-helical GFOGER-containing peptide supports adhesion of Ruggli cells mediated by $\alpha 1\beta 1$, and inhibits adhesion of these same cells to collagen and of the purified receptor to collagen [18]. Other collagen-binding I-domains $\alpha 10$, $\alpha 11$ are expected to follow suit.

Receptor antagonists of $\alpha 2$ I-domain provide for identification of antagonists of other I-domains, and the surface of the $\alpha 2$ I-domain embodied in Table 2 will provide valuable assistance in the model building exercise needed for rational drug design targeting these ubiquitous cellular adhesion receptors.

Further aspects and embodiments of the present invention will be apparent to those skilled in the art. The invention will now be illustrated further with reference to experimental support and use of aspects and embodiments of the invention.

Brief Description of Drawings

Figure 1 shows the melting curve for peptide Ac-[GPO]₂GFOGER[GPO]₂-NH₂. The Figure shows the variation in optical rotation with temperature of a solution of the peptide, indicating the transition from triple helical to random coil conformation as temperature increases.

30

Figure 2 shows the structure of the $\alpha 2$ I-domain in complex with the triple helical synthetic peptide. Beta strands

within the I-domain are shown as broad arrows, and alpha-helices as coiled ribbons. The backbones only of other loops of the I-domain and of the strands of the triple helical peptide are shown.

5

Figure 3 shows that interaction of $\alpha 2$ I-domain and peptide is confined to two strands of triple-helix. The Figure shows the surface of the $\alpha 2$ I-domain in complex with the triple helical synthetic peptide. The footprint of the triple helical peptide on the I-domain surface is shaded, and both sidechains and peptide carbonyls which interact with the I-domain are indicated by arrows.

Figure 4 shows that carbonyl groups on Middle and Trailing strands of the triple-helix interact with I-domain Y185 and H258. Interactions are shown as dashed lines.

Figure 5 illustrates principal conformational changes in I-domain upon binding of peptide. The Figure shows the three-dimensional structure of the $\alpha 2$ I-domain in its resting, unligated form (grey) superimposed on the structure after ligation (dark) with triple-helical Ac-[GPO]₂GFOGER[GPO]₃-NH₂.

The peptide is not shown. I-domain α -helices (with their numbers above them) are shown as coiled ribbons, and β -strands as broad arrows. Conformational changes are indicated by outlined arrows.

Figure 6 shows details of the $\alpha 2$ I-domain MIDAS after ligation with triple-helical Ac-[GPO]₂GFOGER[GPO]₃-NH₂. The peptide glutamate (E) is shown, along with the residues of the I-domain which also co-ordinate the metal ion in the ligated (peptide-bound) state of the I-domain. Amino acids of the I-

30

domain involved in metal ion co-ordination are indicated by letters (single amino-acid nomenclature) and numbers defining their position within the I-domain sequence. Interactions are indicated by dashed lines.

5

Experimental Support and Use of Aspects and Embodiments of the Invention

*Design, Production and Analysis of a Triple Helical Peptide
10 that Binds and Crystallises with Integrin I Domain*

The peptide Ac-(GPO)₂GFOGER(GPO)₃-NH₂ was synthesized (see below for materials and methods) and shown to adopt triple helical conformation, as demonstrated by the melting curve (Figure 1).
15 This indicated that at cold-room temperature, i.e. below 10°C, more than 90 % of the peptide was in triple helical conformation, determined by optical polarimetry. Other methods such as circular dichroism may be used to provide further confirmation of the triple-helical state of the
20 peptide.

Crystallisation of the Peptide of Example 1 and the I-domain of Integrin α2 and Determination of Atom Co-ordinates

25 Materials and methods are described below.

The co-ordinates of the atoms comprising:
(i) the triple-helical structure of peptide
Ac-(GPO)₂GFOGER(GPO)₃-NH₂ ,
30 (ii) the I-domain of the integrin α2 subunit, comprising residues 143 to 326 of the integrin sequence,
(iii) water molecules forming part of the crystal complex, and
(iv) a metal ion bridging the I-domain and collagen.

are shown in Table 1.

The deduced 3-dimensional structure of the complex is shown in Figures 2 - 6.

5

The collagen-like peptide adopts its characteristic triple-helical structure with a 1-residue displacement between strands, these being in parallel rather than anti-parallel alignment. This allows us to define the strands as leading, middle and trailing, with the trailing strand being displaced towards the N-terminus of the triple-helix, relative to the middle strand, and the leading strand displaced towards the C-terminus of the trimeric structure. This is illustrated in Figure 2.

15

In turn, this allows the strands to be seen as non-equivalent; the environment of any specific amino acid is defined by its relationship with different amino acids in each adjacent strand, and so the structure is lacking in radial symmetry.

20

The significance of this is that, if the amino acids interacting with the I-domain were confined to a single strand, any of the three strands could serve this function, and crystallisation would be unlikely, given that there would be three, non-equivalent peptide:I-domain complexes as a consequence of the stagger between the different strands.

25

If two strands engage the I-domain, then two of the three possible orientations of the helix will suffice (after axial rotation by 120° and translation of the helix by one residue) but the third orientation will be non-identical and unfavourable.

30

If three strands engage the I-domain, then a unique complex

will result.

Surprisingly, given that crystal formation of the $\alpha 2$ I-domain:peptide complex is observed, the second possibility
5 proves to be the case. Complex formation could in principle occur in either of two conformations, therefore. The successful crystallisation shows that only one of the two possible orientations occurs within the complex is allowed and suggests that interaction between the ends of adjacent triple-
10 helices within the crystal lattice favours one of the two possible complexes.

This helix:helix interaction is permitted by the unique overlap between the C-termini of triple-helical peptides in
15 adjacent unit cells, which are related by a two-fold axis. This may be the cause of the bend seen in the complexed helix, although it is also possible that interactions of the triple-helix with the I-domain support this perturbation of the triple-helix linear structure.

20

Interaction with the I-domain is restricted to the middle and trailing strands. Multiple sites of interaction are shown in Figure 3. These include interactions of carbonyl groups from the peptide bonds of the triple helix with specific residues
25 within the I-domain (some of which are shown in detail in Figure 4), as well as the key interactions of the middle strand E (which co-ordinates the metal ion) and R residue (which forms a salt-bridge with I-domain D219) and trailing strand F residue. An inhibitor of receptor interaction with
30 collagen and/or function may inhibit one or more of these interactions, and this may be by making the interactions.

The changes in the $\alpha 2$ I-domain upon ligation by the GFOGER-

containing peptide may be summarised thus:

Upon complex formation between the I-domain and the collagen-like peptide, the C-Helix unwinds while the connecting loop
5 coils up to form an extra turn of Helix $\alpha 6$.

Helix $\alpha 7$ undergoes a remarkable displacement upon ligand binding. This helix translates axially towards the base of the I-domain (the C-terminal end of the beta-sheet) by almost
10 its own length, a distance of about 1 nm.

The residues responsible for co-ordinating the cation in the MIDAS are re-arranged, allowing the glutamate residue of the collagen sequence GFOGER to approach the apex of, and so
15 complete, the octahedral co-ordination shell of the divalent cation.

An overview of these changes is shown in Figure 5.

20 The detail of these changes is provided as follows:
Comparison between the collagen-bound and unligated $\alpha 2$ I-domain shows that the central beta-sheet does not change its conformation upon ligation (RMSD = 0.03 nm), providing a convenient reference frame for structural comparison.

25 The structural changes on binding ligand may be described as follows. The metal ion moves 0.26 nm towards MIDAS Loop 2 in order to make a direct bond with T221. MIDAS Loop 1 follows the movement of the metal in order to maintain its direct
30 bonds via S153 and S155. MIDAS Loop 3 undergoes a radical rearrangement: the sidechain of D254 moves laterally so that its direct bond to the metal is lost; the G255 peptide bond flips by 180° so that its C α moves ~0.4 nm away from the metal

ion; and E256 forms a new water-mediated bond to the metal. .
The outcome of these events is shown in Figure 6. The
movement of Loop 1 towards Loop 3 brings the side chains of
Y157 and H258 0.3 nm closer together such that they both fit
5 into grooves of the triple helix.

The shift of Loop 1 and the rearrangement of Loop 3 trigger a
reorganization of the C-helix and Helix $\alpha 7$. Loop 1 is packed
against $\alpha 7$ in the unliganded structure, and the large
10 concerted movement of Loop 1 and Helix $\alpha 1$ appears to squeeze
out the $\alpha 7$ helix, and it drops downwards by 1 nm. This
movement breaks a partly buried salt bridge between E318 from
 $\alpha 7$ and R288 from the C-helix. The flip of Loop 3, which is
packed closely against Helix $\alpha 6$, forces a rearrangement of the
15 sidechain of the buried L296 that would create a close contact
with L286 from the C-helix. In response to the steric
pressure between these leucines, and the loss of the
stabilizing E318-R288 salt-bridge, the C-helix unwinds while
the connecting loop coils up to form an extra turn at the N-
20 terminus of helix $\alpha 6$. The uncoiling of the C-helix produces a
dramatic 180° rotation and shift of Y285, such that its
hydroxyl oxygen moves by 1.7 nm from its location above the
MIDAS motif to form a hydrogen bond with S316 at the top of
the repositioned $\alpha 7$. By contrast, L286 moves 0.4 nm towards
25 the collagen, where it makes van der Waals contacts with the
trailing strand phenylalanine, and R288 moves 0.6 nm closer to
the MIDAS motif, where it forms a water-mediated salt-bridge
to D254.

30 Inhibition of any one or more of these structural changes may
be used to inhibit receptor interaction with collagen and/or
function. An inhibitor or receptor function may inhibit

totally or partially one or more of the conformational changes.

Discussion

5

Several notable features of the structure are revealed, which shed light upon the function of the I-domain as a dynamic piece of cellular machinery, capable of regulating cell function, and whose own function may be regulated by the cell.

10 These conclusions arise from the comparison of the ligated and unligated structures of the $\alpha 2$ I-domain, detailed above.

Firstly, it appears that the role of the C-helix is to regulate ligand binding, since it controls access to the MIDAS. Secondly, the translation of Helix 7 upon ligand binding could serve either of two functions, to regulate the position of the C-helix from within the cell, i.e. to increase the affinity of the integrin, or to transmit signals from the ligated MIDAS to the body of the integrin and thence to the cell. Plausibly, the same molecular movement could serve both purposes.

This level of understanding supports several approaches to rational drug design, assuming that the therapeutic intent is to inhibit integrin function.

Firstly, small molecule analogues of collagen may be designed, of similar shape and charge distribution to the key residues of the sequence GFOGER, which bind to the complementary structure, the binding cleft of the $\alpha 2$ I-domain. Solution of the complex structure provided here enables establishment of the critical determinants of ligand binding, location of key atomic interactions and assignment of binding energies. This

information provides for *in silico* construction of integrin $\alpha 2\beta 1$ antagonists, preferably focussing upon the integrin MIDAS.

5 Secondly, molecules that inhibit the conformational changes described may be designed. For example, small molecule ligands may be designed for regions adjacent to the C-helix to stabilise it in the closed conformation so preventing ligand binding, as discussed already herein. This approach offers an
10 alternative to direct antagonism of the MIDAS.

Similarly, the regions of the I-domain at the C-terminus of Helix $\alpha 7$ (close to the interface between the I-domain and the rest of the integrin $\alpha 2$ subunit) may be targeted. This
15 enables design of small molecules which prevent translation of the helix from occurring, with the consequence of locking the integrin in its inactive conformation, preventing both collagen binding and inwards signal transduction from taking place.

20

Furthermore, the different integrins characterised to date parallel one another in both structure and function. Hence, the other I-domain-containing integrins, known at present to include $\alpha 1$, $\alpha 2$, $\alpha 10$, $\alpha 11$, αD , αE , αL , αM and αX , may be
25 targetted in accordance with the present invention. For instance an inhibitor of $\alpha 2$ or $\alpha 1$ identified using the present invention may be tested for ability to inhibit one or more other integrins containing an I-domain. Additionally, the data presented here allow predictions to be made concerning
30 the active (ligated) form of the integrin based upon the conformation of the resting integrin, or from primary sequence using the co-ordinates of known structures such as $\alpha 2$ I-domain

or α L I-domain as a model. Thus a region of an I-domain considered by analogy with the ligated α 2 I-domain crystal structure information presented herein to be involved in ligand binding and/or involved in a conformational change on ligand binding, may be targeted, for instance by means of an antibody or other specific binding molecule.

These concepts may be extended to other, non-integrin proteins, such as von Willebrand factor, which contain I-domains and which might undergo activation in an analogous fashion.

The knowledge of the structural changes occurring in the integrin upon ligation presented here provides such proteins as targets for rational drug design.

Materials and Methods

Crystallization and data collection

Recombinant α 2-I domain and a synthetic collagen-like peptide, Ac-GPO)₂GFOGER(GPO)₃-NH₂, were produced [18, 26]. See also WO99/50281. Crystallization experiments were performed at 4°C using the sitting drop vapor diffusion method. Initial conditions were established using a 2 ml sample of protein in buffer 0.1 M Tris pH 7.5, 0.15M NaCl, 2 mM MgCl₂ (or MnCl₂) and peptide in 10 mM acetate pH 5.0 mixed in a ratio of 1:4 added to 2 ml of well solution consisting of 25 mM sodium cacodylate pH 6.5, 20% glycerol and 20-30% PEG 5K MME. Small bunched crystals appeared after 2-4 days and had flattened rod-like morphology with dimensions 0.025 x 0.025 x 0.1 mm³. The crystals adopt space group P2₁2₁2₁ with cell dimensions a = 4.2 nm, b = 4.84 nm, c = 11.45 nm. Crystal growth was dependent on

the presence and concentration of divalent cation but was unaffected by the cation species. Similar crystals grew in the presence of Mg^{2+} , Mn^{2+} , Co^{2+} , Cd^{2+} , Ni^{2+} and Zn^{2+} ions. Larger single crystals were rare and improved only marginally by making small changes in the cation concentration and the protein:peptide ratio. Data were collected at the Daresbury Synchrotron Radiation Source using a single crystal flash frozen in a cryo-stream of nitrogen at a temperature of 100 K. Data set Native I was collected from station 9.6 using the Quantum4 CCD detector to 0.25 nm resolution. This crystal was grown in 1 mM $ZnCl_2$ using a protein to triple helical peptide ratio of 1:2.5. A high resolution data set to 0.21 nm resolution (Native II) was subsequently collected on SRS station 7.2 using a MAR345 scanner. This crystal was grown in 1 mM $CoCl_2$ using a protein to peptide ratio of 1:1.6. Data were reduced with DENZO and scaled with SCALEPACK [29]. The overall I/sI for Native II is 12.0 (2.9 in 2.17-2.1 Å shell) with an R_{merge} of 8.9% (34.4% in outer shell), an average redundancy of 2.9 and completeness of 98.2% in the range 20-2.1 Å (14483 reflections).

Structure determination and refinement

Molecular replacement was performed on the Native I data set with AMORE [30] using the crystal structure of the uncomplexed $\alpha 2$ -I domain as the search model. A clear solution was found in the cross rotation function and subsequent translation function. The initial R_{work} was 52.0% with an R_{free} of 54.2%. A $2F_o - F_c$ electron density map calculated at 0.25 nm was of high quality with changes in the MIDAS motif readily apparent. Little density for the collagen peptide could be observed in the $2F_o - F_c$ or $F_o - F_c$ map at this stage. Several rounds of model building and refinement of the I domain using XTALVIEW [31]

resulted in greatly improved density for several regions of the domain which had undergone structural change. Following rebuilding of the I domain some density for the collagen peptide was apparent in the $2F_o - F_c$ and $F_o - F_c$ electron density maps. Solvent flattening using a molecular mask constructed to encompass the predicted peptide region provided unbiased improvement of the peptide electron density, and 24 alanine residues were inserted. At this stage the identification of hydroxyproline hydroxyl groups in the C-terminal GPO triplets allowed the correct assignment of the collagen chain direction. Identification of GFOGER sidechain density and the C-terminal ends of each chain allowed correct positioning of the leading, middle and trailing strands. Several rounds of model building and refinement allowed complete identification of the collagen peptides. At this stage data to 0.21 nm resolution became available from the native II data set showing an initial R_{WORK} of 38.6% and an R_{FREE} of 47.1% against the refined model. Further cycles of model building and refinement, including the insertion of 398 water molecules, gave a final R_{WORK} of 0.203 and R_{FREE} of 0.276 (5% of the reflections). The RMS deviations from ideal bond length and angles are 0.0006 nm and 1.41E. Good density is observed for I domain residues 142 to 326 and for all collagen residues, although the N-terminal GPO triplet of each strand is more mobile than the others. The coordinates and structure factors have been deposited with the PDB (code assigned; 1dzi).

References

1. WO99/50281
2. Barnes (1988) in *Collagen, Vol 1: Biochemistry*, M.E. Nimni, Ed. CRC press: Boca Raton, Fl. p. 275-290.
3. Knight et al. (1999) *Cardiovasc. Res.* 41:450-457.
4. Werkmeister & Ramshaw (1991) *Biochem. J.* 274:895-898.
5. Bella et al. (1994) *Science* 266:75-81.
6. Yang et al. (1997) *J. Biol. Chem.* 272:28837-28840.
7. Morton et al. (1995) *Biochem. J.* 306:337-344.
8. Kehrel et al. (1998) *Blood* 91:491-499.
9. Gibbins et al. (1997) *FEBS Lett.* 413:255-259.
10. Gibbins et al. (1996) *J. Biol. Chem.* 271:18095-18099.
11. Erb et al. (1997) *Biochemistry* 36:7395-7402.
12. Sixma et al. (1997) *Thromb. Haemost.* 78:434-438.
13. Moroi & Jung (1997) *Thromb. Haemost.* 78:439-444.
14. Barnes et al. (1998) *Curr. Opin. Haematol.* 5:314-320.
15. Fields et al. (1993) *J. Biol. Chem.* 268:14153-14160.
16. Morton et al. (1997) *J. Biol. Chem.* 272:11044-11048.
17. Knight et al. (1998) *J. Biol. Chem.* 273:33287-33294.
18. Knight et al. (2000) *J. Biol. Chem.* 275:35-40.
19. Hynes (1992) *Cell* 69:11-25.
20. Humphries (1990) *J. of Cell Science* 97:585-592.
21. Kuhn K & Eble J (1994) *Trends in Cell Biol.* 4:256-261.
22. Casasnovas et al. (1997) *Nature* 387:312-315.
23. Springer (1997) *Proc. Natl. Acad. Sci. (USA)* 94:65-72.
24. Fujimura & Phillips (1983) *J. Biol. Chem.* 258:10247-10252.
25. Tuckwell et al. (1995) *J. Cell Sci.* 108:1629-1637.
26. Emsley et al. (1997) *J. Biol. Chem.* 272:28512-28517.
27. Dickeson et al. (1997) *J. Biol. Chem.* 272:7661-7668.
28. Ducruix & Giege (1992) in *Crystallisation of nucleic acids and proteins: A practical approach*. IRL press: Oxford.

29. Otwinowski (1993) in *Data collection and processing*, L. Sawyer, N. Isaacs, and S. Bailey, Ed. SDERC: Daresbury, UK. p. 59-62.
30. Navaza (1994) *Acta Cryst.* A50:157-163.
- 5 31. McRee (1999) *J. Struct. Biol.* 125:156-165.

All documents cited anywhere in this text are incorporated by reference.

TABLE 1 - Co-ordinates of the crystal formed from the $\alpha 2$ I-domain and triple-helical peptide $\text{Ac}-(\text{GPO})_2\text{GFOGER}(\text{GPO})_3\text{-NH}_2$ in complex.

5 The sequence of each molecular component of the crystal complex is provided:

Fifteen consecutive lines define the amino acid sequence beginning with the N-terminal Alanine (ALA) of the recombinant
10 I-domain, which contains 185 amino acid residues and is defined as A.

Two consecutive lines define the sequence of the 21 amino acids and C-terminal amide of the first chain of the triple
15 helical peptide, defined as B.

Four further consecutive lines define identically the sequence of the second and third chains of the triple-helical peptide, defined as C and D.
20

Thirty-one lines show the water molecules (HOH) which are comprised within the structure of the complex as water of crystallisation, defined collectively as E.

25 One line defines the cobalt ion (CO) as F.

One line (CRYST1) defines the dimensions of the crystal cell, and its spacegroup.

30 Atoms comprising the crystal complex are listed sequentially, identified in Columns 1 and 2; Column 3 defines each specific atom within an amino acid residue; Column 4 defines the identity and position of the amino acid within the sequence,

or of other chemical species such as water (HOH), and the chain (defined above as A, B, C, D, E or F) containing the specific atom; Columns 5, 6 and 7 provide the X, Y and Z co-ordinates respectively of the specific atom; Column 8 provides the occupancy, that is presence or absence for the purposes of analysis; Column 9 provides a parameter of thermal mobility known as the B-factor; Column 10 provides an alternative means of identifying the chain in which the atom resides, useful for certain computer software packages (A defines atoms as being within Chain A, the I-domain: CA, CB and CD identify atoms as residing within the triple-helical peptide chains, Collagen A, Collagen B or Collagen C: W defines an atom as belonging to water, and M as being the metal ion).

```

15  SEQRES  1 A  185  ALA LEU ILE ASP VAL VAL VAL VAL CYS ASP GLU SER ASN
    SEQRES  2 A  185  SER ILE TYR CPR TRP ASP ALA VAL LYS ASN PHE LEU GLU
    SEQRES  3 A  185  LYS PHE VAL GLN GLY LEU ASP ILE GLY PRO THR LYS THR
    SEQRES  4 A  185  GLN VAL GLY LEU ILE GLN TYR ALA ASN ASN PRO ARG VAL
20  SEQRES  5 A  185  VAL PHE ASN LEU ASN THR TYR LYS THR LYS GLU GLU MET
    SEQRES  6 A  185  ILE VAL ALA THR SER GLN THR SER GLN TYR GLY GLY ASP
    SEQRES  7 A  185  LEU THR ASN THR PHE GLY ALA ILE GLN TYR ALA ARG LYS
    SEQRES  8 A  185  TYR ALA TYR SER ALA ALA SER GLY GLY ARG ARG SER ALA
    SEQRES  9 A  185  THR LYS VAL MET VAL VAL VAL THR ASP GLY GLU SER HIS
25  SEQRES 10 A  185  ASP GLY SER MET LEU LYS ALA VAL ILE ASP GLN CYS ASN
    SEQRES 11 A  185  HIS ASP ASN ILE LEU ARG PHE GLY ILE ALA VAL LEU GLY
    SEQRES 12 A  185  TYR LEU ASN ARG ASN ALA LEU ASP THR LYS ASN LEU ILE
    SEQRES 13 A  185  LYS GLU ILE LYS ALA ILE ALA SER ILE PRO THR GLU ARG
    SEQRES 14 A  185  TYR PHE PHE ASN VAL SER ASP GLU ALA ALA LEU LEU GLU
30  SEQRES 15 A  185  LYS ALA GLY .
    SEQRES  1 B   22  GLY PRO HYP GLY PRO HYP GLY PHE HYP GLY GLU ARG GLY
    SEQRES  2 B   22  PRO HYP GLY PRO HYP GLY PRO HYP NHH
    SEQRES  1 C   22  GLY PRO HYP GLY PRO HYP GLY PHE HYP GLY GLU ARG GLY
    SEQRES  2 C   22  PRO HYP GLY PRO HYP GLY PRO HYP NHH
35  SEQRES  1 D   22  GLY PRO HYP GLY PRO HYP GLY PHE HYP GLY GLU ARG GLY
    SEQRES  2 D   22  PRO HYP GLY PRO HYP GLY PRO HYP NHH
    SEQRES  1 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES  2 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES  3 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
40  SEQRES  4 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES  5 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES  6 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES  7 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES  8 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
45  SEQRES  9 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH
    SEQRES 10 E  400  HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH HOH

```


	SEQRES	11	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	12	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	13	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	14	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
5	SEQRES	15	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	16	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	17	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	18	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	19	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
10	SEQRES	20	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	21	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	22	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	23	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	24	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
15	SEQRES	25	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	26	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	27	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	28	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	29	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
20	SEQRES	30	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	31	E	400	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH	HOH
	SEQRES	1	F	1	CO														

	CRYST1	41.994	48.377	114.545	90.00	90.00	90.00	P	21	21	21	24
25	ATOM	1	CB	ALA A 142	11.648	-13.520	47.836	1.00	34.96			A
	ATOM	2	C	ALA A 142	9.671	-12.738	49.142	1.00	34.94			A
	ATOM	3	O	ALA A 142	8.835	-13.081	49.983	1.00	35.57			A
	ATOM	4	N	ALA A 142	9.402	-13.644	46.820	1.00	35.53			A
30	ATOM	5	CA	ALA A 142	10.165	-13.735	48.096	1.00	34.99			A
	ATOM	6	N	LEU A 143	10.173	-11.504	49.092	1.00	33.30			A
	ATOM	7	CA	LEU A 143	9.763	-10.523	50.085	1.00	30.95			A
	ATOM	8	CB	LEU A 143	10.863	-10.384	51.155	1.00	30.60			A
	ATOM	9	CG	LEU A 143	12.286	-9.955	50.765	1.00	31.70			A
35	ATOM	10	CD1	LEU A 143	12.375	-8.444	50.664	1.00	32.35			A
	ATOM	11	CD2	LEU A 143	13.275	-10.423	51.811	1.00	30.98			A
	ATOM	12	C	LEU A 143	9.304	-9.133	49.630	1.00	29.03			A
	ATOM	13	O	LEU A 143	8.144	-8.776	49.845	1.00	28.59			A
	ATOM	14	N	ILE A 144	10.174	-8.354	48.992	1.00	26.76			A
40	ATOM	15	CA	ILE A 144	9.788	-6.988	48.623	1.00	24.45			A
	ATOM	16	CB	ILE A 144	10.354	-5.982	49.660	1.00	24.71			A
	ATOM	17	CG2	ILE A 144	9.884	-4.583	49.339	1.00	24.79			A
	ATOM	18	CG1	ILE A 144	9.898	-6.365	51.072	1.00	25.36			A
	ATOM	19	CD1	ILE A 144	10.517	-5.520	52.173	1.00	25.41			A
45	ATOM	20	C	ILE A 144	10.151	-6.446	47.238	1.00	22.83			A
	ATOM	21	O	ILE A 144	11.317	-6.426	46.842	1.00	22.87			A
	ATOM	22	N	ASP A 145	9.135	-5.980	46.520	1.00	19.93			A
	ATOM	23	CA	ASP A 145	9.330	-5.386	45.210	1.00	18.20			A
	ATOM	24	CB	ASP A 145	8.371	-6.002	44.181	1.00	17.90			A
50	ATOM	25	CG	ASP A 145	8.865	-7.340	43.639	1.00	18.99			A
	ATOM	26	OD1	ASP A 145	10.071	-7.645	43.799	1.00	21.43			A
	ATOM	27	OD2	ASP A 145	8.056	-8.077	43.034	1.00	16.50			A
	ATOM	28	C	ASP A 145	9.056	-3.886	45.363	1.00	17.28			A
	ATOM	29	O	ASP A 145	7.903	-3.463	45.478	1.00	16.93			A
55	ATOM	30	N	VAL A 146	10.120	-3.087	45.383	1.00	16.46			A
	ATOM	31	CA	VAL A 146	9.981	-1.644	45.542	1.00	15.31			A

	ATOM	32	CB	VAL	A	146	10.946	-1.092	46.615	1.00	16.68	A
	ATOM	33	CG1	VAL	A	146	10.681	0.395	46.826	1.00	17.60	A
	ATOM	34	CG2	VAL	A	146	10.780	-1.846	47.916	1.00	17.29	A
	ATOM	35	C	VAL	A	146	10.231	-0.848	44.268	1.00	14.93	A
5	ATOM	36	O	VAL	A	146	11.275	-0.984	43.630	1.00	14.75	A
	ATOM	37	N	VAL	A	147	9.270	-0.002	43.916	1.00	13.85	A
	ATOM	38	CA	VAL	A	147	9.385	0.846	42.741	1.00	13.06	A
	ATOM	39	CB	VAL	A	147	8.215	0.624	41.751	1.00	14.12	A
	ATOM	40	CG1	VAL	A	147	8.284	1.650	40.628	1.00	12.57	A
10	ATOM	41	CG2	VAL	A	147	8.270	-0.797	41.184	1.00	13.32	A
	ATOM	42	C	VAL	A	147	9.384	2.309	43.165	1.00	12.08	A
	ATOM	43	O	VAL	A	147	8.431	2.784	43.791	1.00	12.23	A
	ATOM	44	N	VAL	A	148	10.468	3.004	42.831	1.00	11.18	A
	ATOM	45	CA	VAL	A	148	10.625	4.424	43.130	1.00	9.94	A
15	ATOM	46	CB	VAL	A	148	12.106	4.779	43.401	1.00	10.37	A
	ATOM	47	CG1	VAL	A	148	12.258	6.282	43.621	1.00	10.02	A
	ATOM	48	CG2	VAL	A	148	12.608	4.016	44.615	1.00	11.21	A
	ATOM	49	C	VAL	A	148	10.144	5.254	41.942	1.00	10.76	A
	ATOM	50	O	VAL	A	148	10.622	5.078	40.822	1.00	11.23	A
20	ATOM	51	N	VAL	A	149	9.195	6.152	42.192	1.00	10.14	A
	ATOM	52	CA	VAL	A	149	8.650	7.027	41.154	1.00	9.36	A
	ATOM	53	CB	VAL	A	149	7.099	6.991	41.177	1.00	8.62	A
	ATOM	54	CG1	VAL	A	149	6.523	7.938	40.130	1.00	6.99	A
	ATOM	55	CG2	VAL	A	149	6.617	5.553	40.929	1.00	5.19	A
25	ATOM	56	C	VAL	A	149	9.186	8.421	41.493	1.00	10.37	A
	ATOM	57	O	VAL	A	149	8.677	9.099	42.392	1.00	12.43	A
	ATOM	58	N	CYS	A	150	10.207	8.844	40.757	1.00	8.87	A
	ATOM	59	CA	CYS	A	150	10.890	10.108	41.027	1.00	9.53	A
	ATOM	60	CB	CYS	A	150	12.389	9.812	41.159	1.00	7.66	A
30	ATOM	61	SG	CYS	A	150	13.406	11.182	41.672	1.00	8.78	A
	ATOM	62	C	CYS	A	150	10.678	11.283	40.073	1.00	8.89	A
	ATOM	63	O	CYS	A	150	11.035	11.229	38.895	1.00	10.33	A
	ATOM	64	N	ASP	A	151	10.115	12.356	40.618	1.00	9.37	A
	ATOM	65	CA	ASP	A	151	9.822	13.591	39.890	1.00	9.11	A
35	ATOM	66	CB	ASP	A	151	9.110	14.552	40.840	1.00	11.54	A
	ATOM	67	CG	ASP	A	151	8.410	15.689	40.129	1.00	11.85	A
	ATOM	68	OD1	ASP	A	151	8.906	16.171	39.091	1.00	14.28	A
	ATOM	69	OD2	ASP	A	151	7.357	16.113	40.634	1.00	12.34	A
	ATOM	70	C	ASP	A	151	11.105	14.256	39.356	1.00	10.14	A
40	ATOM	71	O	ASP	A	151	12.012	14.575	40.120	1.00	8.58	A
	ATOM	72	N	GLU	A	152	11.176	14.470	38.045	1.00	9.69	A
	ATOM	73	CA	GLU	A	152	12.349	15.100	37.454	1.00	10.74	A
	ATOM	74	CB	GLU	A	152	13.097	14.106	36.548	1.00	12.08	A
	ATOM	75	CG	GLU	A	152	12.376	13.735	35.251	1.00	12.78	A
45	ATOM	76	CD	GLU	A	152	13.161	12.738	34.402	1.00	13.97	A
	ATOM	77	OE1	GLU	A	152	14.400	12.675	34.534	1.00	12.78	A
	ATOM	78	OE2	GLU	A	152	12.540	12.024	33.588	1.00	14.91	A
	ATOM	79	C	GLU	A	152	11.949	16.344	36.661	1.00	11.12	A
	ATOM	80	O	GLU	A	152	12.709	16.830	35.823	1.00	11.48	A
50	ATOM	81	N	SER	A	153	10.758	16.865	36.942	1.00	10.14	A
	ATOM	82	CA	SER	A	153	10.266	18.048	36.252	1.00	9.70	A
	ATOM	83	CB	SER	A	153	8.803	18.306	36.624	1.00	10.82	A
	ATOM	84	OG	SER	A	153	8.654	18.418	38.025	1.00	7.53	A
	ATOM	85	C	SER	A	153	11.128	19.264	36.589	1.00	10.23	A
55	ATOM	86	O	SER	A	153	11.912	19.235	37.539	1.00	10.08	A
	ATOM	87	N	ASN	A	154	10.976	20.327	35.801	1.00	8.89	A

50

	ATOM	88	CA	ASN A 154	11.760	21.548	35.973	1.00	9.70	A
	ATOM	89	CB	ASN A 154	11.320	22.621	34.959	1.00	9.07	A
	ATOM	90	CG	ASN A 154	11.755	22.300	33.524	1.00	12.54	A
	ATOM	91	OD1	ASN A 154	12.534	21.373	33.284	1.00	13.50	A
5	ATOM	92	ND2	ASN A 154	11.262	23.084	32.568	1.00	11.08	A
	ATOM	93	C	ASN A 154	11.713	22.144	37.369	1.00	9.06	A
	ATOM	94	O	ASN A 154	12.723	22.629	37.870	1.00	7.54	A
	ATOM	95	N	SER A 155	10.539	22.093	37.997	1.00	10.29	A
	ATOM	96	CA	SER A 155	10.352	22.672	39.327	1.00	9.98	A
10	ATOM	97	CB	SER A 155	8.874	22.642	39.710	1.00	9.88	A
	ATOM	98	OG	SER A 155	8.513	21.362	40.193	1.00	11.38	A
	ATOM	99	C	SER A 155	11.159	22.002	40.435	1.00	10.21	A
	ATOM	100	O	SER A 155	11.381	22.601	41.483	1.00	9.99	A
	ATOM	101	N	ILE A 156	11.595	20.766	40.211	1.00	9.91	A
15	ATOM	102	CA	ILE A 156	12.364	20.047	41.219	1.00	9.61	A
	ATOM	103	CB	ILE A 156	12.462	18.546	40.861	1.00	8.85	A
	ATOM	104	CG2	ILE A 156	13.467	17.846	41.775	1.00	8.95	A
	ATOM	105	CG1	ILE A 156	11.070	17.898	40.980	1.00	8.39	A
	ATOM	106	CD1	ILE A 156	10.482	17.937	42.394	1.00	2.79	A
20	ATOM	107	C	ILE A 156	13.761	20.647	41.406	1.00	9.78	A
	ATOM	108	O	ILE A 156	14.466	20.922	40.439	1.00	9.93	A
	ATOM	109	N	TYR A 157	14.140	20.849	42.667	1.00	8.74	A
	ATOM	110	CA	TYR A 157	15.426	21.448	43.028	1.00	9.40	A
	ATOM	111	CB	TYR A 157	15.376	22.955	42.766	1.00	13.35	A
25	ATOM	112	CG	TYR A 157	16.677	23.689	43.009	1.00	14.09	A
	ATOM	113	CD1	TYR A 157	17.557	23.943	41.964	1.00	14.70	A
	ATOM	114	CE1	TYR A 157	18.757	24.621	42.182	1.00	15.23	A
	ATOM	115	CD2	TYR A 157	17.026	24.127	44.289	1.00	15.58	A
	ATOM	116	CE2	TYR A 157	18.222	24.802	44.520	1.00	14.41	A
30	ATOM	117	CZ	TYR A 157	19.080	25.047	43.465	1.00	15.28	A
	ATOM	118	OH	TYR A 157	20.258	25.725	43.687	1.00	14.42	A
	ATOM	119	C	TYR A 157	15.662	21.217	44.523	1.00	9.98	A
	ATOM	120	O	TYR A 157	14.727	21.322	45.318	1.00	8.35	A
	ATOM	121	N	CPR A 158	16.903	20.875	44.924	1.00	10.14	A
35	ATOM	122	CD	CPR A 158	17.241	20.924	46.358	1.00	8.97	A
	ATOM	123	CA	CPR A 158	18.121	20.678	44.124	1.00	11.99	A
	ATOM	124	CB	CPR A 158	19.218	21.139	45.071	1.00	10.42	A
	ATOM	125	CG	CPR A 158	18.726	20.604	46.372	1.00	10.37	A
	ATOM	126	C	CPR A 158	18.256	19.195	43.781	1.00	11.98	A
40	ATOM	127	O	CPR A 158	17.978	18.347	44.618	1.00	13.30	A
	ATOM	128	N	TRP A 159	18.695	18.879	42.569	1.00	13.37	A
	ATOM	129	CA	TRP A 159	18.816	17.481	42.177	1.00	14.62	A
	ATOM	130	CB	TRP A 159	19.273	17.364	40.716	1.00	13.17	A
	ATOM	131	CG	TRP A 159	19.038	16.001	40.141	1.00	12.86	A
45	ATOM	132	CD2	TRP A 159	17.773	15.328	40.002	1.00	12.49	A
	ATOM	133	CE2	TRP A 159	18.039	14.052	39.453	1.00	12.27	A
	ATOM	134	CE3	TRP A 159	16.447	15.680	40.286	1.00	12.37	A
	ATOM	135	CD1	TRP A 159	19.982	15.135	39.682	1.00	11.66	A
	ATOM	136	NE1	TRP A 159	19.391	13.960	39.269	1.00	10.69	A
50	ATOM	137	CZ2	TRP A 159	17.022	13.122	39.183	1.00	12.98	A
	ATOM	138	CZ3	TRP A 159	15.433	14.755	40.019	1.00	12.83	A
	ATOM	139	CH2	TRP A 159	15.731	13.490	39.471	1.00	12.43	A
	ATOM	140	C	TRP A 159	19.760	16.713	43.098	1.00	14.85	A
	ATOM	141	O	TRP A 159	19.552	15.530	43.352	1.00	16.17	A
55	ATOM	142	N	ASP A 160	20.789	17.388	43.603	1.00	15.74	A
	ATOM	143	CA	ASP A 160	21.748	16.761	44.514	1.00	17.53	A

51

	ATOM	144	CB	ASP	A	160	22.715	17.808	45.077	1.00	20.00	A
	ATOM	145	CG	ASP	A	160	23.797	18.194	44.090	1.00	25.18	A
	ATOM	146	OD1	ASP	A	160	24.384	19.282	44.269	1.00	28.54	A
	ATOM	147	OD2	ASP	A	160	24.071	17.414	43.148	1.00	25.23	A
5	ATOM	148	C	ASP	A	160	21.029	16.077	45.676	1.00	15.95	A
	ATOM	149	O	ASP	A	160	21.381	14.967	46.065	1.00	14.81	A
	ATOM	150	N	ALA	A	161	20.032	16.757	46.232	1.00	13.82	A
	ATOM	151	CA	ALA	A	161	19.265	16.213	47.342	1.00	13.97	A
	ATOM	152	CB	ALA	A	161	18.284	17.260	47.863	1.00	13.79	A
10	ATOM	153	C	ALA	A	161	18.513	14.963	46.897	1.00	13.98	A
	ATOM	154	O	ALA	A	161	18.370	14.005	47.660	1.00	13.02	A
	ATOM	155	N	VAL	A	162	18.033	14.973	45.658	1.00	14.83	A
	ATOM	156	CA	VAL	A	162	17.303	13.826	45.128	1.00	14.59	A
	ATOM	157	CB	VAL	A	162	16.614	14.190	43.794	1.00	15.34	A
15	ATOM	158	CG1	VAL	A	162	15.829	12.991	43.254	1.00	14.23	A
	ATOM	159	CG2	VAL	A	162	15.679	15.372	44.011	1.00	13.44	A
	ATOM	160	C	VAL	A	162	18.236	12.621	44.934	1.00	14.98	A
	ATOM	161	O	VAL	A	162	17.923	11.511	45.365	1.00	15.96	A
	ATOM	162	N	LYS	A	163	19.380	12.840	44.290	1.00	15.39	A
20	ATOM	163	CA	LYS	A	163	20.347	11.764	44.074	1.00	15.08	A
	ATOM	164	CB	LYS	A	163	21.593	12.289	43.358	1.00	18.00	A
	ATOM	165	CG	LYS	A	163	21.405	12.638	41.892	1.00	21.39	A
	ATOM	166	CD	LYS	A	163	22.710	13.194	41.333	1.00	24.66	A
	ATOM	167	CE	LYS	A	163	22.648	13.384	39.837	1.00	26.80	A
25	ATOM	168	NZ	LYS	A	163	23.850	14.103	39.348	1.00	29.83	A
	ATOM	169	C	LYS	A	163	20.781	11.158	45.409	1.00	14.49	A
	ATOM	170	O	LYS	A	163	20.870	9.936	45.553	1.00	11.86	A
	ATOM	171	N	ASN	A	164	21.067	12.020	46.380	1.00	13.30	A
	ATOM	172	CA	ASN	A	164	21.494	11.555	47.691	1.00	13.86	A
30	ATOM	173	CB	ASN	A	164	21.719	12.731	48.633	1.00	13.54	A
	ATOM	174	CG	ASN	A	164	22.110	12.286	50.018	1.00	13.56	A
	ATOM	175	OD1	ASN	A	164	21.273	12.193	50.918	1.00	12.49	A
	ATOM	176	ND2	ASN	A	164	23.386	11.985	50.195	1.00	13.32	A
	ATOM	177	C	ASN	A	164	20.462	10.618	48.296	1.00	14.39	A
35	ATOM	178	O	ASN	A	164	20.797	9.564	48.847	1.00	14.01	A
	ATOM	179	N	PHE	A	165	19.201	11.013	48.194	1.00	14.20	A
	ATOM	180	CA	PHE	A	165	18.123	10.202	48.721	1.00	13.04	A
	ATOM	181	CB	PHE	A	165	16.785	10.899	48.509	1.00	12.24	A
	ATOM	182	CG	PHE	A	165	15.613	10.061	48.911	1.00	11.89	A
40	ATOM	183	CD1	PHE	A	165	15.289	9.896	50.250	1.00	12.66	A
	ATOM	184	CD2	PHE	A	165	14.882	9.370	47.954	1.00	12.19	A
	ATOM	185	CE1	PHE	A	165	14.251	9.050	50.630	1.00	12.76	A
	ATOM	186	CE2	PHE	A	165	13.848	8.524	48.323	1.00	12.35	A
	ATOM	187	CZ	PHE	A	165	13.536	8.363	49.664	1.00	11.87	A
45	ATOM	188	C	PHE	A	165	18.093	8.835	48.036	1.00	13.02	A
	ATOM	189	O	PHE	A	165	18.173	7.808	48.695	1.00	14.50	A
	ATOM	190	N	LEU	A	166	17.975	8.834	46.711	1.00	13.00	A
	ATOM	191	CA	LEU	A	166	17.925	7.594	45.937	1.00	13.67	A
	ATOM	192	CB	LEU	A	166	18.004	7.911	44.445	1.00	12.12	A
50	ATOM	193	CG	LEU	A	166	16.904	8.863	43.968	1.00	12.57	A
	ATOM	194	CD1	LEU	A	166	17.103	9.207	42.508	1.00	9.74	A
	ATOM	195	CD2	LEU	A	166	15.552	8.217	44.203	1.00	11.27	A
	ATOM	196	C	LEU	A	166	19.077	6.681	46.319	1.00	14.74	A
	ATOM	197	O	LEU	A	166	18.899	5.488	46.561	1.00	15.55	A
55	ATOM	198	N	GLU	A	167	20.260	7.277	46.357	1.00	15.63	A
	ATOM	199	CA	GLU	A	167	21.496	6.606	46.700	1.00	17.13	A

52

	ATOM	200	CB	GLU A 167	22.623	7.637	46.626	1.00	20.43	A
	ATOM	201	CG	GLU A 167	24.034	7.105	46.610	1.00	25.09	A
	ATOM	202	CD	GLU A 167	24.977	8.066	45.899	1.00	28.66	A
	ATOM	203	OE1	GLU A 167	26.207	7.859	45.974	1.00	31.85	A
5	ATOM	204	OE2	GLU A 167	24.482	9.024	45.254	1.00	29.06	A
	ATOM	205	C	GLU A 167	21.410	5.993	48.095	1.00	16.74	A
	ATOM	206	O	GLU A 167	21.658	4.802	48.265	1.00	16.83	A
	ATOM	207	N	LYS A 168	21.053	6.814	49.084	1.00	16.30	A
	ATOM	208	CA	LYS A 168	20.936	6.373	50.480	1.00	15.74	A
10	ATOM	209	CB	LYS A 168	20.725	7.580	51.406	1.00	13.90	A
	ATOM	210	CG	LYS A 168	21.932	8.493	51.548	1.00	14.49	A
	ATOM	211	CD	LYS A 168	23.035	7.809	52.330	1.00	15.70	A
	ATOM	212	CE	LYS A 168	24.143	8.773	52.698	1.00	16.32	A
	ATOM	213	NZ	LYS A 168	24.818	9.345	51.512	1.00	14.90	A
15	ATOM	214	C	LYS A 168	19.795	5.379	50.698	1.00	15.80	A
	ATOM	215	O	LYS A 168	19.860	4.528	51.586	1.00	15.98	A
	ATOM	216	N	PHE A 169	18.744	5.506	49.897	1.00	15.19	A
	ATOM	217	CA	PHE A 169	17.602	4.615	50.011	1.00	15.65	A
	ATOM	218	CB	PHE A 169	16.452	5.097	49.112	1.00	12.98	A
20	ATOM	219	CG	PHE A 169	15.290	4.146	49.059	1.00	12.73	A
	ATOM	220	CD1	PHE A 169	14.530	3.892	50.192	1.00	12.13	A
	ATOM	221	CD2	PHE A 169	14.988	3.465	47.886	1.00	13.61	A
	ATOM	222	CE1	PHE A 169	13.485	2.971	50.158	1.00	14.03	A
	ATOM	223	CE2	PHE A 169	13.943	2.542	47.846	1.00	13.89	A
25	ATOM	224	CZ	PHE A 169	13.193	2.294	48.983	1.00	12.36	A
	ATOM	225	C	PHE A 169	18.022	3.198	49.618	1.00	16.17	A
	ATOM	226	O	PHE A 169	17.779	2.245	50.354	1.00	15.90	A
	ATOM	227	N	VAL A 170	18.664	3.066	48.462	1.00	17.23	A
	ATOM	228	CA	VAL A 170	19.112	1.762	47.984	1.00	18.56	A
30	ATOM	229	CB	VAL A 170	19.707	1.881	46.553	1.00	18.42	A
	ATOM	230	CG1	VAL A 170	20.408	0.591	46.154	1.00	17.54	A
	ATOM	231	CG2	VAL A 170	18.593	2.199	45.560	1.00	17.05	A
	ATOM	232	C	VAL A 170	20.148	1.132	48.926	1.00	20.05	A
	ATOM	233	O	VAL A 170	20.217	-0.090	49.058	1.00	20.58	A
35	ATOM	234	N	GLN A 171	20.942	1.971	49.584	1.00	21.43	A
	ATOM	235	CA	GLN A 171	21.973	1.504	50.511	1.00	22.80	A
	ATOM	236	CB	GLN A 171	22.786	2.697	51.034	1.00	25.64	A
	ATOM	237	CG	GLN A 171	24.255	2.721	50.617	1.00	27.27	A
	ATOM	238	CD	GLN A 171	25.057	1.580	51.214	1.00	29.69	A
40	ATOM	239	OE1	GLN A 171	25.020	1.346	52.423	1.00	31.25	A
	ATOM	240	NE2	GLN A 171	25.794	0.864	50.367	1.00	29.08	A
	ATOM	241	C	GLN A 171	21.389	0.736	51.698	1.00	22.06	A
	ATOM	242	O	GLN A 171	21.986	-0.227	52.182	1.00	19.91	A
	ATOM	243	N	GLY A 172	20.219	1.158	52.162	1.00	22.43	A
45	ATOM	244	CA	GLY A 172	19.604	0.498	53.301	1.00	21.98	A
	ATOM	245	C	GLY A 172	18.805	-0.749	52.975	1.00	22.83	A
	ATOM	246	O	GLY A 172	18.207	-1.361	53.862	1.00	21.01	A
	ATOM	247	N	LEU A 173	18.797	-1.141	51.706	1.00	22.94	A
	ATOM	248	CA	LEU A 173	18.041	-2.315	51.304	1.00	23.99	A
50	ATOM	249	CB	LEU A 173	17.292	-2.041	50.000	1.00	22.59	A
	ATOM	250	CG	LEU A 173	16.303	-0.875	49.986	1.00	21.28	A
	ATOM	251	CD1	LEU A 173	15.742	-0.728	48.580	1.00	21.16	A
	ATOM	252	CD2	LEU A 173	15.186	-1.109	51.000	1.00	17.99	A
	ATOM	253	C	LEU A 173	18.903	-3.555	51.132	1.00	25.00	A
55	ATOM	254	O	LEU A 173	20.073	-3.471	50.772	1.00	23.71	A
	ATOM	255	N	ASP A 174	18.303	-4.707	51.407	1.00	27.54	A

53

	ATOM	256	CA	ASP	A	174	18.973	-5.993	51.264	1.00	30.47	A
	ATOM	257	CB	ASP	A	174	18.435	-6.980	52.299	1.00	33.48	A
	ATOM	258	CG	ASP	A	174	19.424	-8.072	52.630	1.00	37.17	A
	ATOM	259	OD1	ASP	A	174	20.025	-8.635	51.691	1.00	38.86	A
5	ATOM	260	OD2	ASP	A	174	19.597	-8.372	53.831	1.00	38.36	A
	ATOM	261	C	ASP	A	174	18.590	-6.451	49.858	1.00	30.22	A
	ATOM	262	O	ASP	A	174	17.644	-7.216	49.677	1.00	29.33	A
	ATOM	263	N	ILE	A	175	19.328	-5.957	48.870	1.00	30.40	A
	ATOM	264	CA	ILE	A	175	19.066	-6.258	47.467	1.00	31.71	A
10	ATOM	265	CB	ILE	A	175	20.031	-5.453	46.570	1.00	31.30	A
	ATOM	266	CG2	ILE	A	175	19.507	-5.383	45.148	1.00	30.95	A
	ATOM	267	CG1	ILE	A	175	20.155	-4.027	47.112	1.00	31.50	A
	ATOM	268	CD1	ILE	A	175	18.828	-3.300	47.254	1.00	31.58	A
	ATOM	269	C	ILE	A	175	19.146	-7.747	47.123	1.00	32.27	A
15	ATOM	270	O	ILE	A	175	19.241	-8.594	48.009	1.00	33.75	A
	ATOM	271	N	GLY	A	176	19.089	-8.056	45.831	1.00	32.64	A
	ATOM	272	CA	GLY	A	176	19.143	-9.437	45.386	1.00	32.16	A
	ATOM	273	C	GLY	A	176	17.826	-9.910	44.790	1.00	31.98	A
	ATOM	274	O	GLY	A	176	16.761	-9.471	45.222	1.00	31.33	A
20	ATOM	275	N	PRO	A	177	17.866	-10.796	43.779	1.00	32.34	A
	ATOM	276	CD	PRO	A	177	19.062	-11.093	42.969	1.00	32.81	A
	ATOM	277	CA	PRO	A	177	16.664	-11.328	43.126	1.00	32.50	A
	ATOM	278	CB	PRO	A	177	17.237	-12.152	41.977	1.00	31.55	A
	ATOM	279	CG	PRO	A	177	18.462	-11.390	41.612	1.00	32.20	A
25	ATOM	280	C	PRO	A	177	15.762	-12.167	44.035	1.00	32.37	A
	ATOM	281	O	PRO	A	177	14.625	-12.478	43.673	1.00	33.30	A
	ATOM	282	N	THR	A	178	16.267	-12.536	45.209	1.00	32.01	A
	ATOM	283	CA	THR	A	178	15.493	-13.342	46.150	1.00	30.96	A
	ATOM	284	CB	THR	A	178	16.220	-14.650	46.484	1.00	30.93	A
30	ATOM	285	OG1	THR	A	178	17.517	-14.355	47.019	1.00	29.20	A
	ATOM	286	CG2	THR	A	178	16.363	-15.498	45.235	1.00	30.68	A
	ATOM	287	C	THR	A	178	15.213	-12.599	47.448	1.00	30.22	A
	ATOM	288	O	THR	A	178	14.569	-13.126	48.355	1.00	31.00	A
	ATOM	289	N	LYS	A	179	15.710	-11.372	47.536	1.00	28.83	A
35	ATOM	290	CA	LYS	A	179	15.500	-10.549	48.716	1.00	27.14	A
	ATOM	291	CB	LYS	A	179	16.849	-10.160	49.321	1.00	27.31	A
	ATOM	292	CG	LYS	A	179	17.589	-11.369	49.871	1.00	27.60	A
	ATOM	293	CD	LYS	A	179	18.955	-11.561	49.240	1.00	27.00	A
	ATOM	294	CE	LYS	A	179	20.026	-10.827	50.025	1.00	28.86	A
40	ATOM	295	NZ	LYS	A	179	21.395	-11.054	49.489	1.00	30.25	A
	ATOM	296	C	LYS	A	179	14.692	-9.331	48.287	1.00	25.60	A
	ATOM	297	O	LYS	A	179	13.507	-9.463	48.000	1.00	24.62	A
	ATOM	298	N	THR	A	180	15.314	-8.157	48.221	1.00	23.79	A
	ATOM	299	CA	THR	A	180	14.580	-6.966	47.795	1.00	22.88	A
45	ATOM	300	CB	THR	A	180	14.745	-5.798	48.790	1.00	22.04	A
	ATOM	301	OG1	THR	A	180	14.234	-6.182	50.070	1.00	23.16	A
	ATOM	302	CG2	THR	A	180	13.979	-4.576	48.304	1.00	20.65	A
	ATOM	303	C	THR	A	180	15.002	-6.473	46.414	1.00	21.26	A
	ATOM	304	O	THR	A	180	16.191	-6.322	46.130	1.00	21.51	A
50	ATOM	305	N	GLN	A	181	14.018	-6.225	45.558	1.00	20.39	A
	ATOM	306	CA	GLN	A	181	14.282	-5.722	44.215	1.00	19.27	A
	ATOM	307	CB	GLN	A	181	13.526	-6.552	43.173	1.00	19.23	A
	ATOM	308	CG	GLN	A	181	14.235	-7.832	42.766	1.00	21.63	A
	ATOM	309	CD	GLN	A	181	13.460	-8.635	41.738	1.00	22.21	A
55	ATOM	310	OE1	GLN	A	181	14.044	-9.370	40.946	1.00	25.69	A
	ATOM	311	NE2	GLN	A	181	12.139	-8.506	41.750	1.00	22.55	A

	ATOM	312	C	GLN	A	181	13.836	-4.262	44.150	1.00	18.57	A
	ATOM	313	O	GLN	A	181	12.885	-3.870	44.829	1.00	17.74	A
	ATOM	314	N	VAL	A	182	14.522	-3.466	43.333	1.00	17.44	A
	ATOM	315	CA	VAL	A	182	14.201	-2.048	43.194	1.00	15.50	A
5	ATOM	316	CB	VAL	A	182	15.244	-1.160	43.911	1.00	15.13	A
	ATOM	317	CG1	VAL	A	182	14.778	0.284	43.913	1.00	15.79	A
	ATOM	318	CG2	VAL	A	182	15.482	-1.649	45.322	1.00	16.85	A
	ATOM	319	C	VAL	A	182	14.149	-1.584	41.737	1.00	15.79	A
	ATOM	320	O	VAL	A	182	15.072	-1.831	40.961	1.00	13.82	A
10	ATOM	321	N	GLY	A	183	13.062	-0.910	41.375	1.00	14.94	A
	ATOM	322	CA	GLY	A	183	12.928	-0.375	40.032	1.00	14.95	A
	ATOM	323	C	GLY	A	183	12.910	1.139	40.170	1.00	14.43	A
	ATOM	324	O	GLY	A	183	12.498	1.646	41.211	1.00	14.17	A
	ATOM	325	N	LEU	A	184	13.355	1.870	39.150	1.00	13.48	A
15	ATOM	326	CA	LEU	A	184	13.367	3.331	39.227	1.00	12.24	A
	ATOM	327	CB	LEU	A	184	14.798	3.846	39.406	1.00	11.95	A
	ATOM	328	CG	LEU	A	184	15.071	5.230	40.027	1.00	14.19	A
	ATOM	329	CD1	LEU	A	184	16.134	5.930	39.198	1.00	14.35	A
	ATOM	330	CD2	LEU	A	184	13.816	6.088	40.098	1.00	13.28	A
20	ATOM	331	C	LEU	A	184	12.745	3.986	37.993	1.00	11.99	A
	ATOM	332	O	LEU	A	184	13.199	3.790	36.866	1.00	12.60	A
	ATOM	333	N	ILE	A	185	11.693	4.758	38.221	1.00	11.44	A
	ATOM	334	CA	ILE	A	185	10.998	5.473	37.158	1.00	11.08	A
	ATOM	335	CB	ILE	A	185	9.489	5.055	37.103	1.00	10.82	A
25	ATOM	336	CG2	ILE	A	185	8.675	6.068	36.323	1.00	10.02	A
	ATOM	337	CG1	ILE	A	185	9.331	3.686	36.430	1.00	12.56	A
	ATOM	338	CD1	ILE	A	185	10.111	2.547	37.081	1.00	12.60	A
	ATOM	339	C	ILE	A	185	11.125	6.968	37.473	1.00	11.40	A
	ATOM	340	O	ILE	A	185	11.068	7.363	38.634	1.00	11.46	A
30	ATOM	341	N	GLN	A	186	11.345	7.787	36.446	1.00	12.56	A
	ATOM	342	CA	GLN	A	186	11.438	9.236	36.623	1.00	11.76	A
	ATOM	343	CB	GLN	A	186	12.859	9.726	36.333	1.00	12.89	A
	ATOM	344	CG	GLN	A	186	13.867	9.145	37.316	1.00	14.23	A
	ATOM	345	CD	GLN	A	186	15.273	9.716	37.197	1.00	15.38	A
35	ATOM	346	OE1	GLN	A	186	16.206	9.170	37.771	1.00	15.74	A
	ATOM	347	NE2	GLN	A	186	15.426	10.819	36.466	1.00	17.29	A
	ATOM	348	C	GLN	A	186	10.397	9.886	35.701	1.00	10.97	A
	ATOM	349	O	GLN	A	186	10.150	9.404	34.593	1.00	9.90	A
	ATOM	350	N	TYR	A	187	9.785	10.973	36.158	1.00	9.31	A
40	ATOM	351	CA	TYR	A	187	8.718	11.603	35.383	1.00	8.51	A
	ATOM	352	CB	TYR	A	187	7.374	11.059	35.880	1.00	8.10	A
	ATOM	353	CG	TYR	A	187	6.958	11.613	37.238	1.00	6.73	A
	ATOM	354	CD1	TYR	A	187	6.284	12.833	37.339	1.00	6.75	A
	ATOM	355	CE1	TYR	A	187	5.938	13.373	38.579	1.00	6.68	A
45	ATOM	356	CD2	TYR	A	187	7.274	10.939	38.418	1.00	7.94	A
	ATOM	357	CE2	TYR	A	187	6.932	11.468	39.671	1.00	9.48	A
	ATOM	358	CZ	TYR	A	187	6.267	12.685	39.742	1.00	9.10	A
	ATOM	359	OH	TYR	A	187	5.930	13.210	40.974	1.00	12.69	A
	ATOM	360	C	TYR	A	187	8.622	13.126	35.348	1.00	7.79	A
50	ATOM	361	O	TYR	A	187	9.178	13.833	36.177	1.00	8.04	A
	ATOM	362	N	ALA	A	188	7.865	13.600	34.367	1.00	8.62	A
	ATOM	363	CA	ALA	A	188	7.580	15.011	34.155	1.00	9.11	A
	ATOM	364	CB	ALA	A	188	8.734	15.698	33.428	1.00	9.39	A
	ATOM	365	C	ALA	A	188	6.323	14.985	33.290	1.00	8.41	A
55	ATOM	366	O	ALA	A	188	5.259	14.580	33.760	1.00	7.15	A
	ATOM	367	N	ASN	A	189	6.434	15.386	32.027	1.00	9.04	A

55

	ATOM	368	CA	ASN	A	189	5.265	15.349	31.155	1.00	10.71	A
	ATOM	369	CB	ASN	A	189	5.574	15.979	29.785	1.00	11.19	A
	ATOM	370	CG	ASN	A	189	6.067	17.408	29.899	1.00	9.44	A
	ATOM	371	OD1	ASN	A	189	5.596	18.301	29.192	1.00	10.99	A
5	ATOM	372	ND2	ASN	A	189	7.024	17.631	30.783	1.00	7.94	A
	ATOM	373	C	ASN	A	189	4.870	13.886	30.978	1.00	10.65	A
	ATOM	374	O	ASN	A	189	3.688	13.550	30.898	1.00	10.97	A
	ATOM	375	N	ASN	A	190	5.877	13.020	30.957	1.00	11.36	A
	ATOM	376	CA	ASN	A	190	5.672	11.590	30.776	1.00	14.30	A
10	ATOM	377	CB	ASN	A	190	5.913	11.225	29.307	1.00	16.54	A
	ATOM	378	CG	ASN	A	190	5.100	12.079	28.357	1.00	17.94	A
	ATOM	379	OD1	ASN	A	190	3.880	11.970	28.302	1.00	22.49	A
	ATOM	380	ND2	ASN	A	190	5.773	12.945	27.611	1.00	20.09	A
	ATOM	381	C	ASN	A	190	6.626	10.785	31.661	1.00	14.69	A
15	ATOM	382	O	ASN	A	190	7.659	11.287	32.094	1.00	15.45	A
	ATOM	383	N	PRO	A	191	6.276	9.527	31.959	1.00	14.55	A
	ATOM	384	CD	PRO	A	191	4.934	8.922	31.852	1.00	15.09	A
	ATOM	385	CA	PRO	A	191	7.157	8.705	32.795	1.00	14.77	A
	ATOM	386	CB	PRO	A	191	6.179	7.780	33.506	1.00	15.27	A
20	ATOM	387	CG	PRO	A	191	5.153	7.532	32.434	1.00	14.75	A
	ATOM	388	C	PRO	A	191	8.167	7.927	31.944	1.00	14.27	A
	ATOM	389	O	PRO	A	191	7.879	7.576	30.800	1.00	12.84	A
	ATOM	390	N	ARG	A	192	9.347	7.675	32.502	1.00	14.02	A
	ATOM	391	CA	ARG	A	192	10.386	6.912	31.807	1.00	14.71	A
25	ATOM	392	CB	ARG	A	192	11.442	7.842	31.188	1.00	15.69	A
	ATOM	393	CG	ARG	A	192	12.396	8.499	32.178	1.00	17.79	A
	ATOM	394	CD	ARG	A	192	13.298	9.518	31.477	1.00	18.65	A
	ATOM	395	NE	ARG	A	192	14.250	10.148	32.393	1.00	18.93	A
	ATOM	396	CZ	ARG	A	192	15.453	9.663	32.684	1.00	17.67	A
30	ATOM	397	NH1	ARG	A	192	15.868	8.535	32.127	1.00	18.74	A
	ATOM	398	NH2	ARG	A	192	16.241	10.304	33.540	1.00	16.64	A
	ATOM	399	C	ARG	A	192	11.062	5.941	32.766	1.00	13.25	A
	ATOM	400	O	ARG	A	192	11.181	6.205	33.968	1.00	12.96	A
	ATOM	401	N	VAL	A	193	11.510	4.819	32.220	1.00	12.65	A
35	ATOM	402	CA	VAL	A	193	12.171	3.783	32.997	1.00	10.67	A
	ATOM	403	CB	VAL	A	193	11.864	2.386	32.410	1.00	10.91	A
	ATOM	404	CG1	VAL	A	193	12.505	1.298	33.264	1.00	11.42	A
	ATOM	405	CG2	VAL	A	193	10.364	2.178	32.321	1.00	11.64	A
	ATOM	406	C	VAL	A	193	13.690	3.961	33.025	1.00	11.35	A
40	ATOM	407	O	VAL	A	193	14.331	4.024	31.973	1.00	12.07	A
	ATOM	408	N	VAL	A	194	14.257	4.061	34.226	1.00	8.35	A
	ATOM	409	CA	VAL	A	194	15.706	4.177	34.378	1.00	8.60	A
	ATOM	410	CB	VAL	A	194	16.093	4.934	35.663	1.00	5.55	A
	ATOM	411	CG1	VAL	A	194	17.602	5.133	35.716	1.00	5.04	A
45	ATOM	412	CG2	VAL	A	194	15.393	6.268	35.697	1.00	2.79	A
	ATOM	413	C	VAL	A	194	16.179	2.724	34.467	1.00	8.86	A
	ATOM	414	O	VAL	A	194	17.158	2.331	33.839	1.00	10.78	A
	ATOM	415	N	PHE	A	195	15.465	1.931	35.257	1.00	11.00	A
	ATOM	416	CA	PHE	A	195	15.754	0.507	35.386	1.00	13.26	A
50	ATOM	417	CB	PHE	A	195	17.117	0.259	36.080	1.00	13.43	A
	ATOM	418	CG	PHE	A	195	17.210	0.742	37.510	1.00	14.88	A
	ATOM	419	CD1	PHE	A	195	16.588	0.049	38.543	1.00	16.46	A
	ATOM	420	CD2	PHE	A	195	17.997	1.844	37.831	1.00	15.15	A
	ATOM	421	CE1	PHE	A	195	16.756	0.443	39.875	1.00	16.97	A
55	ATOM	422	CE2	PHE	A	195	18.172	2.245	39.155	1.00	14.80	A
	ATOM	423	CZ	PHE	A	195	17.552	1.543	40.180	1.00	16.03	A

	ATOM	424	C	PHE	A	195	14.608	-0.180	36.109	1.00	13.40	A
	ATOM	425	O	PHE	A	195	13.945	0.435	36.938	1.00	14.78	A
	ATOM	426	N	ASN	A	196	14.333	-1.434	35.755	1.00	14.32	A
	ATOM	427	CA	ASN	A	196	13.245	-2.179	36.392	1.00	13.90	A
5	ATOM	428	CB	ASN	A	196	12.531	-3.082	35.378	1.00	15.25	A
	ATOM	429	CG	ASN	A	196	11.710	-2.302	34.371	1.00	17.15	A
	ATOM	430	OD1	ASN	A	196	11.128	-1.270	34.700	1.00	19.15	A
	ATOM	431	ND2	ASN	A	196	11.642	-2.805	33.137	1.00	16.10	A
	ATOM	432	C	ASN	A	196	13.737	-3.040	37.549	1.00	13.87	A
10	ATOM	433	O	ASN	A	196	14.926	-3.048	37.878	1.00	13.98	A
	ATOM	434	N	LEU	A	197	12.810	-3.765	38.162	1.00	13.49	A
	ATOM	435	CA	LEU	A	197	13.131	-4.655	39.275	1.00	14.75	A
	ATOM	436	CB	LEU	A	197	11.855	-5.361	39.768	1.00	12.51	A
	ATOM	437	CG	LEU	A	197	10.737	-4.523	40.416	1.00	13.99	A
15	ATOM	438	CD1	LEU	A	197	9.439	-5.328	40.476	1.00	13.87	A
	ATOM	439	CD2	LEU	A	197	11.162	-4.096	41.815	1.00	14.46	A
	ATOM	440	C	LEU	A	197	14.128	-5.696	38.776	1.00	15.08	A
	ATOM	441	O	LEU	A	197	14.957	-6.197	39.532	1.00	15.32	A
	ATOM	442	N	ASN	A	198	14.017	-5.983	37.482	1.00	17.33	A
20	ATOM	443	CA	ASN	A	198	14.813	-6.963	36.739	1.00	20.71	A
	ATOM	444	CB	ASN	A	198	14.026	-7.383	35.493	1.00	21.97	A
	ATOM	445	CG	ASN	A	198	13.523	-8.790	35.571	1.00	24.43	A
	ATOM	446	OD1	ASN	A	198	12.727	-9.226	34.735	1.00	24.41	A
	ATOM	447	ND2	ASN	A	198	13.986	-9.525	36.575	1.00	26.72	A
25	ATOM	448	C	ASN	A	198	16.200	-6.532	36.261	1.00	21.07	A
	ATOM	449	O	ASN	A	198	17.111	-7.353	36.151	1.00	20.61	A
	ATOM	450	N	THR	A	199	16.336	-5.252	35.947	1.00	22.19	A
	ATOM	451	CA	THR	A	199	17.572	-4.705	35.400	1.00	23.60	A
	ATOM	452	CB	THR	A	199	17.479	-3.182	35.299	1.00	22.21	A
30	ATOM	453	OG1	THR	A	199	16.295	-2.830	34.575	1.00	20.93	A
	ATOM	454	CG2	THR	A	199	18.696	-2.628	34.580	1.00	20.97	A
	ATOM	455	C	THR	A	199	18.902	-5.048	36.060	1.00	25.62	A
	ATOM	456	O	THR	A	199	19.775	-5.637	35.426	1.00	25.51	A
	ATOM	457	N	TYR	A	200	19.066	-4.678	37.323	1.00	28.07	A
35	ATOM	458	CA	TYR	A	200	20.326	-4.929	37.996	1.00	30.24	A
	ATOM	459	CB	TYR	A	200	20.790	-3.649	38.695	1.00	29.51	A
	ATOM	460	CG	TYR	A	200	21.093	-2.566	37.686	1.00	26.61	A
	ATOM	461	CD1	TYR	A	200	20.342	-1.393	37.638	1.00	25.36	A
	ATOM	462	CE1	TYR	A	200	20.563	-0.440	36.638	1.00	24.79	A
40	ATOM	463	CD2	TYR	A	200	22.078	-2.762	36.715	1.00	25.72	A
	ATOM	464	CE2	TYR	A	200	22.303	-1.823	35.715	1.00	25.09	A
	ATOM	465	CZ	TYR	A	200	21.543	-0.669	35.680	1.00	23.72	A
	ATOM	466	OH	TYR	A	200	21.755	0.238	34.671	1.00	24.44	A
	ATOM	467	C	TYR	A	200	20.385	-6.118	38.932	1.00	32.84	A
45	ATOM	468	O	TYR	A	200	19.412	-6.472	39.593	1.00	34.10	A
	ATOM	469	N	LYS	A	201	21.566	-6.724	38.964	1.00	35.33	A
	ATOM	470	CA	LYS	A	201	21.846	-7.911	39.752	1.00	37.85	A
	ATOM	471	CB	LYS	A	201	22.921	-8.736	39.041	1.00	38.62	A
	ATOM	472	CG	LYS	A	201	22.840	-8.683	37.511	1.00	40.89	A
50	ATOM	473	CD	LYS	A	201	23.303	-7.334	36.957	1.00	41.42	A
	ATOM	474	CE	LYS	A	201	23.243	-7.290	35.435	1.00	41.97	A
	ATOM	475	NZ	LYS	A	201	23.770	-5.999	34.902	1.00	40.92	A
	ATOM	476	C	LYS	A	201	22.297	-7.620	41.182	1.00	38.43	A
	ATOM	477	O	LYS	A	201	21.700	-8.111	42.141	1.00	38.87	A
55	ATOM	478	N	THR	A	202	23.353	-6.825	41.323	1.00	39.09	A
	ATOM	479	CA	THR	A	202	23.881	-6.506	42.643	1.00	39.33	A

	ATOM	480	CB	THR	A	202	25.406	-6.698	42.692	1.00	39.50	A
	ATOM	481	OG1	THR	A	202	26.042	-5.675	41.916	1.00	39.36	A
	ATOM	482	CG2	THR	A	202	25.787	-8.062	42.131	1.00	38.99	A
	ATOM	483	C	THR	A	202	23.576	-5.092	43.112	1.00	39.86	A
5	ATOM	484	O	THR	A	202	23.195	-4.222	42.328	1.00	40.54	A
	ATOM	485	N	LYS	A	203	23.766	-4.880	44.408	1.00	39.50	A
	ATOM	486	CA	LYS	A	203	23.531	-3.598	45.053	1.00	39.14	A
	ATOM	487	CB	LYS	A	203	23.718	-3.775	46.561	1.00	39.00	A
	ATOM	488	CG	LYS	A	203	23.223	-2.641	47.432	1.00	38.99	A
10	ATOM	489	CD	LYS	A	203	23.210	-3.101	48.881	1.00	38.85	A
	ATOM	490	CE	LYS	A	203	22.743	-2.017	49.823	1.00	38.65	A
	ATOM	491	NZ	LYS	A	203	22.657	-2.540	51.210	1.00	39.40	A
	ATOM	492	C	LYS	A	203	24.495	-2.540	44.516	1.00	39.51	A
	ATOM	493	O	LYS	A	203	24.171	-1.350	44.462	1.00	39.55	A
15	ATOM	494	N	GLU	A	204	25.681	-2.990	44.118	1.00	39.07	A
	ATOM	495	CA	GLU	A	204	26.715	-2.110	43.582	1.00	38.48	A
	ATOM	496	CB	GLU	A	204	28.023	-2.886	43.406	1.00	38.84	A
	ATOM	497	CG	GLU	A	204	27.969	-4.318	43.910	1.00	39.73	A
	ATOM	498	CD	GLU	A	204	27.896	-4.399	45.421	1.00	40.43	A
20	ATOM	499	OE1	GLU	A	204	27.004	-5.107	45.943	1.00	39.63	A
	ATOM	500	OE2	GLU	A	204	28.740	-3.756	46.085	1.00	41.63	A
	ATOM	501	C	GLU	A	204	26.295	-1.538	42.234	1.00	37.65	A
	ATOM	502	O	GLU	A	204	26.323	-0.326	42.019	1.00	37.61	A
	ATOM	503	N	GLU	A	205	25.917	-2.429	41.326	1.00	36.53	A
25	ATOM	504	CA	GLU	A	205	25.496	-2.043	39.989	1.00	36.06	A
	ATOM	505	CB	GLU	A	205	25.192	-3.298	39.176	1.00	37.10	A
	ATOM	506	CG	GLU	A	205	26.288	-4.343	39.278	1.00	39.86	A
	ATOM	507	CD	GLU	A	205	25.919	-5.646	38.607	1.00	41.30	A
	ATOM	508	OE1	GLU	A	205	25.768	-5.656	37.368	1.00	42.71	A
30	ATOM	509	OE2	GLU	A	205	25.778	-6.660	39.324	1.00	42.41	A
	ATOM	510	C	GLU	A	205	24.267	-1.144	40.046	1.00	34.97	A
	ATOM	511	O	GLU	A	205	23.984	-0.402	39.102	1.00	34.32	A
	ATOM	512	N	MET	A	206	23.542	-1.209	41.158	1.00	33.42	A
	ATOM	513	CA	MET	A	206	22.349	-0.396	41.333	1.00	32.37	A
35	ATOM	514	CB	MET	A	206	21.351	-1.094	42.260	1.00	32.31	A
	ATOM	515	CG	MET	A	206	20.103	-0.266	42.541	1.00	31.24	A
	ATOM	516	SD	MET	A	206	18.839	-1.174	43.439	1.00	31.05	A
	ATOM	517	CE	MET	A	206	18.222	-2.247	42.128	1.00	30.66	A
	ATOM	518	C	MET	A	206	22.694	0.978	41.891	1.00	32.05	A
40	ATOM	519	O	MET	A	206	22.024	1.960	41.576	1.00	32.40	A
	ATOM	520	N	ILE	A	207	23.726	1.044	42.730	1.00	31.87	A
	ATOM	521	CA	ILE	A	207	24.159	2.317	43.307	1.00	31.74	A
	ATOM	522	CB	ILE	A	207	25.070	2.111	44.543	1.00	33.09	A
	ATOM	523	CG2	ILE	A	207	25.792	3.411	44.893	1.00	32.55	A
45	ATOM	524	CG1	ILE	A	207	24.226	1.642	45.730	1.00	33.77	A
	ATOM	525	CD1	ILE	A	207	23.174	2.655	46.162	1.00	34.33	A
	ATOM	526	C	ILE	A	207	24.926	3.092	42.248	1.00	30.68	A
	ATOM	527	O	ILE	A	207	24.890	4.325	42.210	1.00	29.86	A
	ATOM	528	N	VAL	A	208	25.623	2.355	41.391	1.00	30.42	A
50	ATOM	529	CA	VAL	A	208	26.381	2.964	40.311	1.00	31.48	A
	ATOM	530	CB	VAL	A	208	27.281	1.918	39.612	1.00	31.48	A
	ATOM	531	CG1	VAL	A	208	27.992	2.544	38.432	1.00	32.42	A
	ATOM	532	CG2	VAL	A	208	28.301	1.369	40.602	1.00	31.32	A
	ATOM	533	C	VAL	A	208	25.383	3.547	39.305	1.00	32.02	A
55	ATOM	534	O	VAL	A	208	25.626	4.595	38.706	1.00	33.11	A
	ATOM	535	N	ALA	A	209	24.253	2.869	39.135	1.00	32.28	A

58

	ATOM	536	CA	ALA	A	209	23.223	3.329	38.211	1.00	32.70	A
	ATOM	537	CB	ALA	A	209	22.272	2.191	37.880	1.00	32.73	A
	ATOM	538	C	ALA	A	209	22.451	4.496	38.813	1.00	32.58	A
	ATOM	539	O	ALA	A	209	21.990	5.384	38.095	1.00	33.82	A
5	ATOM	540	N	THR	A	210	22.321	4.488	40.136	1.00	32.14	A
	ATOM	541	CA	THR	A	210	21.607	5.535	40.855	1.00	32.31	A
	ATOM	542	CB	THR	A	210	21.264	5.069	42.302	1.00	33.35	A
	ATOM	543	OG1	THR	A	210	20.037	4.328	42.288	1.00	33.29	A
	ATOM	544	CG2	THR	A	210	21.126	6.255	43.243	1.00	33.92	A
10	ATOM	545	C	THR	A	210	22.400	6.839	40.916	1.00	32.17	A
	ATOM	546	O	THR	A	210	21.841	7.925	40.749	1.00	32.64	A
	ATOM	547	N	SER	A	211	23.702	6.730	41.153	1.00	30.78	A
	ATOM	548	CA	SER	A	211	24.557	7.908	41.247	1.00	29.00	A
	ATOM	549	CB	SER	A	211	25.908	7.527	41.856	1.00	28.21	A
15	ATOM	550	OG	SER	A	211	26.634	6.686	40.979	1.00	27.75	A
	ATOM	551	C	SER	A	211	24.784	8.578	39.896	1.00	27.56	A
	ATOM	552	O	SER	A	211	25.278	9.697	39.833	1.00	27.13	A
	ATOM	553	N	GLN	A	212	24.431	7.892	38.815	1.00	28.19	A
	ATOM	554	CA	GLN	A	212	24.613	8.452	37.479	1.00	27.49	A
20	ATOM	555	CB	GLN	A	212	25.237	7.412	36.544	1.00	30.62	A
	ATOM	556	CG	GLN	A	212	26.642	6.967	36.924	1.00	34.70	A
	ATOM	557	CD	GLN	A	212	27.162	5.863	36.023	1.00	36.58	A
	ATOM	558	OE1	GLN	A	212	27.340	6.057	34.821	1.00	38.55	A
	ATOM	559	NE2	GLN	A	212	27.402	4.694	36.599	1.00	38.36	A
25	ATOM	560	C	GLN	A	212	23.318	8.954	36.849	1.00	25.98	A
	ATOM	561	O	GLN	A	212	23.321	9.377	35.692	1.00	26.21	A
	ATOM	562	N	THR	A	213	22.210	8.910	37.589	1.00	23.91	A
	ATOM	563	CA	THR	A	213	20.937	9.365	37.023	1.00	21.37	A
	ATOM	564	CB	THR	A	213	19.722	8.884	37.870	1.00	22.04	A
30	ATOM	565	OG1	THR	A	213	18.516	9.079	37.118	1.00	20.11	A
	ATOM	566	CG2	THR	A	213	19.618	9.662	39.185	1.00	20.81	A
	ATOM	567	C	THR	A	213	20.908	10.889	36.884	1.00	19.19	A
	ATOM	568	O	THR	A	213	21.407	11.608	37.746	1.00	19.45	A
	ATOM	569	N	SER	A	214	20.330	11.371	35.789	1.00	17.46	A
35	ATOM	570	CA	SER	A	214	20.249	12.809	35.516	1.00	15.88	A
	ATOM	571	CB	SER	A	214	20.904	13.102	34.170	1.00	17.30	A
	ATOM	572	OG	SER	A	214	20.408	12.205	33.192	1.00	17.87	A
	ATOM	573	C	SER	A	214	18.816	13.343	35.500	1.00	13.83	A
	ATOM	574	O	SER	A	214	17.867	12.577	35.390	1.00	13.38	A
40	ATOM	575	N	GLN	A	215	18.669	14.662	35.604	1.00	13.31	A
	ATOM	576	CA	GLN	A	215	17.346	15.291	35.599	1.00	11.72	A
	ATOM	577	CB	GLN	A	215	17.325	16.517	36.523	1.00	8.11	A
	ATOM	578	CG	GLN	A	215	15.926	17.142	36.665	1.00	8.56	A
	ATOM	579	CD	GLN	A	215	15.882	18.365	37.572	1.00	8.42	A
45	ATOM	580	OE1	GLN	A	215	14.814	18.935	37.815	1.00	7.13	A
	ATOM	581	NE2	GLN	A	215	17.041	18.775	38.076	1.00	10.20	A
	ATOM	582	C	GLN	A	215	16.951	15.720	34.186	1.00	12.51	A
	ATOM	583	O	GLN	A	215	17.490	16.687	33.658	1.00	11.99	A
	ATOM	584	N	TYR	A	216	16.015	15.008	33.569	1.00	13.04	A
50	ATOM	585	CA	TYR	A	216	15.602	15.363	32.216	1.00	14.05	A
	ATOM	586	CB	TYR	A	216	14.882	14.195	31.536	1.00	15.39	A
	ATOM	587	CG	TYR	A	216	15.804	13.142	30.955	1.00	18.06	A
	ATOM	588	CD1	TYR	A	216	15.354	12.272	29.966	1.00	19.67	A
	ATOM	589	CE1	TYR	A	216	16.192	11.298	29.423	1.00	21.91	A
55	ATOM	590	CD2	TYR	A	216	17.124	13.013	31.392	1.00	19.95	A
	ATOM	591	CE2	TYR	A	216	17.967	12.047	30.859	1.00	20.95	A

	ATOM	592	CZ	TYR	A	216	17.493	11.192	29.874	1.00	22.84	A
	ATOM	593	OH	TYR	A	216	18.318	10.228	29.341	1.00	26.01	A
	ATOM	594	C	TYR	A	216	14.731	16.612	32.113	1.00	14.20	A
	ATOM	595	O	TYR	A	216	14.634	17.202	31.042	1.00	13.97	A
5	ATOM	596	N	GLY	A	217	14.098	17.017	33.211	1.00	13.36	A
	ATOM	597	CA	GLY	A	217	13.253	18.201	33.167	1.00	12.97	A
	ATOM	598	C	GLY	A	217	11.888	17.993	32.527	1.00	12.66	A
	ATOM	599	O	GLY	A	217	11.501	16.870	32.222	1.00	12.59	A
	ATOM	600	N	GLY	A	218	11.155	19.087	32.330	1.00	12.62	A
10	ATOM	601	CA	GLY	A	218	9.830	19.012	31.737	1.00	12.30	A
	ATOM	602	C	GLY	A	218	8.964	20.163	32.223	1.00	12.00	A
	ATOM	603	O	GLY	A	218	9.017	20.515	33.402	1.00	12.24	A
	ATOM	604	N	ASP	A	219	8.164	20.749	31.332	1.00	11.18	A
	ATOM	605	CA	ASP	A	219	7.321	21.878	31.709	1.00	10.02	A
15	ATOM	606	CB	ASP	A	219	7.130	22.830	30.516	1.00	11.41	A
	ATOM	607	CG	ASP	A	219	6.441	22.173	29.324	1.00	12.87	A
	ATOM	608	OD1	ASP	A	219	6.287	22.858	28.292	1.00	14.29	A
	ATOM	609	OD2	ASP	A	219	6.053	20.992	29.406	1.00	12.54	A
	ATOM	610	C	ASP	A	219	5.971	21.502	32.312	1.00	9.50	A
20	ATOM	611	O	ASP	A	219	5.110	22.362	32.522	1.00	7.36	A
	ATOM	612	N	LEU	A	220	5.795	20.212	32.587	1.00	9.79	A
	ATOM	613	CA	LEU	A	220	4.571	19.696	33.199	1.00	9.49	A
	ATOM	614	CB	LEU	A	220	3.662	19.065	32.148	1.00	9.54	A
	ATOM	615	CG	LEU	A	220	2.915	19.975	31.180	1.00	11.66	A
25	ATOM	616	CD1	LEU	A	220	2.134	19.116	30.186	1.00	9.54	A
	ATOM	617	CD2	LEU	A	220	1.985	20.892	31.970	1.00	9.87	A
	ATOM	618	C	LEU	A	220	4.951	18.629	34.218	1.00	9.13	A
	ATOM	619	O	LEU	A	220	5.960	17.957	34.050	1.00	8.03	A
	ATOM	620	N	THR	A	221	4.142	18.475	35.265	1.00	9.46	A
30	ATOM	621	CA	THR	A	221	4.398	17.468	36.301	1.00	8.93	A
	ATOM	622	CB	THR	A	221	4.666	18.134	37.666	1.00	8.64	A
	ATOM	623	OG1	THR	A	221	5.695	19.117	37.506	1.00	9.50	A
	ATOM	624	CG2	THR	A	221	5.119	17.105	38.702	1.00	7.39	A
	ATOM	625	C	THR	A	221	3.177	16.559	36.404	1.00	8.53	A
35	ATOM	626	O	THR	A	221	2.223	16.841	37.135	1.00	8.33	A
	ATOM	627	N	ASN	A	222	3.198	15.472	35.647	1.00	8.72	A
	ATOM	628	CA	ASN	A	222	2.086	14.536	35.654	1.00	10.94	A
	ATOM	629	CB	ASN	A	222	1.851	14.007	34.235	1.00	10.58	A
	ATOM	630	CG	ASN	A	222	1.276	15.072	33.302	1.00	9.81	A
40	ATOM	631	OD1	ASN	A	222	1.610	15.132	32.116	1.00	11.30	A
	ATOM	632	ND2	ASN	A	222	0.401	15.907	33.835	1.00	8.55	A
	ATOM	633	C	ASN	A	222	2.364	13.399	36.631	1.00	11.86	A
	ATOM	634	O	ASN	A	222	2.607	12.261	36.236	1.00	13.30	A
	ATOM	635	N	THR	A	223	2.319	13.733	37.916	1.00	12.19	A
45	ATOM	636	CA	THR	A	223	2.575	12.783	38.993	1.00	12.73	A
	ATOM	637	CB	THR	A	223	2.471	13.486	40.370	1.00	13.31	A
	ATOM	638	OG1	THR	A	223	3.541	14.429	40.506	1.00	12.62	A
	ATOM	639	CG2	THR	A	223	2.537	12.470	41.508	1.00	12.94	A
	ATOM	640	C	THR	A	223	1.661	11.563	39.004	1.00	13.25	A
50	ATOM	641	O	THR	A	223	2.132	10.427	39.102	1.00	14.41	A
	ATOM	642	N	PHE	A	224	0.356	11.788	38.904	1.00	11.80	A
	ATOM	643	CA	PHE	A	224	-0.579	10.674	38.939	1.00	10.73	A
	ATOM	644	CB	PHE	A	224	-1.961	11.199	39.308	1.00	10.15	A
	ATOM	645	CG	PHE	A	224	-1.977	11.869	40.644	1.00	8.46	A
55	ATOM	646	CD1	PHE	A	224	-1.826	13.249	40.750	1.00	6.48	A
	ATOM	647	CD2	PHE	A	224	-2.000	11.104	41.811	1.00	8.25	A

60

	ATOM	648	CE1	PHE	A	224	-1.688	13.857	41.995	1.00	4.99	A
	ATOM	649	CE2	PHE	A	224	-1.863	11.704	43.058	1.00	8.12	A
	ATOM	650	CZ	PHE	A	224	-1.704	13.090	43.148	1.00	5.58	A
	ATOM	651	C	PHE	A	224	-0.582	9.820	37.678	1.00	10.20	A
5	ATOM	652	O	PHE	A	224	-0.927	8.639	37.718	1.00	9.26	A
	ATOM	653	N	GLY	A	225	-0.167	10.406	36.563	1.00	10.24	A
	ATOM	654	CA	GLY	A	225	-0.079	9.633	35.341	1.00	9.66	A
	ATOM	655	C	GLY	A	225	1.059	8.643	35.535	1.00	10.12	A
	ATOM	656	O	GLY	A	225	0.958	7.479	35.143	1.00	10.28	A
10	ATOM	657	N	ALA	A	226	2.143	9.107	36.159	1.00	9.46	A
	ATOM	658	CA	ALA	A	226	3.312	8.263	36.426	1.00	8.28	A
	ATOM	659	CB	ALA	A	226	4.473	9.119	36.924	1.00	7.03	A
	ATOM	660	C	ALA	A	226	3.004	7.169	37.447	1.00	9.17	A
	ATOM	661	O	ALA	A	226	3.409	6.013	37.281	1.00	10.19	A
15	ATOM	662	N	ILE	A	227	2.309	7.541	38.516	1.00	9.78	A
	ATOM	663	CA	ILE	A	227	1.941	6.584	39.550	1.00	9.72	A
	ATOM	664	CB	ILE	A	227	1.149	7.271	40.688	1.00	10.17	A
	ATOM	665	CG2	ILE	A	227	0.449	6.220	41.559	1.00	8.49	A
	ATOM	666	CG1	ILE	A	227	2.102	8.141	41.520	1.00	5.96	A
20	ATOM	667	CD1	ILE	A	227	1.422	8.912	42.637	1.00	4.20	A
	ATOM	668	C	ILE	A	227	1.086	5.510	38.901	1.00	10.73	A
	ATOM	669	O	ILE	A	227	1.295	4.316	39.119	1.00	9.03	A
	ATOM	670	N	GLN	A	228	0.141	5.952	38.077	1.00	13.02	A
	ATOM	671	CA	GLN	A	228	-0.755	5.054	37.361	1.00	15.61	A
25	ATOM	672	CB	GLN	A	228	-1.747	5.880	36.528	1.00	20.26	A
	ATOM	673	CG	GLN	A	228	-2.777	5.082	35.738	1.00	22.92	A
	ATOM	674	CD	GLN	A	228	-3.870	5.971	35.157	1.00	26.27	A
	ATOM	675	OE1	GLN	A	228	-4.806	6.365	35.853	1.00	26.95	A
	ATOM	676	NE2	GLN	A	228	-3.745	6.304	33.879	1.00	28.79	A
30	ATOM	677	C	GLN	A	228	0.046	4.106	36.472	1.00	15.48	A
	ATOM	678	O	GLN	A	228	-0.303	2.940	36.338	1.00	14.93	A
	ATOM	679	N	TYR	A	229	1.130	4.606	35.883	1.00	17.26	A
	ATOM	680	CA	TYR	A	229	1.979	3.794	35.016	1.00	17.37	A
	ATOM	681	CB	TYR	A	229	2.998	4.667	34.274	1.00	20.45	A
35	ATOM	682	CG	TYR	A	229	4.128	3.858	33.669	1.00	21.99	A
	ATOM	683	CD1	TYR	A	229	3.983	3.231	32.430	1.00	23.54	A
	ATOM	684	CE1	TYR	A	229	4.985	2.394	31.923	1.00	23.85	A
	ATOM	685	CD2	TYR	A	229	5.306	3.637	34.385	1.00	24.04	A
	ATOM	686	CE2	TYR	A	229	6.311	2.803	33.891	1.00	24.50	A
40	ATOM	687	CZ	TYR	A	229	6.146	2.183	32.662	1.00	25.44	A
	ATOM	688	OH	TYR	A	229	7.140	1.345	32.189	1.00	25.30	A
	ATOM	689	C	TYR	A	229	2.734	2.732	35.810	1.00	16.60	A
	ATOM	690	O	TYR	A	229	2.780	1.565	35.417	1.00	15.96	A
	ATOM	691	N	ALA	A	230	3.338	3.148	36.918	1.00	14.62	A
45	ATOM	692	CA	ALA	A	230	4.101	2.235	37.760	1.00	14.49	A
	ATOM	693	CB	ALA	A	230	4.723	2.993	38.917	1.00	11.62	A
	ATOM	694	C	ALA	A	230	3.211	1.109	38.281	1.00	14.68	A
	ATOM	695	O	ALA	A	230	3.644	-0.039	38.384	1.00	14.61	A
	ATOM	696	N	ARG	A	231	1.968	1.449	38.606	1.00	14.64	A
50	ATOM	697	CA	ARG	A	231	1.001	0.475	39.099	1.00	16.45	A
	ATOM	698	CB	ARG	A	231	-0.317	1.174	39.469	1.00	18.66	A
	ATOM	699	CG	ARG	A	231	-1.423	0.214	39.908	1.00	22.57	A
	ATOM	700	CD	ARG	A	231	-2.787	0.889	40.034	1.00	24.72	A
	ATOM	701	NE	ARG	A	231	-3.701	0.479	38.968	1.00	27.48	A
55	ATOM	702	CZ	ARG	A	231	-3.796	1.080	37.786	1.00	29.16	A
	ATOM	703	NH1	ARG	A	231	-3.039	2.134	37.506	1.00	31.61	A

61

	ATOM	704	NH2	ARG	A	231	-4.639	0.618	36.875	1.00	28.80	A
	ATOM	705	C	ARG	A	231	0.720	-0.574	38.027	1.00	16.48	A
	ATOM	706	O	ARG	A	231	0.720	-1.778	38.295	1.00	16.36	A
	ATOM	707	N	LYS	A	232	0.491	-0.092	36.809	1.00	16.71	A
5	ATOM	708	CA	LYS	A	232	0.172	-0.929	35.663	1.00	17.22	A
	ATOM	709	CB	LYS	A	232	-0.400	-0.064	34.536	1.00	19.84	A
	ATOM	710	CG	LYS	A	232	-1.869	-0.315	34.226	1.00	22.04	A
	ATOM	711	CD	LYS	A	232	-2.329	0.535	33.048	1.00	24.75	A
	ATOM	712	CE	LYS	A	232	-3.755	0.200	32.631	1.00	25.02	A
10	ATOM	713	NZ	LYS	A	232	-4.201	1.048	31.488	1.00	25.38	A
	ATOM	714	C	LYS	A	232	1.293	-1.784	35.087	1.00	17.72	A
	ATOM	715	O	LYS	A	232	1.034	-2.900	34.635	1.00	17.20	A
	ATOM	716	N	TYR	A	233	2.528	-1.282	35.101	1.00	17.41	A
	ATOM	717	CA	TYR	A	233	3.649	-2.024	34.512	1.00	15.33	A
15	ATOM	718	CB	TYR	A	233	4.139	-1.307	33.244	1.00	16.24	A
	ATOM	719	CG	TYR	A	233	3.065	-1.019	32.218	1.00	16.40	A
	ATOM	720	CD1	TYR	A	233	2.234	0.091	32.342	1.00	16.16	A
	ATOM	721	CE1	TYR	A	233	1.233	0.355	31.404	1.00	16.64	A
	ATOM	722	CD2	TYR	A	233	2.873	-1.867	31.129	1.00	17.49	A
20	ATOM	723	CE2	TYR	A	233	1.879	-1.616	30.185	1.00	18.11	A
	ATOM	724	CZ	TYR	A	233	1.062	-0.502	30.329	1.00	17.98	A
	ATOM	725	OH	TYR	A	233	0.083	-0.252	29.395	1.00	18.24	A
	ATOM	726	C	TYR	A	233	4.879	-2.300	35.377	1.00	14.96	A
	ATOM	727	O	TYR	A	233	5.531	-3.329	35.212	1.00	13.87	A
25	ATOM	728	N	ALA	A	234	5.213	-1.380	36.275	1.00	14.34	A
	ATOM	729	CA	ALA	A	234	6.407	-1.524	37.105	1.00	12.68	A
	ATOM	730	CB	ALA	A	234	6.546	-0.319	38.020	1.00	14.11	A
	ATOM	731	C	ALA	A	234	6.524	-2.815	37.914	1.00	12.51	A
	ATOM	732	O	ALA	A	234	7.635	-3.227	38.264	1.00	10.34	A
30	ATOM	733	N	TYR	A	235	5.392	-3.448	38.211	1.00	13.05	A
	ATOM	734	CA	TYR	A	235	5.388	-4.697	38.976	1.00	13.59	A
	ATOM	735	CB	TYR	A	235	4.434	-4.600	40.176	1.00	12.71	A
	ATOM	736	CG	TYR	A	235	4.647	-3.390	41.068	1.00	11.29	A
	ATOM	737	CD1	TYR	A	235	4.002	-2.179	40.800	1.00	8.56	A
35	ATOM	738	CE1	TYR	A	235	4.206	-1.055	41.605	1.00	8.57	A
	ATOM	739	CD2	TYR	A	235	5.508	-3.454	42.172	1.00	9.88	A
	ATOM	740	CE2	TYR	A	235	5.721	-2.337	42.985	1.00	9.49	A
	ATOM	741	CZ	TYR	A	235	5.067	-1.137	42.697	1.00	9.85	A
	ATOM	742	OH	TYR	A	235	5.276	-0.031	43.504	1.00	6.17	A
40	ATOM	743	C	TYR	A	235	4.976	-5.899	38.120	1.00	14.95	A
	ATOM	744	O	TYR	A	235	4.813	-7.005	38.633	1.00	14.95	A
	ATOM	745	N	SER	A	236	4.803	-5.688	36.819	1.00	15.83	A
	ATOM	746	CA	SER	A	236	4.406	-6.780	35.937	1.00	16.58	A
	ATOM	747	CB	SER	A	236	4.101	-6.248	34.537	1.00	15.85	A
45	ATOM	748	OG	SER	A	236	5.278	-5.798	33.897	1.00	15.96	A
	ATOM	749	C	SER	A	236	5.499	-7.843	35.854	1.00	18.03	A
	ATOM	750	O	SER	A	236	6.672	-7.570	36.110	1.00	18.46	A
	ATOM	751	N	ALA	A	237	5.114	-9.063	35.502	1.00	19.89	A
	ATOM	752	CA	ALA	A	237	6.090	-10.138	35.394	1.00	20.13	A
50	ATOM	753	CB	ALA	A	237	5.401	-11.426	34.961	1.00	21.77	A
	ATOM	754	C	ALA	A	237	7.192	-9.759	34.399	1.00	19.78	A
	ATOM	755	O	ALA	A	237	8.356	-10.100	34.598	1.00	20.26	A
	ATOM	756	N	ALA	A	238	6.827	-9.045	33.337	1.00	19.06	A
	ATOM	757	CA	ALA	A	238	7.804	-8.627	32.331	1.00	18.56	A
55	ATOM	758	CB	ALA	A	238	7.097	-7.926	31.173	1.00	19.27	A
	ATOM	759	C	ALA	A	238	8.887	-7.709	32.913	1.00	18.35	A

62

	ATOM	760	O	ALA	A	238	10.042	-7.760	32.487	1.00	16.90	A
	ATOM	761	N	SER	A	239	8.514	-6.875	33.885	1.00	17.63	A
	ATOM	762	CA	SER	A	239	9.465	-5.954	34.514	1.00	16.36	A
	ATOM	763	CB	SER	A	239	8.742	-4.711	35.040	1.00	16.10	A
5	ATOM	764	OG	SER	A	239	8.150	-3.987	33.978	1.00	13.99	A
	ATOM	765	C	SER	A	239	10.257	-6.594	35.654	1.00	16.21	A
	ATOM	766	O	SER	A	239	11.139	-5.960	36.233	1.00	14.92	A
	ATOM	767	N	GLY	A	240	9.939	-7.847	35.971	1.00	17.34	A
	ATOM	768	CA	GLY	A	240	10.641	-8.549	37.034	1.00	19.06	A
10	ATOM	769	C	GLY	A	240	9.887	-8.734	38.343	1.00	19.17	A
	ATOM	770	O	GLY	A	240	10.481	-9.135	39.349	1.00	18.10	A
	ATOM	771	N	GLY	A	241	8.587	-8.447	38.336	1.00	19.87	A
	ATOM	772	CA	GLY	A	241	7.785	-8.589	39.544	1.00	21.03	A
	ATOM	773	C	GLY	A	241	7.571	-10.037	39.955	1.00	23.23	A
15	ATOM	774	O	GLY	A	241	7.305	-10.891	39.101	1.00	20.87	A
	ATOM	775	N	ARG	A	242	7.683	-10.313	41.258	1.00	23.63	A
	ATOM	776	CA	ARG	A	242	7.516	-11.667	41.781	1.00	25.27	A
	ATOM	777	CB	ARG	A	242	8.598	-11.984	42.824	1.00	25.03	A
	ATOM	778	CG	ARG	A	242	10.024	-11.754	42.341	1.00	24.85	A
20	ATOM	779	CD	ARG	A	242	10.718	-10.684	43.178	1.00	26.43	A
	ATOM	780	NE	ARG	A	242	11.165	-11.200	44.466	1.00	27.59	A
	ATOM	781	CZ	ARG	A	242	11.636	-10.450	45.457	1.00	28.68	A
	ATOM	782	NH1	ARG	A	242	11.724	-9.134	45.325	1.00	28.64	A
	ATOM	783	NH2	ARG	A	242	12.028	-11.021	46.583	1.00	30.13	A
25	ATOM	784	C	ARG	A	242	6.132	-11.897	42.387	1.00	26.63	A
	ATOM	785	O	ARG	A	242	5.470	-10.967	42.853	1.00	25.37	A
	ATOM	786	N	ARG	A	243	5.720	-13.160	42.383	1.00	28.15	A
	ATOM	787	CA	ARG	A	243	4.415	-13.586	42.881	1.00	31.23	A
	ATOM	788	CB	ARG	A	243	4.268	-15.095	42.676	1.00	32.92	A
30	ATOM	789	CG	ARG	A	243	5.308	-15.917	43.430	1.00	36.39	A
	ATOM	790	CD	ARG	A	243	4.923	-17.386	43.486	1.00	38.87	A
	ATOM	791	NE	ARG	A	243	4.656	-17.908	42.151	1.00	42.37	A
	ATOM	792	CZ	ARG	A	243	5.564	-17.979	41.183	1.00	43.39	A
	ATOM	793	NH1	ARG	A	243	6.807	-17.568	41.399	1.00	43.57	A
35	ATOM	794	NH2	ARG	A	243	5.226	-18.454	39.995	1.00	44.19	A
	ATOM	795	C	ARG	A	243	4.083	-13.271	44.337	1.00	31.11	A
	ATOM	796	O	ARG	A	243	3.090	-12.608	44.634	1.00	31.87	A
	ATOM	797	N	SER	A	244	4.915	-13.768	45.240	1.00	32.34	A
	ATOM	798	CA	SER	A	244	4.706	-13.605	46.671	1.00	33.36	A
40	ATOM	799	CB	SER	A	244	5.399	-14.751	47.400	1.00	34.95	A
	ATOM	800	OG	SER	A	244	6.798	-14.710	47.156	1.00	37.15	A
	ATOM	801	C	SER	A	244	5.173	-12.290	47.286	1.00	32.42	A
	ATOM	802	O	SER	A	244	4.932	-12.045	48.472	1.00	34.13	A
	ATOM	803	N	ALA	A	245	5.830	-11.449	46.495	1.00	30.06	A
45	ATOM	804	CA	ALA	A	245	6.360	-10.184	46.995	1.00	27.25	A
	ATOM	805	CB	ALA	A	245	7.360	-9.617	45.989	1.00	26.52	A
	ATOM	806	C	ALA	A	245	5.334	-9.111	47.359	1.00	25.79	A
	ATOM	807	O	ALA	A	245	4.293	-8.978	46.720	1.00	26.17	A
	ATOM	808	N	THR	A	246	5.650	-8.351	48.404	1.00	24.39	A
50	ATOM	809	CA	THR	A	246	4.809	-7.252	48.863	1.00	22.15	A
	ATOM	810	CB	THR	A	246	5.113	-6.891	50.335	1.00	22.79	A
	ATOM	811	OG1	THR	A	246	4.507	-7.857	51.196	1.00	20.97	A
	ATOM	812	CG2	THR	A	246	4.590	-5.500	50.680	1.00	23.06	A
	ATOM	813	C	THR	A	246	5.160	-6.068	47.968	1.00	22.02	A
55	ATOM	814	O	THR	A	246	6.339	-5.789	47.733	1.00	21.73	A
	ATOM	815	N	LYS	A	247	4.140	-5.381	47.466	1.00	20.19	A

63

	ATOM	816	CA	LYS	A	247	4.345	-4.246	46.574	1.00	19.02	A
	ATOM	817	CB	LYS	A	247	3.193	-4.161	45.573	1.00	19.65	A
	ATOM	818	CG	LYS	A	247	3.074	-5.343	44.614	1.00	21.06	A
	ATOM	819	CD	LYS	A	247	1.889	-5.127	43.680	1.00	23.15	A
5	ATOM	820	CE	LYS	A	247	1.777	-6.205	42.612	1.00	24.77	A
	ATOM	821	NZ	LYS	A	247	0.745	-5.834	41.592	1.00	25.30	A
	ATOM	822	C	LYS	A	247	4.477	-2.906	47.296	1.00	17.94	A
	ATOM	823	O	LYS	A	247	3.604	-2.517	48.074	1.00	16.18	A
	ATOM	824	N	VAL	A	248	5.569	-2.200	47.015	1.00	15.60	A
10	ATOM	825	CA	VAL	A	248	5.823	-0.895	47.611	1.00	14.60	A
	ATOM	826	CB	VAL	A	248	7.005	-0.934	48.606	1.00	12.63	A
	ATOM	827	CG1	VAL	A	248	7.176	0.427	49.239	1.00	12.28	A
	ATOM	828	CG2	VAL	A	248	6.775	-2.000	49.686	1.00	14.36	A
	ATOM	829	C	VAL	A	248	6.179	0.128	46.525	1.00	13.82	A
15	ATOM	830	O	VAL	A	248	6.907	-0.190	45.581	1.00	14.75	A
	ATOM	831	N	MET	A	249	5.664	1.348	46.665	1.00	13.36	A
	ATOM	832	CA	MET	A	249	5.958	2.432	45.721	1.00	12.42	A
	ATOM	833	CB	MET	A	249	4.715	2.834	44.922	1.00	12.10	A
	ATOM	834	CG	MET	A	249	5.019	3.890	43.854	1.00	12.46	A
20	ATOM	835	SD	MET	A	249	3.586	4.612	43.039	1.00	16.07	A
	ATOM	836	CE	MET	A	249	3.108	3.259	41.935	1.00	17.64	A
	ATOM	837	C	MET	A	249	6.451	3.636	46.518	1.00	12.45	A
	ATOM	838	O	MET	A	249	5.857	3.991	47.538	1.00	13.01	A
	ATOM	839	N	VAL	A	250	7.539	4.252	46.060	1.00	11.98	A
25	ATOM	840	CA	VAL	A	250	8.115	5.412	46.738	1.00	10.91	A
	ATOM	841	CB	VAL	A	250	9.590	5.139	47.159	1.00	11.37	A
	ATOM	842	CG1	VAL	A	250	10.140	6.308	47.953	1.00	10.05	A
	ATOM	843	CG2	VAL	A	250	9.670	3.869	47.978	1.00	9.66	A
	ATOM	844	C	VAL	A	250	8.075	6.626	45.805	1.00	10.65	A
30	ATOM	845	O	VAL	A	250	8.809	6.692	44.814	1.00	9.79	A
	ATOM	846	N	VAL	A	251	7.217	7.587	46.128	1.00	8.23	A
	ATOM	847	CA	VAL	A	251	7.069	8.776	45.303	1.00	8.84	A
	ATOM	848	CB	VAL	A	251	5.578	9.163	45.195	1.00	7.93	A
	ATOM	849	CG1	VAL	A	251	5.393	10.275	44.192	1.00	8.30	A
35	ATOM	850	CG2	VAL	A	251	4.768	7.950	44.791	1.00	6.06	A
	ATOM	851	C	VAL	A	251	7.870	9.954	45.846	1.00	7.73	A
	ATOM	852	O	VAL	A	251	7.661	10.400	46.974	1.00	8.35	A
	ATOM	853	N	VAL	A	252	8.798	10.447	45.040	1.00	7.77	A
	ATOM	854	CA	VAL	A	252	9.636	11.572	45.435	1.00	7.58	A
40	ATOM	855	CB	VAL	A	252	11.122	11.249	45.185	1.00	8.48	A
	ATOM	856	CG1	VAL	A	252	12.009	12.339	45.785	1.00	8.93	A
	ATOM	857	CG2	VAL	A	252	11.459	9.880	45.769	1.00	8.20	A
	ATOM	858	C	VAL	A	252	9.219	12.782	44.599	1.00	7.83	A
	ATOM	859	O	VAL	A	252	9.455	12.822	43.382	1.00	8.22	A
45	ATOM	860	N	THR	A	253	8.602	13.767	45.247	1.00	7.14	A
	ATOM	861	CA	THR	A	253	8.124	14.956	44.538	1.00	6.30	A
	ATOM	862	CB	THR	A	253	6.795	14.639	43.808	1.00	4.22	A
	ATOM	863	OG1	THR	A	253	6.307	15.819	43.163	1.00	6.07	A
	ATOM	864	CG2	THR	A	253	5.751	14.116	44.796	1.00	5.03	A
50	ATOM	865	C	THR	A	253	7.907	16.163	45.449	1.00	6.67	A
	ATOM	866	O	THR	A	253	7.897	16.037	46.667	1.00	8.59	A
	ATOM	867	N	ASP	A	254	7.726	17.336	44.852	1.00	8.22	A
	ATOM	868	CA	ASP	A	254	7.501	18.559	45.618	1.00	7.68	A
	ATOM	869	CB	ASP	A	254	8.158	19.756	44.914	1.00	6.78	A
55	ATOM	870	CG	ASP	A	254	7.714	19.897	43.464	1.00	9.84	A
	ATOM	871	OD1	ASP	A	254	6.727	19.230	43.081	1.00	8.18	A

64

	ATOM	872	OD2	ASP	A	254	8.340	20.680	42.714	1.00	9.72	A
	ATOM	873	C	ASP	A	254	5.998	18.811	45.796	1.00	7.73	A
	ATOM	874	O	ASP	A	254	5.589	19.837	46.339	1.00	6.75	A
	ATOM	875	N	GLY	A	255	5.188	17.874	45.314	1.00	7.48	A
5	ATOM	876	CA	GLY	A	255	3.745	17.981	45.441	1.00	8.81	A
	ATOM	877	C	GLY	A	255	3.033	18.954	44.517	1.00	10.43	A
	ATOM	878	O	GLY	A	255	1.849	19.212	44.697	1.00	11.40	A
	ATOM	879	N	GLU	A	256	3.734	19.480	43.521	1.00	10.74	A
	ATOM	880	CA	GLU	A	256	3.141	20.438	42.590	1.00	10.42	A
10	ATOM	881	CB	GLU	A	256	4.080	21.634	42.434	1.00	10.18	A
	ATOM	882	CG	GLU	A	256	3.510	22.804	41.657	1.00	10.67	A
	ATOM	883	CD	GLU	A	256	4.526	23.916	41.501	1.00	12.63	A
	ATOM	884	OE1	GLU	A	256	5.582	23.679	40.871	1.00	11.76	A
	ATOM	885	OE2	GLU	A	256	4.275	25.024	42.018	1.00	17.05	A
15	ATOM	886	C	GLU	A	256	2.873	19.802	41.224	1.00	11.06	A
	ATOM	887	O	GLU	A	256	3.612	20.028	40.267	1.00	9.35	A
	ATOM	888	N	SER	A	257	1.800	19.019	41.142	1.00	11.83	A
	ATOM	889	CA	SER	A	257	1.429	18.336	39.908	1.00	12.36	A
	ATOM	890	CB	SER	A	257	0.797	16.983	40.238	1.00	13.41	A
20	ATOM	891	OG	SER	A	257	-0.402	17.165	40.973	1.00	15.55	A
	ATOM	892	C	SER	A	257	0.449	19.130	39.055	1.00	12.39	A
	ATOM	893	O	SER	A	257	-0.123	20.119	39.500	1.00	11.98	A
	ATOM	894	N	HIS	A	258	0.259	18.678	37.819	1.00	13.45	A
	ATOM	895	CA	HIS	A	258	-0.676	19.313	36.904	1.00	13.92	A
25	ATOM	896	CB	HIS	A	258	-0.047	19.496	35.514	1.00	14.39	A
	ATOM	897	CG	HIS	A	258	0.973	20.588	35.446	1.00	15.31	A
	ATOM	898	CD2	HIS	A	258	0.856	21.893	35.100	1.00	16.93	A
	ATOM	899	ND1	HIS	A	258	2.297	20.399	35.783	1.00	15.95	A
	ATOM	900	CE1	HIS	A	258	2.949	21.540	35.648	1.00	17.37	A
30	ATOM	901	NE2	HIS	A	258	2.099	22.463	35.236	1.00	15.99	A
	ATOM	902	C	HIS	A	258	-1.928	18.444	36.781	1.00	14.43	A
	ATOM	903	O	HIS	A	258	-3.002	18.940	36.428	1.00	14.21	A
	ATOM	904	N	ASP	A	259	-1.788	17.152	37.081	1.00	13.61	A
	ATOM	905	CA	ASP	A	259	-2.916	16.228	36.972	1.00	14.20	A
35	ATOM	906	CB	ASP	A	259	-2.536	15.034	36.076	1.00	14.11	A
	ATOM	907	CG	ASP	A	259	-1.374	14.212	36.632	1.00	14.29	A
	ATOM	908	OD1	ASP	A	259	-0.966	14.438	37.791	1.00	12.82	A
	ATOM	909	OD2	ASP	A	259	-0.878	13.323	35.905	1.00	12.48	A
	ATOM	910	C	ASP	A	259	-3.499	15.713	38.296	1.00	14.24	A
40	ATOM	911	O	ASP	A	259	-3.927	14.557	38.384	1.00	13.26	A
	ATOM	912	N	GLY	A	260	-3.531	16.575	39.309	1.00	13.52	A
	ATOM	913	CA	GLY	A	260	-4.072	16.190	40.601	1.00	15.49	A
	ATOM	914	C	GLY	A	260	-5.550	15.814	40.601	1.00	17.20	A
	ATOM	915	O	GLY	A	260	-6.059	15.265	41.584	1.00	17.99	A
45	ATOM	916	N	SER	A	261	-6.255	16.100	39.515	1.00	17.56	A
	ATOM	917	CA	SER	A	261	-7.672	15.764	39.453	1.00	20.43	A
	ATOM	918	CB	SER	A	261	-8.303	16.341	38.183	1.00	19.97	A
	ATOM	919	OG	SER	A	261	-7.769	15.726	37.025	1.00	22.72	A
	ATOM	920	C	SER	A	261	-7.880	14.246	39.485	1.00	21.99	A
50	ATOM	921	O	SER	A	261	-8.981	13.769	39.766	1.00	23.07	A
	ATOM	922	N	MET	A	262	-6.817	13.494	39.211	1.00	22.29	A
	ATOM	923	CA	MET	A	262	-6.880	12.038	39.193	1.00	22.48	A
	ATOM	924	CB	MET	A	262	-5.974	11.494	38.087	1.00	23.03	A
	ATOM	925	CG	MET	A	262	-6.258	12.065	36.708	1.00	24.64	A
55	ATOM	926	SD	MET	A	262	-5.131	11.417	35.452	1.00	27.40	A
	ATOM	927	CE	MET	A	262	-3.565	11.957	36.091	1.00	27.77	A

65

	ATOM	928	C	MET	A	262	-6.492	11.387	40.523	1.00	22.57	A
	ATOM	929	O	MET	A	262	-6.538	10.168	40.655	1.00	23.23	A
	ATOM	930	N	LEU	A	263	-6.107	12.197	41.502	1.00	23.04	A
	ATOM	931	CA	LEU	A	263	-5.707	11.694	42.817	1.00	23.03	A
5	ATOM	932	CB	LEU	A	263	-5.775	12.839	43.840	1.00	22.96	A
	ATOM	933	CG	LEU	A	263	-5.290	12.652	45.285	1.00	22.74	A
	ATOM	934	CD1	LEU	A	263	-5.364	13.999	45.984	1.00	24.94	A
	ATOM	935	CD2	LEU	A	263	-6.134	11.637	46.038	1.00	23.03	A
	ATOM	936	C	LEU	A	263	-6.552	10.511	43.310	1.00	22.95	A
10	ATOM	937	O	LEU	A	263	-6.071	9.376	43.398	1.00	23.38	A
	ATOM	938	N	LYS	A	264	-7.807	10.799	43.642	1.00	22.68	A
	ATOM	939	CA	LYS	A	264	-8.761	9.811	44.154	1.00	22.38	A
	ATOM	940	CB	LYS	A	264	-10.162	10.429	44.161	1.00	22.83	A
	ATOM	941	CG	LYS	A	264	-11.251	9.581	44.782	1.00	23.74	A
15	ATOM	942	CD	LYS	A	264	-11.152	9.568	46.291	1.00	25.46	A
	ATOM	943	CE	LYS	A	264	-12.536	9.481	46.904	1.00	27.18	A
	ATOM	944	NZ	LYS	A	264	-13.317	8.347	46.335	1.00	27.63	A
	ATOM	945	C	LYS	A	264	-8.793	8.513	43.352	1.00	21.28	A
	ATOM	946	O	LYS	A	264	-8.706	7.417	43.913	1.00	19.95	A
20	ATOM	947	N	ALA	A	265	-8.925	8.651	42.037	1.00	20.39	A
	ATOM	948	CA	ALA	A	265	-8.991	7.508	41.136	1.00	18.47	A
	ATOM	949	CB	ALA	A	265	-9.264	7.989	39.715	1.00	19.33	A
	ATOM	950	C	ALA	A	265	-7.742	6.637	41.153	1.00	17.32	A
	ATOM	951	O	ALA	A	265	-7.838	5.412	41.229	1.00	16.33	A
25	ATOM	952	N	VAL	A	266	-6.573	7.267	41.079	1.00	15.33	A
	ATOM	953	CA	VAL	A	266	-5.312	6.530	41.063	1.00	14.14	A
	ATOM	954	CB	VAL	A	266	-4.163	7.449	40.580	1.00	15.25	A
	ATOM	955	CG1	VAL	A	266	-2.822	6.744	40.713	1.00	12.74	A
	ATOM	956	CG2	VAL	A	266	-4.412	7.845	39.122	1.00	14.35	A
30	ATOM	957	C	VAL	A	266	-4.953	5.907	42.417	1.00	13.82	A
	ATOM	958	O	VAL	A	266	-4.544	4.744	42.493	1.00	11.03	A
	ATOM	959	N	ILE	A	267	-5.123	6.679	43.483	1.00	13.92	A
	ATOM	960	CA	ILE	A	267	-4.820	6.203	44.826	1.00	14.29	A
	ATOM	961	CB	ILE	A	267	-4.981	7.353	45.849	1.00	13.44	A
35	ATOM	962	CG2	ILE	A	267	-4.768	6.845	47.269	1.00	12.64	A
	ATOM	963	CG1	ILE	A	267	-3.994	8.475	45.503	1.00	13.65	A
	ATOM	964	CD1	ILE	A	267	-2.565	8.013	45.313	1.00	12.83	A
	ATOM	965	C	ILE	A	267	-5.708	5.019	45.220	1.00	15.77	A
	ATOM	966	O	ILE	A	267	-5.248	4.081	45.869	1.00	14.63	A
40	ATOM	967	N	ASP	A	268	-6.976	5.064	44.820	1.00	17.07	A
	ATOM	968	CA	ASP	A	268	-7.908	3.985	45.133	1.00	18.52	A
	ATOM	969	CB	ASP	A	268	-9.293	4.292	44.567	1.00	21.82	A
	ATOM	970	CG	ASP	A	268	-10.330	4.518	45.646	1.00	24.24	A
	ATOM	971	OD1	ASP	A	268	-10.429	3.674	46.566	1.00	27.22	A
45	ATOM	972	OD2	ASP	A	268	-11.055	5.532	45.566	1.00	25.15	A
	ATOM	973	C	ASP	A	268	-7.408	2.681	44.530	1.00	18.70	A
	ATOM	974	O	ASP	A	268	-7.378	1.642	45.195	1.00	17.59	A
	ATOM	975	N	GLN	A	269	-7.017	2.742	43.260	1.00	17.82	A
	ATOM	976	CA	GLN	A	269	-6.520	1.559	42.571	1.00	17.98	A
50	ATOM	977	CB	GLN	A	269	-6.177	1.894	41.121	1.00	19.75	A
	ATOM	978	CG	GLN	A	269	-7.371	2.329	40.299	1.00	24.17	A
	ATOM	979	CD	GLN	A	269	-7.025	2.532	38.839	1.00	27.38	A
	ATOM	980	OE1	GLN	A	269	-6.679	1.583	38.133	1.00	31.17	A
	ATOM	981	NE2	GLN	A	269	-7.112	3.773	38.377	1.00	28.54	A
55	ATOM	982	C	GLN	A	269	-5.295	1.005	43.282	1.00	16.45	A
	ATOM	983	O	GLN	A	269	-5.183	-0.207	43.487	1.00	13.95	A

66

	ATOM	984	N	CYS A 270	-4.378	1.896	43.657	1.00	14.73	A
	ATOM	985	CA	CYS A 270	-3.175	1.478	44.359	1.00	15.16	A
	ATOM	986	CB	CYS A 270	-2.299	2.688	44.709	1.00	14.54	A
	ATOM	987	SG	CYS A 270	-1.455	3.488	43.295	1.00	12.41	A
5	ATOM	988	C	CYS A 270	-3.570	0.730	45.627	1.00	15.14	A
	ATOM	989	O	CYS A 270	-2.974	-0.294	45.957	1.00	15.57	A
	ATOM	990	N	ASN A 271	-4.587	1.228	46.329	1.00	17.79	A
	ATOM	991	CA	ASN A 271	-5.042	0.577	47.556	1.00	18.54	A
	ATOM	992	CB	ASN A 271	-6.154	1.383	48.240	1.00	18.69	A
10	ATOM	993	CG	ASN A 271	-5.628	2.595	48.997	1.00	19.21	A
	ATOM	994	OD1	ASN A 271	-4.474	2.628	49.423	1.00	19.65	A
	ATOM	995	ND2	ASN A 271	-6.485	3.586	49.188	1.00	18.35	A
	ATOM	996	C	ASN A 271	-5.534	-0.843	47.297	1.00	19.85	A
	ATOM	997	O	ASN A 271	-5.217	-1.756	48.054	1.00	19.38	A
15	ATOM	998	N	HIS A 272	-6.298	-1.034	46.225	1.00	20.77	A
	ATOM	999	CA	HIS A 272	-6.816	-2.361	45.898	1.00	22.45	A
	ATOM	1000	CB	HIS A 272	-7.961	-2.240	44.894	1.00	26.64	A
	ATOM	1001	CG	HIS A 272	-9.210	-1.673	45.494	1.00	30.29	A
	ATOM	1002	CD2	HIS A 272	-9.798	-0.464	45.353	1.00	31.55	A
20	ATOM	1003	ND1	HIS A 272	-9.955	-2.355	46.432	1.00	32.65	A
	ATOM	1004	CE1	HIS A 272	-10.947	-1.588	46.847	1.00	32.98	A
	ATOM	1005	NE2	HIS A 272	-10.874	-0.433	46.208	1.00	33.31	A
	ATOM	1006	C	HIS A 272	-5.756	-3.337	45.398	1.00	21.74	A
	ATOM	1007	O	HIS A 272	-5.947	-4.549	45.475	1.00	21.48	A
25	ATOM	1008	N	ASP A 273	-4.644	-2.811	44.883	1.00	20.99	A
	ATOM	1009	CA	ASP A 273	-3.536	-3.650	44.420	1.00	19.25	A
	ATOM	1010	CB	ASP A 273	-2.721	-2.943	43.330	1.00	18.34	A
	ATOM	1011	CG	ASP A 273	-3.410	-2.952	41.979	1.00	18.54	A
	ATOM	1012	OD1	ASP A 273	-4.474	-3.584	41.851	1.00	18.73	A
30	ATOM	1013	OD2	ASP A 273	-2.883	-2.326	41.039	1.00	19.50	A
	ATOM	1014	C	ASP A 273	-2.628	-3.923	45.617	1.00	18.38	A
	ATOM	1015	O	ASP A 273	-1.597	-4.586	45.497	1.00	17.39	A
	ATOM	1016	N	ASN A 274	-3.025	-3.395	46.771	1.00	18.11	A
	ATOM	1017	CA	ASN A 274	-2.276	-3.552	48.013	1.00	17.29	A
35	ATOM	1018	CB	ASN A 274	-2.258	-5.016	48.450	1.00	18.34	A
	ATOM	1019	CG	ASN A 274	-3.650	-5.565	48.681	1.00	20.60	A
	ATOM	1020	OD1	ASN A 274	-4.483	-4.927	49.331	1.00	20.94	A
	ATOM	1021	ND2	ASN A 274	-3.912	-6.754	48.154	1.00	22.78	A
	ATOM	1022	C	ASN A 274	-0.855	-3.037	47.889	1.00	16.90	A
40	ATOM	1023	O	ASN A 274	0.104	-3.725	48.249	1.00	16.67	A
	ATOM	1024	N	ILE A 275	-0.725	-1.819	47.375	1.00	16.97	A
	ATOM	1025	CA	ILE A 275	0.583	-1.194	47.210	1.00	15.59	A
	ATOM	1026	CB	ILE A 275	0.693	-0.453	45.855	1.00	14.51	A
	ATOM	1027	CG2	ILE A 275	2.027	0.279	45.764	1.00	13.97	A
45	ATOM	1028	CG1	ILE A 275	0.563	-1.442	44.699	1.00	14.72	A
	ATOM	1029	CD1	ILE A 275	0.834	-0.824	43.342	1.00	13.73	A
	ATOM	1030	C	ILE A 275	0.829	-0.189	48.335	1.00	15.36	A
	ATOM	1031	O	ILE A 275	0.092	0.789	48.475	1.00	14.71	A
	ATOM	1032	N	LEU A 276	1.856	-0.446	49.143	1.00	15.48	A
50	ATOM	1033	CA	LEU A 276	2.217	0.448	50.240	1.00	15.30	A
	ATOM	1034	CB	LEU A 276	3.178	-0.248	51.204	1.00	17.87	A
	ATOM	1035	CG	LEU A 276	2.627	-1.353	52.108	1.00	20.34	A
	ATOM	1036	CD1	LEU A 276	1.537	-0.773	52.994	1.00	22.51	A
	ATOM	1037	CD2	LEU A 276	2.091	-2.504	51.268	1.00	21.16	A
55	ATOM	1038	C	LEU A 276	2.906	1.652	49.619	1.00	14.60	A
	ATOM	1039	O	LEU A 276	3.788	1.482	48.777	1.00	16.04	A

	ATOM	1040	N	ARG	A	277	2.524	2.859	50.036	1.00	13.49	A
	ATOM	1041	CA	ARG	A	277	3.101	4.074	49.463	1.00	12.06	A
	ATOM	1042	CB	ARG	A	277	2.026	4.855	48.698	1.00	10.92	A
	ATOM	1043	CG	ARG	A	277	1.334	4.078	47.586	1.00	6.86	A
5	ATOM	1044	CD	ARG	A	277	0.192	4.898	46.985	1.00	6.96	A
	ATOM	1045	NE	ARG	A	277	-0.789	5.303	47.992	1.00	6.18	A
	ATOM	1046	CZ	ARG	A	277	-1.687	4.492	48.543	1.00	7.31	A
	ATOM	1047	NH1	ARG	A	277	-2.537	4.955	49.452	1.00	6.68	A
	ATOM	1048	NH2	ARG	A	277	-1.748	3.217	48.182	1.00	7.09	A
10	ATOM	1049	C	ARG	A	277	3.788	5.050	50.414	1.00	11.97	A
	ATOM	1050	O	ARG	A	277	3.225	5.453	51.431	1.00	13.23	A
	ATOM	1051	N	PHE	A	278	5.009	5.435	50.057	1.00	10.69	A
	ATOM	1052	CA	PHE	A	278	5.767	6.409	50.826	1.00	11.20	A
	ATOM	1053	CB	PHE	A	278	7.239	6.000	50.983	1.00	9.58	A
15	ATOM	1054	CG	PHE	A	278	7.484	4.944	52.027	1.00	11.91	A
	ATOM	1055	CD1	PHE	A	278	7.231	3.603	51.759	1.00	12.77	A
	ATOM	1056	CD2	PHE	A	278	7.985	5.293	53.280	1.00	12.69	A
	ATOM	1057	CE1	PHE	A	278	7.475	2.620	52.727	1.00	12.09	A
	ATOM	1058	CE2	PHE	A	278	8.230	4.318	54.251	1.00	13.27	A
20	ATOM	1059	CZ	PHE	A	278	7.974	2.978	53.969	1.00	11.23	A
	ATOM	1060	C	PHE	A	278	5.718	7.717	50.042	1.00	11.02	A
	ATOM	1061	O	PHE	A	278	5.787	7.718	48.808	1.00	12.54	A
	ATOM	1062	N	GLY	A	279	5.587	8.822	50.758	1.00	10.43	A
	ATOM	1063	CA	GLY	A	279	5.579	10.121	50.114	1.00	10.44	A
25	ATOM	1064	C	GLY	A	279	6.841	10.824	50.572	1.00	10.00	A
	ATOM	1065	O	GLY	A	279	7.000	11.069	51.767	1.00	8.22	A
	ATOM	1066	N	ILE	A	280	7.741	11.135	49.641	1.00	9.32	A
	ATOM	1067	CA	ILE	A	280	9.006	11.800	49.976	1.00	8.94	A
	ATOM	1068	CB	ILE	A	280	10.210	11.086	49.297	1.00	9.74	A
30	ATOM	1069	CG2	ILE	A	280	11.518	11.635	49.851	1.00	6.76	A
	ATOM	1070	CG1	ILE	A	280	10.104	9.564	49.484	1.00	7.75	A
	ATOM	1071	CD1	ILE	A	280	10.002	9.104	50.927	1.00	8.44	A
	ATOM	1072	C	ILE	A	280	8.982	13.258	49.511	1.00	9.08	A
	ATOM	1073	O	ILE	A	280	9.072	13.540	48.314	1.00	8.74	A
35	ATOM	1074	N	ALA	A	281	8.890	14.183	50.461	1.00	8.56	A
	ATOM	1075	CA	ALA	A	281	8.813	15.606	50.132	1.00	9.58	A
	ATOM	1076	CB	ALA	A	281	8.092	16.351	51.255	1.00	9.06	A
	ATOM	1077	C	ALA	A	281	10.112	16.335	49.793	1.00	9.24	A
	ATOM	1078	O	ALA	A	281	10.994	16.500	50.631	1.00	9.20	A
40	ATOM	1079	N	VAL	A	282	10.202	16.773	48.544	1.00	9.69	A
	ATOM	1080	CA	VAL	A	282	11.334	17.544	48.058	1.00	11.46	A
	ATOM	1081	CB	VAL	A	282	11.549	17.337	46.539	1.00	12.19	A
	ATOM	1082	CG1	VAL	A	282	12.695	18.198	46.046	1.00	10.75	A
	ATOM	1083	CG2	VAL	A	282	11.823	15.861	46.245	1.00	12.21	A
45	ATOM	1084	C	VAL	A	282	10.899	18.986	48.306	1.00	12.35	A
	ATOM	1085	O	VAL	A	282	10.298	19.629	47.444	1.00	12.44	A
	ATOM	1086	N	LEU	A	283	11.173	19.473	49.509	1.00	12.18	A
	ATOM	1087	CA	LEU	A	283	10.808	20.829	49.898	1.00	12.59	A
	ATOM	1088	CB	LEU	A	283	9.432	20.839	50.584	1.00	11.98	A
50	ATOM	1089	CG	LEU	A	283	8.169	20.217	49.972	1.00	11.80	A
	ATOM	1090	CD1	LEU	A	283	7.058	20.286	51.002	1.00	10.46	A
	ATOM	1091	CD2	LEU	A	283	7.747	20.940	48.698	1.00	11.27	A
	ATOM	1092	C	LEU	A	283	11.852	21.323	50.892	1.00	13.20	A
	ATOM	1093	O	LEU	A	283	12.496	20.515	51.565	1.00	13.05	A
55	ATOM	1094	N	GLY	A	284	12.028	22.641	50.977	1.00	15.10	A
	ATOM	1095	CA	GLY	A	284	12.973	23.191	51.931	1.00	16.65	A

68

	ATOM	1096	C	GLY A 284	14.057	24.118	51.408	1.00	18.34	A
	ATOM	1097	O	GLY A 284	14.597	24.927	52.163	1.00	17.39	A
	ATOM	1098	N	TYR A 285	14.379	24.007	50.126	1.00	19.40	A
	ATOM	1099	CA	TYR A 285	15.424	24.829	49.528	1.00	21.96	A
5	ATOM	1100	CB	TYR A 285	16.262	23.973	48.591	1.00	22.25	A
	ATOM	1101	CG	TYR A 285	16.946	22.812	49.285	1.00	25.63	A
	ATOM	1102	CD1	TYR A 285	18.230	22.950	49.816	1.00	25.35	A
	ATOM	1103	CE1	TYR A 285	18.878	21.869	50.420	1.00	27.84	A
	ATOM	1104	CD2	TYR A 285	16.321	21.564	49.383	1.00	24.77	A
10	ATOM	1105	CE2	TYR A 285	16.958	20.483	49.983	1.00	25.71	A
	ATOM	1106	CZ	TYR A 285	18.236	20.639	50.498	1.00	27.19	A
	ATOM	1107	OH	TYR A 285	18.880	19.567	51.081	1.00	28.61	A
	ATOM	1108	C	TYR A 285	14.863	26.032	48.781	1.00	22.57	A
	ATOM	1109	O	TYR A 285	15.523	27.062	48.669	1.00	24.02	A
15	ATOM	1110	N	LEU A 286	13.645	25.896	48.268	1.00	23.97	A
	ATOM	1111	CA	LEU A 286	12.991	26.984	47.553	1.00	24.44	A
	ATOM	1112	CB	LEU A 286	12.109	26.433	46.424	1.00	23.78	A
	ATOM	1113	CG	LEU A 286	12.733	25.452	45.424	1.00	23.33	A
	ATOM	1114	CD1	LEU A 286	11.768	25.238	44.268	1.00	22.08	A
20	ATOM	1115	CD2	LEU A 286	14.052	25.995	44.895	1.00	23.54	A
	ATOM	1116	C	LEU A 286	12.130	27.754	48.550	1.00	25.62	A
	ATOM	1117	O	LEU A 286	11.432	27.158	49.367	1.00	25.02	A
	ATOM	1118	N	ASN A 287	12.185	29.079	48.484	1.00	28.24	A
	ATOM	1119	CA	ASN A 287	11.414	29.924	49.391	1.00	28.80	A
25	ATOM	1120	CB	ASN A 287	12.072	31.298	49.505	1.00	30.42	A
	ATOM	1121	CG	ASN A 287	11.674	32.030	50.769	1.00	31.82	A
	ATOM	1122	OD1	ASN A 287	10.490	32.180	51.072	1.00	32.26	A
	ATOM	1123	ND2	ASN A 287	12.667	32.496	51.513	1.00	33.25	A
	ATOM	1124	C	ASN A 287	9.980	30.085	48.901	1.00	29.54	A
30	ATOM	1125	O	ASN A 287	9.740	30.651	47.833	1.00	29.75	A
	ATOM	1126	N	ARG A 288	9.029	29.594	49.688	1.00	29.81	A
	ATOM	1127	CA	ARG A 288	7.614	29.677	49.331	1.00	30.68	A
	ATOM	1128	CB	ARG A 288	7.063	28.285	49.002	1.00	30.29	A
	ATOM	1129	CG	ARG A 288	7.722	27.568	47.834	1.00	27.73	A
35	ATOM	1130	CD	ARG A 288	6.856	26.381	47.427	1.00	28.24	A
	ATOM	1131	NE	ARG A 288	7.279	25.765	46.173	1.00	26.45	A
	ATOM	1132	CZ	ARG A 288	8.232	24.846	46.075	1.00	27.37	A
	ATOM	1133	NH1	ARG A 288	8.866	24.430	47.164	1.00	26.30	A
	ATOM	1134	NH2	ARG A 288	8.550	24.342	44.888	1.00	26.61	A
40	ATOM	1135	C	ARG A 288	6.798	30.267	50.477	1.00	31.67	A
	ATOM	1136	O	ARG A 288	7.298	30.396	51.591	1.00	31.76	A
	ATOM	1137	N	ASN A 289	5.544	30.621	50.196	1.00	33.77	A
	ATOM	1138	CA	ASN A 289	4.646	31.176	51.212	1.00	35.84	A
	ATOM	1139	CB	ASN A 289	3.265	31.491	50.624	1.00	36.52	A
45	ATOM	1140	CG	ASN A 289	3.293	32.598	49.611	1.00	37.86	A
	ATOM	1141	OD1	ASN A 289	3.777	33.697	49.883	1.00	39.91	A
	ATOM	1142	ND2	ASN A 289	2.753	32.325	48.431	1.00	38.60	A
	ATOM	1143	C	ASN A 289	4.429	30.146	52.310	1.00	36.64	A
	ATOM	1144	O	ASN A 289	5.315	29.358	52.642	1.00	37.87	A
50	ATOM	1145	N	ALA A 290	3.220	30.165	52.861	1.00	36.43	A
	ATOM	1146	CA	ALA A 290	2.815	29.225	53.894	1.00	35.71	A
	ATOM	1147	CB	ALA A 290	2.333	29.970	55.133	1.00	35.62	A
	ATOM	1148	C	ALA A 290	1.673	28.423	53.275	1.00	35.14	A
	ATOM	1149	O	ALA A 290	1.576	27.210	53.458	1.00	34.29	A
55	ATOM	1150	N	LEU A 291	0.820	29.120	52.527	1.00	34.35	A
	ATOM	1151	CA	LEU A 291	-0.315	28.498	51.857	1.00	33.93	A

	ATOM	1152	CB	LEU A 291	-1.304	29.563	51.378	1.00	34.50	A
	ATOM	1153	CG	LEU A 291	-2.443	29.050	50.486	1.00	35.78	A
	ATOM	1154	CD1	LEU A 291	-3.223	27.957	51.211	1.00	35.87	A
	ATOM	1155	CD2	LEU A 291	-3.358	30.205	50.108	1.00	35.64	A
5	ATOM	1156	C	LEU A 291	0.151	27.672	50.665	1.00	33.30	A
	ATOM	1157	O	LEU A 291	-0.473	26.670	50.309	1.00	33.11	A
	ATOM	1158	N	ASP A 292	1.241	28.109	50.041	1.00	32.39	A
	ATOM	1159	CA	ASP A 292	1.795	27.401	48.898	1.00	30.79	A
	ATOM	1160	CB	ASP A 292	2.782	28.298	48.144	1.00	31.69	A
10	ATOM	1161	CG	ASP A 292	2.084	29.335	47.269	1.00	32.74	A
	ATOM	1162	OD1	ASP A 292	2.768	30.243	46.753	1.00	33.80	A
	ATOM	1163	OD2	ASP A 292	0.854	29.237	47.084	1.00	32.42	A
	ATOM	1164	C	ASP A 292	2.493	26.144	49.395	1.00	29.78	A
	ATOM	1165	O	ASP A 292	2.436	25.104	48.754	1.00	29.16	A
15	ATOM	1166	N	THR A 293	3.143	26.247	50.548	1.00	29.30	A
	ATOM	1167	CA	THR A 293	3.842	25.109	51.132	1.00	28.64	A
	ATOM	1168	CB	THR A 293	4.788	25.548	52.273	1.00	29.16	A
	ATOM	1169	OG1	THR A 293	5.832	26.379	51.747	1.00	29.06	A
	ATOM	1170	CG2	THR A 293	5.409	24.330	52.942	1.00	29.62	A
20	ATOM	1171	C	THR A 293	2.836	24.104	51.691	1.00	28.42	A
	ATOM	1172	O	THR A 293	3.013	22.890	51.556	1.00	28.33	A
	ATOM	1173	N	LYS A 294	1.781	24.614	52.319	1.00	27.12	A
	ATOM	1174	CA	LYS A 294	0.754	23.753	52.894	1.00	25.88	A
	ATOM	1175	CB	LYS A 294	-0.296	24.585	53.631	1.00	27.50	A
25	ATOM	1176	CG	LYS A 294	-0.503	24.160	55.074	1.00	31.01	A
	ATOM	1177	CD	LYS A 294	0.711	24.528	55.925	1.00	32.77	A
	ATOM	1178	CE	LYS A 294	0.624	23.964	57.345	1.00	32.54	A
	ATOM	1179	NZ	LYS A 294	1.096	22.554	57.413	1.00	34.00	A
	ATOM	1180	C	LYS A 294	0.070	22.922	51.815	1.00	23.90	A
30	ATOM	1181	O	LYS A 294	-0.100	21.713	51.960	1.00	22.61	A
	ATOM	1182	N	ASN A 295	-0.329	23.575	50.732	1.00	21.38	A
	ATOM	1183	CA	ASN A 295	-0.992	22.870	49.646	1.00	21.12	A
	ATOM	1184	CB	ASN A 295	-1.479	23.863	48.594	1.00	23.57	A
	ATOM	1185	CG	ASN A 295	-2.890	24.347	48.870	1.00	26.26	A
35	ATOM	1186	OD1	ASN A 295	-3.860	23.616	48.666	1.00	28.01	A
	ATOM	1187	ND2	ASN A 295	-3.010	25.581	49.347	1.00	27.75	A
	ATOM	1188	C	ASN A 295	-0.077	21.825	49.020	1.00	18.46	A
	ATOM	1189	O	ASN A 295	-0.547	20.788	48.554	1.00	16.78	A
	ATOM	1190	N	LEU A 296	1.226	22.098	49.018	1.00	15.33	A
40	ATOM	1191	CA	LEU A 296	2.191	21.153	48.469	1.00	14.78	A
	ATOM	1192	CB	LEU A 296	3.571	21.809	48.321	1.00	14.17	A
	ATOM	1193	CG	LEU A 296	3.720	22.917	47.271	1.00	15.83	A
	ATOM	1194	CD1	LEU A 296	5.130	23.495	47.336	1.00	13.92	A
	ATOM	1195	CD2	LEU A 296	3.424	22.359	45.877	1.00	15.72	A
45	ATOM	1196	C	LEU A 296	2.288	19.937	49.391	1.00	13.30	A
	ATOM	1197	O	LEU A 296	2.190	18.798	48.939	1.00	13.73	A
	ATOM	1198	N	ILE A 297	2.479	20.184	50.681	1.00	13.90	A
	ATOM	1199	CA	ILE A 297	2.578	19.107	51.664	1.00	12.57	A
	ATOM	1200	CB	ILE A 297	2.704	19.667	53.099	1.00	13.20	A
50	ATOM	1201	CG2	ILE A 297	2.581	18.539	54.120	1.00	10.79	A
	ATOM	1202	CG1	ILE A 297	4.041	20.389	53.263	1.00	13.18	A
	ATOM	1203	CD1	ILE A 297	4.169	21.157	54.579	1.00	13.83	A
	ATOM	1204	C	ILE A 297	1.336	18.229	51.601	1.00	13.43	A
	ATOM	1205	O	ILE A 297	1.426	16.999	51.647	1.00	14.67	A
55	ATOM	1206	N	LYS A 298	0.173	18.867	51.498	1.00	13.02	A
	ATOM	1207	CA	LYS A 298	-1.089	18.147	51.435	1.00	14.37	A

	ATOM	1208	CB	LYS	A	298	-2.245	19.114	51.175	1.00	15.32	A
	ATOM	1209	CG	LYS	A	298	-3.565	18.420	50.872	1.00	17.06	A
	ATOM	1210	CD	LYS	A	298	-4.742	19.363	51.029	1.00	18.40	A
	ATOM	1211	CE	LYS	A	298	-4.571	20.626	50.198	1.00	19.78	A
5	ATOM	1212	NZ	LYS	A	298	-5.760	21.518	50.326	1.00	20.25	A
	ATOM	1213	C	LYS	A	298	-1.101	17.054	50.372	1.00	13.87	A
	ATOM	1214	O	LYS	A	298	-1.484	15.920	50.652	1.00	14.22	A
	ATOM	1215	N	GLU	A	299	-0.685	17.394	49.155	1.00	14.10	A
	ATOM	1216	CA	GLU	A	299	-0.666	16.411	48.078	1.00	13.13	A
10	ATOM	1217	CB	GLU	A	299	-0.296	17.056	46.737	1.00	13.37	A
	ATOM	1218	CG	GLU	A	299	-0.391	16.065	45.571	1.00	14.38	A
	ATOM	1219	CD	GLU	A	299	-0.037	16.669	44.227	1.00	13.17	A
	ATOM	1220	OE1	GLU	A	299	1.136	16.562	43.805	1.00	13.60	A
	ATOM	1221	OE2	GLU	A	299	-0.936	17.257	43.595	1.00	13.39	A
15	ATOM	1222	C	GLU	A	299	0.317	15.289	48.369	1.00	11.75	A
	ATOM	1223	O	GLU	A	299	0.023	14.121	48.134	1.00	12.23	A
	ATOM	1224	N	ILE	A	300	1.486	15.636	48.885	1.00	11.21	A
	ATOM	1225	CA	ILE	A	300	2.480	14.616	49.168	1.00	9.40	A
	ATOM	1226	CB	ILE	A	300	3.817	15.251	49.613	1.00	9.90	A
20	ATOM	1227	CG2	ILE	A	300	4.856	14.164	49.842	1.00	7.33	A
	ATOM	1228	CG1	ILE	A	300	4.306	16.222	48.531	1.00	9.03	A
	ATOM	1229	CD1	ILE	A	300	5.517	17.046	48.922	1.00	10.70	A
	ATOM	1230	C	ILE	A	300	1.980	13.633	50.222	1.00	10.09	A
	ATOM	1231	O	ILE	A	300	2.172	12.425	50.084	1.00	9.54	A
25	ATOM	1232	N	LYS	A	301	1.332	14.143	51.268	1.00	10.44	A
	ATOM	1233	CA	LYS	A	301	0.805	13.280	52.324	1.00	10.83	A
	ATOM	1234	CB	LYS	A	301	0.377	14.111	53.546	1.00	11.26	A
	ATOM	1235	CG	LYS	A	301	1.514	14.819	54.281	1.00	9.39	A
	ATOM	1236	CD	LYS	A	301	1.026	15.364	55.618	1.00	8.55	A
30	ATOM	1237	CE	LYS	A	301	2.156	16.015	56.411	1.00	8.26	A
	ATOM	1238	NZ	LYS	A	301	1.803	16.140	57.858	1.00	8.59	A
	ATOM	1239	C	LYS	A	301	-0.393	12.476	51.812	1.00	10.73	A
	ATOM	1240	O	LYS	A	301	-0.679	11.382	52.300	1.00	10.91	A
	ATOM	1241	N	ALA	A	302	-1.087	13.033	50.828	1.00	9.99	A
35	ATOM	1242	CA	ALA	A	302	-2.250	12.389	50.232	1.00	9.05	A
	ATOM	1243	CB	ALA	A	302	-3.002	13.389	49.348	1.00	7.59	A
	ATOM	1244	C	ALA	A	302	-1.846	11.170	49.414	1.00	8.86	A
	ATOM	1245	O	ALA	A	302	-2.646	10.265	49.199	1.00	8.67	A
	ATOM	1246	N	ILE	A	303	-0.600	11.151	48.960	1.00	9.67	A
40	ATOM	1247	CA	ILE	A	303	-0.083	10.041	48.166	1.00	10.19	A
	ATOM	1248	CB	ILE	A	303	1.121	10.510	47.291	1.00	9.99	A
	ATOM	1249	CG2	ILE	A	303	1.770	9.326	46.599	1.00	8.69	A
	ATOM	1250	CG1	ILE	A	303	0.644	11.539	46.258	1.00	11.14	A
	ATOM	1251	CD1	ILE	A	303	1.781	12.236	45.465	1.00	10.23	A
45	ATOM	1252	C	ILE	A	303	0.357	8.890	49.080	1.00	11.36	A
	ATOM	1253	O	ILE	A	303	0.172	7.715	48.760	1.00	9.99	A
	ATOM	1254	N	ALA	A	304	0.935	9.233	50.225	1.00	11.53	A
	ATOM	1255	CA	ALA	A	304	1.402	8.225	51.162	1.00	11.59	A
	ATOM	1256	CB	ALA	A	304	2.190	8.885	52.274	1.00	11.10	A
50	ATOM	1257	C	ALA	A	304	0.271	7.391	51.757	1.00	12.66	A
	ATOM	1258	O	ALA	A	304	-0.883	7.818	51.806	1.00	13.35	A
	ATOM	1259	N	SER	A	305	0.617	6.189	52.203	1.00	13.47	A
	ATOM	1260	CA	SER	A	305	-0.348	5.297	52.825	1.00	14.24	A
	ATOM	1261	CB	SER	A	305	0.188	3.863	52.845	1.00	12.61	A
55	ATOM	1262	OG	SER	A	305	0.197	3.295	51.553	1.00	15.04	A
	ATOM	1263	C	SER	A	305	-0.598	5.755	54.259	1.00	14.09	A

	ATOM	1264	O	SER A 305	0.227	6.451	54.850	1.00	13.19	A
	ATOM	1265	N	ILE A 306	-1.739	5.361	54.814	1.00	14.63	A
	ATOM	1266	CA	ILE A 306	-2.082	5.711	56.189	1.00	15.34	A
	ATOM	1267	CB	ILE A 306	-3.601	5.980	56.316	1.00	16.66	A
5	ATOM	1268	CG2	ILE A 306	-3.960	6.292	57.758	1.00	15.49	A
	ATOM	1269	CG1	ILE A 306	-3.997	7.141	55.400	1.00	16.61	A
	ATOM	1270	CD1	ILE A 306	-5.497	7.343	55.272	1.00	17.56	A
	ATOM	1271	C	ILE A 306	-1.690	4.523	57.076	1.00	15.24	A
	ATOM	1272	O	ILE A 306	-1.898	3.374	56.695	1.00	14.01	A
10	ATOM	1273	N	PRO A 307	-1.102	4.774	58.263	1.00	15.58	A
	ATOM	1274	CD	PRO A 307	-0.741	3.622	59.105	1.00	15.34	A
	ATOM	1275	CA	PRO A 307	-0.734	6.032	58.931	1.00	15.50	A
	ATOM	1276	CB	PRO A 307	-0.091	5.558	60.231	1.00	15.22	A
	ATOM	1277	CG	PRO A 307	-0.732	4.223	60.473	1.00	16.17	A
15	ATOM	1278	C	PRO A 307	0.233	6.893	58.118	1.00	14.70	A
	ATOM	1279	O	PRO A 307	1.327	6.450	57.770	1.00	14.97	A
	ATOM	1280	N	THR A 308	-0.166	8.127	57.837	1.00	14.00	A
	ATOM	1281	CA	THR A 308	0.670	9.037	57.063	1.00	13.42	A
	ATOM	1282	CB	THR A 308	-0.014	10.400	56.895	1.00	12.26	A
20	ATOM	1283	OG1	THR A 308	-1.382	10.200	56.525	1.00	11.53	A
	ATOM	1284	CG2	THR A 308	0.681	11.214	55.811	1.00	11.72	A
	ATOM	1285	C	THR A 308	2.015	9.246	57.744	1.00	13.18	A
	ATOM	1286	O	THR A 308	3.048	9.305	57.084	1.00	12.83	A
	ATOM	1287	N	GLU A 309	1.982	9.366	59.068	1.00	13.59	A
25	ATOM	1288	CA	GLU A 309	3.178	9.567	59.879	1.00	16.27	A
	ATOM	1289	CB	GLU A 309	2.800	9.547	61.369	1.00	18.18	A
	ATOM	1290	CG	GLU A 309	3.854	8.954	62.303	1.00	22.15	A
	ATOM	1291	CD	GLU A 309	5.121	9.782	62.391	1.00	25.47	A
	ATOM	1292	OE1	GLU A 309	6.111	9.287	62.974	1.00	27.57	A
30	ATOM	1293	OE2	GLU A 309	5.130	10.926	61.890	1.00	26.88	A
	ATOM	1294	C	GLU A 309	4.268	8.531	59.618	1.00	16.07	A
	ATOM	1295	O	GLU A 309	5.455	8.827	59.734	1.00	15.96	A
	ATOM	1296	N	ARG A 310	3.865	7.316	59.275	1.00	17.19	A
	ATOM	1297	CA	ARG A 310	4.831	6.253	59.032	1.00	18.70	A
35	ATOM	1298	CB	ARG A 310	4.242	4.898	59.428	1.00	22.99	A
	ATOM	1299	CG	ARG A 310	4.005	4.714	60.917	1.00	28.37	A
	ATOM	1300	CD	ARG A 310	3.387	3.353	61.180	1.00	32.66	A
	ATOM	1301	NE	ARG A 310	3.293	3.045	62.605	1.00	36.84	A
	ATOM	1302	CZ	ARG A 310	2.722	1.948	63.089	1.00	37.07	A
40	ATOM	1303	NH1	ARG A 310	2.191	1.057	62.261	1.00	39.09	A
	ATOM	1304	NH2	ARG A 310	2.685	1.739	64.397	1.00	39.15	A
	ATOM	1305	C	ARG A 310	5.308	6.170	57.592	1.00	17.16	A
	ATOM	1306	O	ARG A 310	6.280	5.469	57.303	1.00	17.79	A
	ATOM	1307	N	TYR A 311	4.645	6.883	56.691	1.00	14.11	A
45	ATOM	1308	CA	TYR A 311	5.031	6.817	55.285	1.00	13.57	A
	ATOM	1309	CB	TYR A 311	3.943	6.083	54.490	1.00	12.91	A
	ATOM	1310	CG	TYR A 311	3.664	4.697	55.016	1.00	13.42	A
	ATOM	1311	CD1	TYR A 311	2.685	4.482	55.986	1.00	16.46	A
	ATOM	1312	CE1	TYR A 311	2.490	3.224	56.547	1.00	16.91	A
50	ATOM	1313	CD2	TYR A 311	4.438	3.615	54.615	1.00	14.44	A
	ATOM	1314	CE2	TYR A 311	4.257	2.360	55.168	1.00	16.71	A
	ATOM	1315	CZ	TYR A 311	3.283	2.169	56.138	1.00	18.56	A
	ATOM	1316	OH	TYR A 311	3.131	0.927	56.718	1.00	21.20	A
	ATOM	1317	C	TYR A 311	5.332	8.157	54.629	1.00	12.97	A
55	ATOM	1318	O	TYR A 311	5.315	8.268	53.401	1.00	12.31	A
	ATOM	1319	N	PHE A 312	5.623	9.166	55.443	1.00	12.60	A

	ATOM	1320	CA	PHE	A	312	5.917	10.496	54.930	1.00	12.48	A
	ATOM	1321	CB	PHE	A	312	4.688	11.402	55.097	1.00	12.89	A
	ATOM	1322	CG	PHE	A	312	4.973	12.862	54.860	1.00	13.09	A
	ATOM	1323	CD1	PHE	A	312	4.861	13.409	53.585	1.00	11.61	A
5	ATOM	1324	CD2	PHE	A	312	5.389	13.681	55.907	1.00	12.16	A
	ATOM	1325	CE1	PHE	A	312	5.159	14.744	53.353	1.00	12.83	A
	ATOM	1326	CE2	PHE	A	312	5.691	15.022	55.685	1.00	13.25	A
	ATOM	1327	CZ	PHE	A	312	5.576	15.555	54.402	1.00	13.34	A
	ATOM	1328	C	PHE	A	312	7.110	11.150	55.624	1.00	12.93	A
10	ATOM	1329	O	PHE	A	312	7.212	11.127	56.853	1.00	13.06	A
	ATOM	1330	N	PHE	A	313	8.016	11.721	54.833	1.00	12.17	A
	ATOM	1331	CA	PHE	A	313	9.168	12.432	55.385	1.00	12.08	A
	ATOM	1332	CB	PHE	A	313	10.118	11.466	56.118	1.00	12.85	A
	ATOM	1333	CG	PHE	A	313	10.760	10.426	55.244	1.00	14.22	A
15	ATOM	1334	CD1	PHE	A	313	11.835	10.749	54.428	1.00	14.31	A
	ATOM	1335	CD2	PHE	A	313	10.315	9.108	55.274	1.00	14.25	A
	ATOM	1336	CE1	PHE	A	313	12.465	9.773	53.656	1.00	15.02	A
	ATOM	1337	CE2	PHE	A	313	10.938	8.126	54.505	1.00	14.36	A
	ATOM	1338	CZ	PHE	A	313	12.015	8.459	53.695	1.00	13.62	A
20	ATOM	1339	C	PHE	A	313	9.903	13.257	54.330	1.00	12.75	A
	ATOM	1340	O	PHE	A	313	9.659	13.099	53.127	1.00	12.22	A
	ATOM	1341	N	ASN	A	314	10.784	14.149	54.785	1.00	11.08	A
	ATOM	1342	CA	ASN	A	314	11.543	15.024	53.892	1.00	10.49	A
	ATOM	1343	CB	ASN	A	314	12.032	16.250	54.671	1.00	12.41	A
25	ATOM	1344	CG	ASN	A	314	12.615	17.332	53.771	1.00	11.22	A
	ATOM	1345	OD1	ASN	A	314	13.747	17.227	53.308	1.00	12.26	A
	ATOM	1346	ND2	ASN	A	314	11.837	18.381	53.526	1.00	10.25	A
	ATOM	1347	C	ASN	A	314	12.717	14.293	53.238	1.00	10.74	A
	ATOM	1348	O	ASN	A	314	13.433	13.532	53.890	1.00	8.98	A
30	ATOM	1349	N	VAL	A	315	12.897	14.534	51.940	1.00	10.78	A
	ATOM	1350	CA	VAL	A	315	13.952	13.900	51.152	1.00	10.36	A
	ATOM	1351	CB	VAL	A	315	13.967	14.458	49.711	1.00	9.40	A
	ATOM	1352	CG1	VAL	A	315	14.196	15.962	49.741	1.00	9.49	A
	ATOM	1353	CG2	VAL	A	315	15.053	13.774	48.898	1.00	11.21	A
35	ATOM	1354	C	VAL	A	315	15.354	14.051	51.748	1.00	10.97	A
	ATOM	1355	O	VAL	A	315	16.208	13.185	51.566	1.00	11.43	A
	ATOM	1356	N	SER	A	316	15.587	15.146	52.460	1.00	12.23	A
	ATOM	1357	CA	SER	A	316	16.893	15.403	53.068	1.00	12.04	A
	ATOM	1358	CB	SER	A	316	17.167	16.903	53.090	1.00	10.52	A
40	ATOM	1359	OG	SER	A	316	17.337	17.393	51.771	1.00	16.34	A
	ATOM	1360	C	SER	A	316	17.022	14.855	54.481	1.00	11.85	A
	ATOM	1361	O	SER	A	316	18.048	15.045	55.131	1.00	10.15	A
	ATOM	1362	N	ASP	A	317	15.982	14.171	54.949	1.00	11.31	A
	ATOM	1363	CA	ASP	A	317	15.970	13.611	56.299	1.00	10.43	A
45	ATOM	1364	CB	ASP	A	317	14.572	13.793	56.901	1.00	8.97	A
	ATOM	1365	CG	ASP	A	317	14.504	13.410	58.372	1.00	11.08	A
	ATOM	1366	OD1	ASP	A	317	13.452	13.672	59.003	1.00	12.28	A
	ATOM	1367	OD2	ASP	A	317	15.488	12.844	58.893	1.00	7.73	A
	ATOM	1368	C	ASP	A	317	16.364	12.134	56.286	1.00	10.67	A
50	ATOM	1369	O	ASP	A	317	15.505	11.260	56.203	1.00	11.01	A
	ATOM	1370	N	GLU	A	318	17.666	11.863	56.366	1.00	10.77	A
	ATOM	1371	CA	GLU	A	318	18.172	10.489	56.351	1.00	12.17	A
	ATOM	1372	CB	GLU	A	318	19.696	10.484	56.131	1.00	12.51	A
	ATOM	1373	CG	GLU	A	318	20.129	11.110	54.810	1.00	11.53	A
55	ATOM	1374	CD	GLU	A	318	21.635	11.139	54.623	1.00	12.31	A
	ATOM	1375	OE1	GLU	A	318	22.093	11.729	53.627	1.00	13.78	A

73

	ATOM	1376	OE2	GLU	A	318	22.364	10.573	55.462	1.00	13.40	A
	ATOM	1377	C	GLU	A	318	17.835	9.698	57.612	1.00	12.49	A
	ATOM	1378	O	GLU	A	318	17.821	8.468	57.593	1.00	13.32	A
	ATOM	1379	N	ALA	A	319	17.576	10.397	58.712	1.00	13.21	A
5	ATOM	1380	CA	ALA	A	319	17.231	9.730	59.965	1.00	12.18	A
	ATOM	1381	CB	ALA	A	319	17.169	10.737	61.101	1.00	10.58	A
	ATOM	1382	C	ALA	A	319	15.878	9.054	59.789	1.00	12.66	A
	ATOM	1383	O	ALA	A	319	15.727	7.859	60.056	1.00	13.04	A
	ATOM	1384	N	ALA	A	320	14.895	9.826	59.337	1.00	12.52	A
10	ATOM	1385	CA	ALA	A	320	13.557	9.300	59.109	1.00	11.74	A
	ATOM	1386	CB	ALA	A	320	12.618	10.420	58.663	1.00	12.20	A
	ATOM	1387	C	ALA	A	320	13.613	8.210	58.050	1.00	10.80	A
	ATOM	1388	O	ALA	A	320	12.840	7.259	58.095	1.00	11.42	A
	ATOM	1389	N	LEU	A	321	14.519	8.351	57.086	1.00	12.37	A
15	ATOM	1390	CA	LEU	A	321	14.663	7.341	56.033	1.00	11.66	A
	ATOM	1391	CB	LEU	A	321	15.769	7.737	55.049	1.00	11.52	A
	ATOM	1392	CG	LEU	A	321	16.168	6.650	54.039	1.00	11.08	A
	ATOM	1393	CD1	LEU	A	321	14.991	6.348	53.135	1.00	11.70	A
	ATOM	1394	CD2	LEU	A	321	17.374	7.100	53.224	1.00	9.59	A
20	ATOM	1395	C	LEU	A	321	14.996	5.979	56.647	1.00	12.69	A
	ATOM	1396	O	LEU	A	321	14.381	4.963	56.313	1.00	11.66	A
	ATOM	1397	N	LEU	A	322	15.984	5.958	57.539	1.00	14.23	A
	ATOM	1398	CA	LEU	A	322	16.382	4.720	58.201	1.00	13.49	A
	ATOM	1399	CB	LEU	A	322	17.680	4.922	58.983	1.00	14.50	A
25	ATOM	1400	CG	LEU	A	322	19.004	4.955	58.223	1.00	13.92	A
	ATOM	1401	CD1	LEU	A	322	20.113	5.395	59.171	1.00	14.87	A
	ATOM	1402	CD2	LEU	A	322	19.297	3.564	57.643	1.00	13.58	A
	ATOM	1403	C	LEU	A	322	15.296	4.255	59.165	1.00	15.38	A
	ATOM	1404	O	LEU	A	322	15.114	3.054	59.381	1.00	15.20	A
30	ATOM	1405	N	GLU	A	323	14.578	5.210	59.747	1.00	15.18	A
	ATOM	1406	CA	GLU	A	323	13.518	4.887	60.693	1.00	18.29	A
	ATOM	1407	CB	GLU	A	323	13.138	6.116	61.518	1.00	18.66	A
	ATOM	1408	CG	GLU	A	323	12.001	5.857	62.490	1.00	21.49	A
	ATOM	1409	CD	GLU	A	323	11.437	7.128	63.089	1.00	24.28	A
35	ATOM	1410	OE1	GLU	A	323	10.674	7.831	62.393	1.00	22.67	A
	ATOM	1411	OE2	GLU	A	323	11.765	7.429	64.259	1.00	27.85	A
	ATOM	1412	C	GLU	A	323	12.257	4.365	60.026	1.00	18.63	A
	ATOM	1413	O	GLU	A	323	11.669	3.392	60.479	1.00	19.52	A
	ATOM	1414	N	LYS	A	324	11.843	5.022	58.952	1.00	20.07	A
40	ATOM	1415	CA	LYS	A	324	10.620	4.646	58.264	1.00	21.79	A
	ATOM	1416	CB	LYS	A	324	9.922	5.917	57.780	1.00	21.00	A
	ATOM	1417	CG	LYS	A	324	9.671	6.890	58.926	1.00	21.15	A
	ATOM	1418	CD	LYS	A	324	8.868	8.113	58.522	1.00	20.19	A
	ATOM	1419	CE	LYS	A	324	8.583	8.984	59.741	1.00	20.66	A
45	ATOM	1420	NZ	LYS	A	324	7.690	10.134	59.411	1.00	23.09	A
	ATOM	1421	C	LYS	A	324	10.791	3.645	57.126	1.00	23.43	A
	ATOM	1422	O	LYS	A	324	10.040	2.678	57.043	1.00	23.83	A
	ATOM	1423	N	ALA	A	325	11.770	3.869	56.254	1.00	25.84	A
	ATOM	1424	CA	ALA	A	325	12.021	2.961	55.138	1.00	27.84	A
50	ATOM	1425	CB	ALA	A	325	12.364	3.746	53.890	1.00	26.82	A
	ATOM	1426	C	ALA	A	325	13.175	2.044	55.510	1.00	30.67	A
	ATOM	1427	O	ALA	A	325	13.892	1.541	54.647	1.00	32.48	A
	ATOM	1428	N	GLY	A	326	13.346	1.839	56.811	1.00	33.73	A
	ATOM	1429	CA	GLY	A	326	14.417	0.997	57.314	1.00	36.36	A
55	ATOM	1430	C	GLY	A	326	14.545	-0.348	56.630	1.00	37.69	A
	ATOM	1431	OT1	GLY	A	326	14.039	-1.339	57.197	1.00	38.55	A

	ATOM	1432	OT2	GLY A 326	15.140	-0.415	55.530	1.00	38.84	A
	TER									
	ATOM	1433	C	GLY B 1	27.024	31.838	46.808	1.00	46.99	CA
	ATOM	1434	O	GLY B 1	25.970	32.170	47.352	1.00	47.64	CA
5	ATOM	1435	N	GLY B 1	28.053	29.559	47.038	1.00	48.37	CA
	ATOM	1436	CA	GLY B 1	28.019	30.960	47.548	1.00	47.58	CA
	ATOM	1437	N	PRO B 2	27.344	32.250	45.570	1.00	45.71	CA
	ATOM	1438	CD	PRO B 2	28.729	32.222	45.063	1.00	45.50	CA
	ATOM	1439	CA	PRO B 2	26.500	33.098	44.719	1.00	44.55	CA
10	ATOM	1440	CB	PRO B 2	27.520	34.005	44.055	1.00	44.60	CA
	ATOM	1441	CG	PRO B 2	28.640	33.039	43.793	1.00	45.19	CA
	ATOM	1442	C	PRO B 2	25.681	32.303	43.689	1.00	42.88	CA
	ATOM	1443	O	PRO B 2	26.113	32.125	42.547	1.00	43.57	CA
	ATOM	1444	N	HYP B 3	24.480	31.829	44.077	1.00	40.90	CA
15	ATOM	1445	CD	HYP B 3	23.853	31.959	45.404	1.00	39.90	CA
	ATOM	1446	CA	HYP B 3	23.620	31.053	43.172	1.00	37.74	CA
	ATOM	1447	CB	HYP B 3	22.372	30.790	44.019	1.00	38.68	CA
	ATOM	1448	CG	HYP B 3	22.917	30.779	45.414	1.00	39.07	CA
	ATOM	1449	C	HYP B 3	23.287	31.766	41.864	1.00	34.90	CA
20	ATOM	1450	O	HYP B 3	23.009	32.965	41.852	1.00	34.40	CA
	ATOM	1451	OD	HYP B 3	21.922	30.851	46.427	1.00	38.93	CA
	ATOM	1452	N	GLY B 4	23.312	31.014	40.767	1.00	30.95	CA
	ATOM	1453	CA	GLY B 4	23.008	31.583	39.470	1.00	26.85	CA
	ATOM	1454	C	GLY B 4	21.622	32.197	39.402	1.00	24.34	CA
25	ATOM	1455	O	GLY B 4	20.841	32.078	40.344	1.00	23.22	CA
	ATOM	1456	N	PRO B 5	21.286	32.870	38.295	1.00	22.36	CA
	ATOM	1457	CD	PRO B 5	22.104	33.084	37.086	1.00	22.48	CA
	ATOM	1458	CA	PRO B 5	19.966	33.493	38.150	1.00	21.43	CA
	ATOM	1459	CB	PRO B 5	20.144	34.374	36.920	1.00	22.25	CA
30	ATOM	1460	CG	PRO B 5	21.075	33.559	36.076	1.00	23.04	CA
	ATOM	1461	C	PRO B 5	18.867	32.455	37.959	1.00	19.31	CA
	ATOM	1462	O	PRO B 5	19.131	31.347	37.498	1.00	17.49	CA
	ATOM	1463	N	HYP B 6	17.619	32.798	38.320	1.00	18.67	CA
	ATOM	1464	CD	HYP B 6	17.170	34.008	39.031	1.00	18.03	CA
35	ATOM	1465	CA	HYP B 6	16.516	31.841	38.152	1.00	17.47	CA
	ATOM	1466	CB	HYP B 6	15.343	32.512	38.872	1.00	18.15	CA
	ATOM	1467	CG	HYP B 6	16.002	33.485	39.813	1.00	17.95	CA
	ATOM	1468	C	HYP B 6	16.223	31.664	36.666	1.00	17.02	CA
	ATOM	1469	O	HYP B 6	16.597	32.516	35.851	1.00	13.78	CA
40	ATOM	1470	OD	HYP B 6	16.366	32.917	41.063	1.00	17.03	CA
	ATOM	1471	N	GLY B 7	15.554	30.567	36.315	1.00	16.69	CA
	ATOM	1472	CA	GLY B 7	15.211	30.333	34.921	1.00	17.54	CA
	ATOM	1473	C	GLY B 7	14.116	31.297	34.496	1.00	18.10	CA
	ATOM	1474	O	GLY B 7	13.595	32.034	35.331	1.00	18.65	CA
45	ATOM	1475	N	PHE B 8	13.768	31.308	33.211	1.00	18.05	CA
	ATOM	1476	CA	PHE B 8	12.724	32.201	32.719	1.00	20.44	CA
	ATOM	1477	CB	PHE B 8	12.758	32.294	31.191	1.00	24.57	CA
	ATOM	1478	CG	PHE B 8	13.366	33.569	30.675	1.00	28.99	CA
	ATOM	1479	CD1	PHE B 8	14.744	33.782	30.745	1.00	31.01	CA
50	ATOM	1480	CD2	PHE B 8	12.559	34.566	30.132	1.00	30.61	CA
	ATOM	1481	CE1	PHE B 8	15.310	34.969	30.276	1.00	31.21	CA
	ATOM	1482	CE2	PHE B 8	13.112	35.753	29.662	1.00	33.13	CA
	ATOM	1483	CZ	PHE B 8	14.494	35.956	29.735	1.00	33.64	CA
	ATOM	1484	C	PHE B 8	11.334	31.758	33.160	1.00	20.03	CA
55	ATOM	1485	O	PHE B 8	11.090	30.575	33.386	1.00	21.24	CA
	ATOM	1486	N	HYP B 9	10.401	32.714	33.285	1.00	19.18	CA

75

	ATOM	1487	CD	HYP	B	9	10.596	34.152	33.031	1.00	19.09	CA
	ATOM	1488	CA	HYP	B	9	9.023	32.425	33.704	1.00	18.49	CA
	ATOM	1489	CB	HYP	B	9	8.354	33.804	33.689	1.00	18.16	CA
	ATOM	1490	CG	HYP	B	9	9.528	34.762	33.877	1.00	19.48	CA
5	ATOM	1491	C	HYP	B	9	8.338	31.436	32.754	1.00	17.86	CA
	ATOM	1492	O	HYP	B	9	8.523	31.503	31.539	1.00	16.69	CA
	ATOM	1493	OD	HYP	B	9	9.934	34.942	35.228	1.00	19.21	CA
	ATOM	1494	N	GLY	B	10	7.549	30.523	33.315	1.00	18.32	CA
	ATOM	1495	CA	GLY	B	10	6.853	29.534	32.510	1.00	16.17	CA
10	ATOM	1496	C	GLY	B	10	5.674	30.093	31.732	1.00	17.31	CA
	ATOM	1497	O	GLY	B	10	5.255	31.237	31.942	1.00	16.56	CA
	ATOM	1498	N	GLU	B	11	5.127	29.273	30.839	1.00	18.09	CA
	ATOM	1499	CA	GLU	B	11	4.001	29.678	30.009	1.00	19.81	CA
	ATOM	1500	CB	GLU	B	11	4.092	29.010	28.631	1.00	23.10	CA
15	ATOM	1501	CG	GLU	B	11	5.378	29.311	27.853	1.00	27.78	CA
	ATOM	1502	CD	GLU	B	11	5.602	30.797	27.595	1.00	31.41	CA
	ATOM	1503	OE1	GLU	B	11	6.604	31.130	26.918	1.00	33.15	CA
	ATOM	1504	OE2	GLU	B	11	4.791	31.631	28.065	1.00	32.81	CA
	ATOM	1505	C	GLU	B	11	2.644	29.363	30.633	1.00	19.40	CA
20	ATOM	1506	O	GLU	B	11	2.560	28.777	31.715	1.00	17.55	CA
	ATOM	1507	N	ARG	B	12	1.590	29.763	29.927	1.00	18.86	CA
	ATOM	1508	CA	ARG	B	12	0.205	29.562	30.345	1.00	17.24	CA
	ATOM	1509	CB	ARG	B	12	-0.716	30.084	29.241	1.00	20.84	CA
	ATOM	1510	CG	ARG	B	12	-2.198	29.983	29.527	1.00	24.57	CA
25	ATOM	1511	CD	ARG	B	12	-3.024	30.038	28.231	1.00	28.77	CA
	ATOM	1512	NE	ARG	B	12	-2.686	31.166	27.361	1.00	30.12	CA
	ATOM	1513	CZ	ARG	B	12	-1.675	31.176	26.496	1.00	30.49	CA
	ATOM	1514	NH1	ARG	B	12	-0.889	30.115	26.372	1.00	32.79	CA
	ATOM	1515	NH2	ARG	B	12	-1.441	32.249	25.756	1.00	29.66	CA
30	ATOM	1516	C	ARG	B	12	-0.100	28.080	30.613	1.00	15.45	CA
	ATOM	1517	O	ARG	B	12	0.424	27.194	29.939	1.00	13.71	CA
	ATOM	1518	N	GLY	B	13	-0.961	27.818	31.588	1.00	13.54	CA
	ATOM	1519	CA	GLY	B	13	-1.306	26.445	31.911	1.00	13.61	CA
	ATOM	1520	C	GLY	B	13	-2.249	25.800	30.908	1.00	14.71	CA
35	ATOM	1521	O	GLY	B	13	-2.823	26.492	30.060	1.00	12.72	CA
	ATOM	1522	N	PRO	B	14	-2.421	24.464	30.969	1.00	15.39	CA
	ATOM	1523	CD	PRO	B	14	-1.663	23.508	31.797	1.00	14.36	CA
	ATOM	1524	CA	PRO	B	14	-3.315	23.753	30.047	1.00	14.99	CA
	ATOM	1525	CB	PRO	B	14	-3.052	22.279	30.369	1.00	14.60	CA
40	ATOM	1526	CG	PRO	B	14	-1.631	22.288	30.905	1.00	15.31	CA
	ATOM	1527	C	PRO	B	14	-4.775	24.130	30.301	1.00	15.89	CA
	ATOM	1528	O	PRO	B	14	-5.107	24.718	31.335	1.00	15.18	CA
	ATOM	1529	N	HYP	B	15	-5.668	23.795	29.357	1.00	16.77	CA
	ATOM	1530	CD	HYP	B	15	-5.431	23.164	28.046	1.00	15.95	CA
45	ATOM	1531	CA	HYP	B	15	-7.084	24.123	29.546	1.00	17.68	CA
	ATOM	1532	CB	HYP	B	15	-7.709	23.788	28.191	1.00	18.28	CA
	ATOM	1533	CG	HYP	B	15	-6.821	22.717	27.647	1.00	16.55	CA
	ATOM	1534	C	HYP	B	15	-7.689	23.310	30.683	1.00	19.44	CA
	ATOM	1535	O	HYP	B	15	-7.169	22.259	31.053	1.00	18.88	CA
50	ATOM	1536	OD	HYP	B	15	-6.966	22.530	26.236	1.00	17.79	CA
	ATOM	1537	N	GLY	B	16	-8.785	23.810	31.239	1.00	20.37	CA
	ATOM	1538	CA	GLY	B	16	-9.434	23.116	32.333	1.00	21.79	CA
	ATOM	1539	C	GLY	B	16	-10.233	21.920	31.862	1.00	22.72	CA
	ATOM	1540	O	GLY	B	16	-10.466	21.755	30.661	1.00	22.43	CA
55	ATOM	1541	N	PRO	B	17	-10.666	21.057	32.792	1.00	24.17	CA
	ATOM	1542	CD	PRO	B	17	-10.472	21.137	34.252	1.00	24.95	CA

	ATOM	1543	CA	PRO	B	17	-11.446	19.874	32.434	1.00	26.22	CA
	ATOM	1544	CB	PRO	B	17	-11.562	19.126	33.758	1.00	26.53	CA
	ATOM	1545	CG	PRO	B	17	-11.556	20.225	34.768	1.00	25.15	CA
	ATOM	1546	C	PRO	B	17	-12.803	20.235	31.847	1.00	27.93	CA
5	ATOM	1547	O	PRO	B	17	-13.339	21.315	32.107	1.00	27.72	CA
	ATOM	1548	N	HYP	B	18	-13.371	19.335	31.032	1.00	29.77	CA
	ATOM	1549	CD	HYP	B	18	-12.833	18.023	30.625	1.00	29.92	CA
	ATOM	1550	CA	HYP	B	18	-14.679	19.591	30.420	1.00	30.56	CA
	ATOM	1551	CB	HYP	B	18	-15.021	18.263	29.747	1.00	30.75	CA
10	ATOM	1552	CG	HYP	B	18	-13.678	17.690	29.426	1.00	30.63	CA
	ATOM	1553	C	HYP	B	18	-15.705	19.957	31.477	1.00	31.35	CA
	ATOM	1554	O	HYP	B	18	-15.523	19.677	32.662	1.00	32.13	CA
	ATOM	1555	OD	HYP	B	18	-13.134	18.149	28.197	1.00	31.27	CA
	ATOM	1556	N	GLY	B	19	-16.780	20.603	31.051	1.00	32.29	CA
15	ATOM	1557	CA	GLY	B	19	-17.829	20.951	31.990	1.00	32.48	CA
	ATOM	1558	C	GLY	B	19	-18.840	19.817	31.903	1.00	33.06	CA
	ATOM	1559	O	GLY	B	19	-18.815	19.070	30.926	1.00	31.96	CA
	ATOM	1560	N	PRO	B	20	-19.723	19.649	32.896	1.00	34.64	CA
	ATOM	1561	CD	PRO	B	20	-19.991	20.482	34.080	1.00	34.66	CA
20	ATOM	1562	CA	PRO	B	20	-20.694	18.555	32.792	1.00	34.86	CA
	ATOM	1563	CB	PRO	B	20	-21.571	18.748	34.025	1.00	34.62	CA
	ATOM	1564	CG	PRO	B	20	-21.457	20.218	34.307	1.00	35.11	CA
	ATOM	1565	C	PRO	B	20	-21.476	18.610	31.477	1.00	35.93	CA
	ATOM	1566	O	PRO	B	20	-21.684	19.689	30.917	1.00	35.62	CA
25	ATOM	1567	N	HYP	B	21	-21.915	17.443	30.973	1.00	36.92	CA
	ATOM	1568	CD	HYP	B	21	-21.636	16.123	31.566	1.00	37.42	CA
	ATOM	1569	CA	HYP	B	21	-22.684	17.306	29.723	1.00	37.36	CA
	ATOM	1570	CB	HYP	B	21	-23.146	15.844	29.760	1.00	37.79	CA
	ATOM	1571	CG	HYP	B	21	-22.011	15.169	30.442	1.00	38.04	CA
30	ATOM	1572	C	HYP	B	21	-23.851	18.280	29.636	1.00	37.37	CA
	ATOM	1573	O	HYP	B	21	-24.393	18.515	28.554	1.00	37.88	CA
	ATOM	1574	OD	HYP	B	21	-20.938	14.807	29.569	1.00	39.73	CA
	ATOM	1575	N	NHH	B	22	-24.252	18.843	30.764	1.00	37.11	CA
	TER											
35	ATOM	1576	C	GLY	C	1	35.293	30.667	43.820	1.00	42.71	CB
	ATOM	1577	O	GLY	C	1	35.319	30.946	42.621	1.00	42.96	CB
	ATOM	1578	N	GLY	C	1	35.242	32.981	44.701	1.00	43.02	CB
	ATOM	1579	CA	GLY	C	1	35.861	31.634	44.838	1.00	42.85	CB
	ATOM	1580	N	PRO	C	2	34.789	29.507	44.263	1.00	42.50	CB
40	ATOM	1581	CD	PRO	C	2	34.909	28.933	45.614	1.00	42.71	CB
	ATOM	1582	CA	PRO	C	2	34.218	28.530	43.333	1.00	41.69	CB
	ATOM	1583	CB	PRO	C	2	33.847	27.366	44.247	1.00	42.23	CB
	ATOM	1584	CG	PRO	C	2	34.875	27.450	45.329	1.00	42.25	CB
	ATOM	1585	C	PRO	C	2	32.993	29.123	42.640	1.00	41.38	CB
45	ATOM	1586	O	PRO	C	2	32.420	30.109	43.113	1.00	40.38	CB
	ATOM	1587	N	HYP	C	3	32.576	28.538	41.506	1.00	41.08	CB
	ATOM	1588	CD	HYP	C	3	33.085	27.350	40.795	1.00	41.06	CB
	ATOM	1589	CA	HYP	C	3	31.395	29.105	40.841	1.00	39.79	CB
	ATOM	1590	CB	HYP	C	3	31.311	28.320	39.532	1.00	40.33	CB
50	ATOM	1591	CG	HYP	C	3	31.925	26.997	39.886	1.00	41.40	CB
	ATOM	1592	C	HYP	C	3	30.151	28.938	41.710	1.00	38.06	CB
	ATOM	1593	O	HYP	C	3	30.065	28.007	42.517	1.00	36.78	CB
	ATOM	1594	OD	HYP	C	3	31.010	26.058	40.447	1.00	40.66	CB
	ATOM	1595	N	GLY	C	4	29.199	29.851	41.550	1.00	36.06	CB
55	ATOM	1596	CA	GLY	C	4	27.978	29.787	42.330	1.00	33.48	CB
	ATOM	1597	C	GLY	C	4	27.149	28.549	42.031	1.00	31.26	CB

	ATOM	1598	O	GLY	C	4	27.274	27.958	40.957	1.00	29.93	CB
	ATOM	1599	N	PRO	C	5	26.288	28.130	42.972	1.00	29.27	CB
	ATOM	1600	CD	PRO	C	5	25.996	28.786	44.260	1.00	29.55	CB
	ATOM	1601	CA	PRO	C	5	25.439	26.951	42.789	1.00	27.57	CB
5	ATOM	1602	CB	PRO	C	5	24.900	26.705	44.190	1.00	29.16	CB
	ATOM	1603	CG	PRO	C	5	24.708	28.101	44.691	1.00	29.18	CB
	ATOM	1604	C	PRO	C	5	24.325	27.240	41.782	1.00	24.50	CB
	ATOM	1605	O	PRO	C	5	23.970	28.397	41.554	1.00	23.77	CB
	ATOM	1606	N	HYP	C	6	23.769	26.190	41.162	1.00	23.07	CB
10	ATOM	1607	CD	HYP	C	6	24.191	24.781	41.263	1.00	23.05	CB
	ATOM	1608	CA	HYP	C	6	22.693	26.336	40.177	1.00	22.11	CB
	ATOM	1609	CB	HYP	C	6	22.223	24.903	39.975	1.00	22.93	CB
	ATOM	1610	CG	HYP	C	6	23.502	24.157	40.067	1.00	24.04	CB
	ATOM	1611	C	HYP	C	6	21.562	27.253	40.621	1.00	20.21	CB
15	ATOM	1612	O	HYP	C	6	21.185	27.275	41.790	1.00	19.92	CB
	ATOM	1613	OD	HYP	C	6	24.272	24.224	38.878	1.00	25.59	CB
	ATOM	1614	N	GLY	C	7	21.020	28.004	39.673	1.00	18.24	CB
	ATOM	1615	CA	GLY	C	7	19.929	28.908	39.982	1.00	18.08	CB
	ATOM	1616	C	GLY	C	7	18.631	28.158	40.205	1.00	16.18	CB
20	ATOM	1617	O	GLY	C	7	18.453	27.058	39.687	1.00	15.68	CB
	ATOM	1618	N	PHE	C	8	17.736	28.753	40.991	1.00	16.45	CB
	ATOM	1619	CA	PHE	C	8	16.433	28.162	41.297	1.00	15.97	CB
	ATOM	1620	CB	PHE	C	8	15.684	29.024	42.326	1.00	19.10	CB
	ATOM	1621	CG	PHE	C	8	16.405	29.201	43.641	1.00	22.85	CB
25	ATOM	1622	CD1	PHE	C	8	17.639	29.847	43.705	1.00	25.50	CB
	ATOM	1623	CD2	PHE	C	8	15.823	28.769	44.827	1.00	25.25	CB
	ATOM	1624	CE1	PHE	C	8	18.275	30.069	44.936	1.00	26.15	CB
	ATOM	1625	CE2	PHE	C	8	16.450	28.984	46.062	1.00	26.74	CB
	ATOM	1626	CZ	PHE	C	8	17.676	29.634	46.115	1.00	25.84	CB
30	ATOM	1627	C	PHE	C	8	15.580	28.067	40.025	1.00	13.88	CB
	ATOM	1628	O	PHE	C	8	15.840	28.758	39.043	1.00	9.98	CB
	ATOM	1629	N	HYP	C	9	14.556	27.192	40.026	1.00	13.66	CB
	ATOM	1630	CD	HYP	C	9	14.269	26.169	41.046	1.00	12.78	CB
	ATOM	1631	CA	HYP	C	9	13.678	27.034	38.858	1.00	12.96	CB
35	ATOM	1632	CB	HYP	C	9	12.718	25.924	39.289	1.00	13.91	CB
	ATOM	1633	CG	HYP	C	9	13.551	25.116	40.242	1.00	14.02	CB
	ATOM	1634	C	HYP	C	9	12.943	28.350	38.612	1.00	12.77	CB
	ATOM	1635	O	HYP	C	9	12.730	29.123	39.543	1.00	12.44	CB
	ATOM	1636	OD	HYP	C	9	14.426	24.210	39.593	1.00	14.70	CB
40	ATOM	1637	N	GLY	C	10	12.557	28.607	37.369	1.00	11.71	CB
	ATOM	1638	CA	GLY	C	10	11.855	29.845	37.076	1.00	13.31	CB
	ATOM	1639	C	GLY	C	10	10.401	29.830	37.520	1.00	13.58	CB
	ATOM	1640	O	GLY	C	10	9.823	28.767	37.734	1.00	13.71	CB
	ATOM	1641	N	GLU	C	11	9.814	31.015	37.667	1.00	14.37	CB
45	ATOM	1642	CA	GLU	C	11	8.422	31.147	38.076	1.00	15.28	CB
	ATOM	1643	CB	GLU	C	11	7.982	32.612	37.999	1.00	16.41	CB
	ATOM	1644	CG	GLU	C	11	8.639	33.530	39.015	1.00	16.23	CB
	ATOM	1645	CD	GLU	C	11	8.383	33.087	40.441	1.00	16.67	CB
	ATOM	1646	OE1	GLU	C	11	9.296	32.503	41.064	1.00	18.10	CB
50	ATOM	1647	OE2	GLU	C	11	7.262	33.310	40.935	1.00	17.35	CB
	ATOM	1648	C	GLU	C	11	7.505	30.313	37.187	1.00	15.50	CB
	ATOM	1649	O	GLU	C	11	7.720	30.211	35.979	1.00	13.06	CB
	ATOM	1650	N	ARG	C	12	6.480	29.719	37.793	1.00	17.27	CB
	ATOM	1651	CA	ARG	C	12	5.523	28.903	37.054	1.00	18.14	CB
55	ATOM	1652	CB	ARG	C	12	4.729	28.023	38.020	1.00	20.84	CB
	ATOM	1653	CG	ARG	C	12	3.932	26.932	37.347	1.00	23.28	CB

78

	ATOM	1654	CD	ARG	C	12	3.098	26.164	38.356	1.00	25.19	CB
	ATOM	1655	NE	ARG	C	12	2.324	25.099	37.725	1.00	25.98	CB
	ATOM	1656	CZ	ARG	C	12	1.444	24.341	38.371	1.00	27.02	CB
	ATOM	1657	NH1	ARG	C	12	1.229	24.535	39.665	1.00	26.61	CB
5	ATOM	1658	NH2	ARG	C	12	0.780	23.390	37.728	1.00	26.52	CB
	ATOM	1659	C	ARG	C	12	4.586	29.843	36.299	1.00	18.11	CB
	ATOM	1660	O	ARG	C	12	4.235	30.912	36.807	1.00	18.92	CB
	ATOM	1661	N	GLY	C	13	4.198	29.459	35.086	1.00	16.77	CB
	ATOM	1662	CA	GLY	C	13	3.317	30.300	34.297	1.00	15.62	CB
10	ATOM	1663	C	GLY	C	13	2.003	30.595	34.998	1.00	16.24	CB
	ATOM	1664	O	GLY	C	13	1.769	30.107	36.105	1.00	15.03	CB
	ATOM	1665	N	PRO	C	14	1.128	31.412	34.388	1.00	16.73	CB
	ATOM	1666	CD	PRO	C	14	1.348	32.224	33.174	1.00	16.28	CB
	ATOM	1667	CA	PRO	C	14	-0.162	31.736	35.007	1.00	16.91	CB
15	ATOM	1668	CB	PRO	C	14	-0.526	33.065	34.359	1.00	17.54	CB
	ATOM	1669	CG	PRO	C	14	-0.009	32.879	32.957	1.00	17.17	CB
	ATOM	1670	C	PRO	C	14	-1.190	30.646	34.702	1.00	16.45	CB
	ATOM	1671	O	PRO	C	14	-0.983	29.820	33.820	1.00	13.87	CB
	ATOM	1672	N	HYP	C	15	-2.313	30.637	35.433	1.00	17.28	CB
20	ATOM	1673	CD	HYP	C	15	-2.597	31.470	36.615	1.00	17.85	CB
	ATOM	1674	CA	HYP	C	15	-3.370	29.639	35.224	1.00	16.58	CB
	ATOM	1675	CB	HYP	C	15	-4.470	30.097	36.174	1.00	18.24	CB
	ATOM	1676	CG	HYP	C	15	-3.696	30.684	37.300	1.00	18.18	CB
	ATOM	1677	C	HYP	C	15	-3.863	29.580	33.784	1.00	15.70	CB
25	ATOM	1678	O	HYP	C	15	-4.031	30.612	33.137	1.00	15.03	CB
	ATOM	1679	OD	HYP	C	15	-3.209	29.719	38.215	1.00	19.41	CB
	ATOM	1680	N	GLY	C	16	-4.088	28.363	33.292	1.00	15.59	CB
	ATOM	1681	CA	GLY	C	16	-4.586	28.171	31.943	1.00	12.51	CB
	ATOM	1682	C	GLY	C	16	-6.038	28.619	31.839	1.00	13.38	CB
30	ATOM	1683	O	GLY	C	16	-6.658	28.942	32.861	1.00	10.23	CB
	ATOM	1684	N	PRO	C	17	-6.616	28.637	30.624	1.00	12.36	CB
	ATOM	1685	CD	PRO	C	17	-5.984	28.233	29.354	1.00	12.72	CB
	ATOM	1686	CA	PRO	C	17	-8.003	29.056	30.396	1.00	13.23	CB
	ATOM	1687	CB	PRO	C	17	-8.023	29.337	28.900	1.00	14.02	CB
35	ATOM	1688	CG	PRO	C	17	-7.154	28.252	28.377	1.00	10.82	CB
	ATOM	1689	C	PRO	C	17	-9.041	28.003	30.791	1.00	13.57	CB
	ATOM	1690	O	PRO	C	17	-8.714	26.821	30.965	1.00	11.15	CB
	ATOM	1691	N	HYP	C	18	-10.313	28.425	30.926	1.00	12.83	CB
	ATOM	1692	CD	HYP	C	18	-10.797	29.804	30.744	1.00	11.99	CB
40	ATOM	1693	CA	HYP	C	18	-11.418	27.532	31.298	1.00	13.95	CB
	ATOM	1694	CB	HYP	C	18	-12.636	28.460	31.291	1.00	11.62	CB
	ATOM	1695	CG	HYP	C	18	-12.048	29.793	31.565	1.00	12.88	CB
	ATOM	1696	C	HYP	C	18	-11.569	26.406	30.279	1.00	14.31	CB
	ATOM	1697	O	HYP	C	18	-11.328	26.611	29.093	1.00	15.44	CB
45	ATOM	1698	OD	HYP	C	18	-11.810	30.040	32.943	1.00	13.37	CB
	ATOM	1699	N	GLY	C	19	-11.968	25.227	30.742	1.00	14.55	CB
	ATOM	1700	CA	GLY	C	19	-12.143	24.102	29.846	1.00	13.79	CB
	ATOM	1701	C	GLY	C	19	-13.352	24.277	28.942	1.00	14.74	CB
	ATOM	1702	O	GLY	C	19	-14.112	25.234	29.098	1.00	13.65	CB
50	ATOM	1703	N	PRO	C	20	-13.564	23.368	27.980	1.00	15.70	CB
	ATOM	1704	CD	PRO	C	20	-12.694	22.250	27.562	1.00	15.16	CB
	ATOM	1705	CA	PRO	C	20	-14.725	23.500	27.093	1.00	16.72	CB
	ATOM	1706	CB	PRO	C	20	-14.347	22.622	25.912	1.00	15.89	CB
	ATOM	1707	CG	PRO	C	20	-13.562	21.518	26.567	1.00	17.28	CB
55	ATOM	1708	C	PRO	C	20	-16.004	23.036	27.774	1.00	17.49	CB
	ATOM	1709	O	PRO	C	20	-15.962	22.474	28.870	1.00	18.83	CB

	ATOM	1710	N	HYP	C	21	-17.171	23.285	27.139	1.00	18.90	CB
	ATOM	1711	CD	HYP	C	21	-17.323	24.107	25.924	1.00	20.00	CB
	ATOM	1712	CA	HYP	C	21	-18.489	22.895	27.667	1.00	19.37	CB
	ATOM	1713	CB	HYP	C	21	-19.455	23.295	26.540	1.00	20.77	CB
5	ATOM	1714	CG	HYP	C	21	-18.797	24.467	25.957	1.00	19.53	CB
	ATOM	1715	C	HYP	C	21	-18.536	21.401	27.950	1.00	20.63	CB
	ATOM	1716	O	HYP	C	21	-17.942	20.627	27.218	1.00	20.57	CB
	ATOM	1717	OD	HYP	C	21	-19.098	25.673	26.637	1.00	21.66	CB
	ATOM	1718	N	NHH	C	22	-19.227	20.988	29.001	1.00	19.10	CB
10	TER											
	ATOM	1719	C	GLY	D	1	31.268	34.798	43.143	1.00	52.14	CC
	ATOM	1720	O	GLY	D	1	30.268	35.506	43.021	1.00	52.89	CC
	ATOM	1721	N	GLY	D	1	31.780	33.147	44.952	1.00	53.28	CC
	ATOM	1722	CA	GLY	D	1	31.873	34.570	44.517	1.00	52.57	CC
15	ATOM	1723	N	PRO	D	2	31.857	34.209	42.087	1.00	51.43	CC
	ATOM	1724	CD	PRO	D	2	33.111	33.443	42.215	1.00	51.55	CC
	ATOM	1725	CA	PRO	D	2	31.448	34.287	40.676	1.00	50.79	CC
	ATOM	1726	CB	PRO	D	2	32.376	33.279	40.005	1.00	51.06	CC
	ATOM	1727	CG	PRO	D	2	33.628	33.426	40.796	1.00	51.42	CC
20	ATOM	1728	C	PRO	D	2	29.960	33.984	40.413	1.00	49.69	CC
	ATOM	1729	O	PRO	D	2	29.157	33.928	41.336	1.00	49.54	CC
	ATOM	1730	N	HYP	D	3	29.577	33.803	39.135	1.00	48.62	CC
	ATOM	1731	CD	HYP	D	3	30.283	34.328	37.950	1.00	48.82	CC
	ATOM	1732	CA	HYP	D	3	28.171	33.508	38.814	1.00	46.31	CC
25	ATOM	1733	CB	HYP	D	3	27.945	34.309	37.538	1.00	47.40	CC
	ATOM	1734	CG	HYP	D	3	29.259	34.142	36.847	1.00	48.30	CC
	ATOM	1735	C	HYP	D	3	27.806	32.037	38.623	1.00	43.31	CC
	ATOM	1736	O	HYP	D	3	28.461	31.308	37.872	1.00	43.51	CC
	ATOM	1737	OD	HYP	D	3	29.400	32.904	36.166	1.00	49.71	CC
30	ATOM	1738	N	GLY	D	4	26.746	31.608	39.301	1.00	40.44	CC
	ATOM	1739	CA	GLY	D	4	26.299	30.234	39.171	1.00	36.00	CC
	ATOM	1740	C	GLY	D	4	25.518	30.054	37.881	1.00	32.49	CC
	ATOM	1741	O	GLY	D	4	25.111	31.040	37.265	1.00	31.46	CC
	ATOM	1742	N	PRO	D	5	25.300	28.809	37.433	1.00	30.10	CC
35	ATOM	1743	CD	PRO	D	5	25.830	27.545	37.974	1.00	30.57	CC
	ATOM	1744	CA	PRO	D	5	24.553	28.569	36.197	1.00	27.85	CC
	ATOM	1745	CB	PRO	D	5	24.874	27.112	35.883	1.00	28.49	CC
	ATOM	1746	CG	PRO	D	5	25.011	26.512	37.237	1.00	29.90	CC
	ATOM	1747	C	PRO	D	5	23.051	28.822	36.347	1.00	25.42	CC
40	ATOM	1748	O	PRO	D	5	22.496	28.711	37.440	1.00	24.50	CC
	ATOM	1749	N	HYP	D	6	22.378	29.174	35.240	1.00	23.36	CC
	ATOM	1750	CD	HYP	D	6	22.987	29.406	33.920	1.00	22.17	CC
	ATOM	1751	CA	HYP	D	6	20.935	29.453	35.210	1.00	21.50	CC
	ATOM	1752	CB	HYP	D	6	20.696	29.920	33.771	1.00	21.57	CC
45	ATOM	1753	CG	HYP	D	6	22.059	30.432	33.343	1.00	23.24	CC
	ATOM	1754	C	HYP	D	6	20.116	28.209	35.546	1.00	19.47	CC
	ATOM	1755	O	HYP	D	6	20.454	27.110	35.120	1.00	19.29	CC
	ATOM	1756	OD	HYP	D	6	22.348	31.750	33.794	1.00	24.53	CC
	ATOM	1757	N	GLY	D	7	19.044	28.381	36.309	1.00	17.93	CC
50	ATOM	1758	CA	GLY	D	7	18.216	27.240	36.666	1.00	17.76	CC
	ATOM	1759	C	GLY	D	7	17.295	26.813	35.535	1.00	16.59	CC
	ATOM	1760	O	GLY	D	7	17.386	27.333	34.422	1.00	14.21	CC
	ATOM	1761	N	PHE	D	8	16.415	25.854	35.804	1.00	16.53	CC
	ATOM	1762	CA	PHE	D	8	15.476	25.406	34.778	1.00	15.90	CC
55	ATOM	1763	CB	PHE	D	8	14.733	24.132	35.199	1.00	14.16	CC
	ATOM	1764	CG	PHE	D	8	15.528	22.869	35.040	1.00	12.37	CC

80

	ATOM	1765	CD1	PHE	D	8	16.339	22.405	36.070	1.00	12.14	CC
	ATOM	1766	CD2	PHE	D	8	15.428	22.116	33.875	1.00	9.69	CC
	ATOM	1767	CE1	PHE	D	8	17.037	21.197	35.945	1.00	12.19	CC
	ATOM	1768	CE2	PHE	D	8	16.120	20.910	33.737	1.00	10.35	CC
5	ATOM	1769	CZ	PHE	D	8	16.924	20.448	34.771	1.00	8.89	CC
	ATOM	1770	C	PHE	D	8	14.430	26.485	34.574	1.00	15.73	CC
	ATOM	1771	O	PHE	D	8	14.135	27.252	35.490	1.00	16.97	CC
	ATOM	1772	N	HYP	D	9	13.882	26.584	33.358	1.00	16.42	CC
	ATOM	1773	CD	HYP	D	9	14.495	26.153	32.089	1.00	18.36	CC
10	ATOM	1774	CA	HYP	D	9	12.847	27.596	33.117	1.00	16.58	CC
	ATOM	1775	CB	HYP	D	9	12.654	27.534	31.609	1.00	17.03	CC
	ATOM	1776	CG	HYP	D	9	14.036	27.243	31.136	1.00	17.77	CC
	ATOM	1777	C	HYP	D	9	11.599	27.148	33.887	1.00	15.93	CC
	ATOM	1778	O	HYP	D	9	11.501	25.982	34.293	1.00	15.10	CC
15	ATOM	1779	OD	HYP	D	9	14.095	26.856	29.776	1.00	21.73	CC
	ATOM	1780	N	GLY	D	10	10.653	28.055	34.094	1.00	13.77	CC
	ATOM	1781	CA	GLY	D	10	9.453	27.691	34.831	1.00	13.02	CC
	ATOM	1782	C	GLY	D	10	8.510	26.738	34.109	1.00	12.42	CC
	ATOM	1783	O	GLY	D	10	8.501	26.687	32.878	1.00	12.88	CC
20	ATOM	1784	N	GLU	D	11	7.720	25.974	34.863	1.00	11.80	CC
	ATOM	1785	CA	GLU	D	11	6.754	25.051	34.260	1.00	12.74	CC
	ATOM	1786	CB	GLU	D	11	6.389	23.913	35.220	1.00	10.65	CC
	ATOM	1787	CG	GLU	D	11	7.500	22.914	35.476	1.00	10.47	CC
	ATOM	1788	CD	GLU	D	11	7.058	21.735	36.342	1.00	9.64	CC
25	ATOM	1789	OE1	GLU	D	11	7.903	21.213	37.093	1.00	10.29	CC
	ATOM	1790	OE2	GLU	D	11	5.884	21.318	36.268	1.00	7.01	CC
	ATOM	1791	C	GLU	D	11	5.475	25.810	33.898	1.00	13.76	CC
	ATOM	1792	O	GLU	D	11	5.269	26.942	34.341	1.00	13.67	CC
	ATOM	1793	N	ARG	D	12	4.615	25.188	33.098	1.00	14.12	CC
30	ATOM	1794	CA	ARG	D	12	3.356	25.828	32.709	1.00	14.59	CC
	ATOM	1795	CB	ARG	D	12	2.601	24.958	31.710	1.00	14.27	CC
	ATOM	1796	CG	ARG	D	12	3.451	24.479	30.569	1.00	16.49	CC
	ATOM	1797	CD	ARG	D	12	2.655	23.601	29.646	1.00	19.21	CC
	ATOM	1798	NE	ARG	D	12	3.525	22.833	28.762	1.00	22.96	CC
35	ATOM	1799	CZ	ARG	D	12	3.096	21.868	27.963	1.00	21.61	CC
	ATOM	1800	NH1	ARG	D	12	1.806	21.563	27.940	1.00	22.39	CC
	ATOM	1801	NH2	ARG	D	12	3.954	21.199	27.207	1.00	23.45	CC
	ATOM	1802	C	ARG	D	12	2.508	25.990	33.959	1.00	13.43	CC
	ATOM	1803	O	ARG	D	12	2.670	25.239	34.916	1.00	13.31	CC
40	ATOM	1804	N	GLY	D	13	1.602	26.961	33.948	1.00	12.98	CC
	ATOM	1805	CA	GLY	D	13	0.750	27.170	35.104	1.00	11.53	CC
	ATOM	1806	C	GLY	D	13	-0.199	26.006	35.345	1.00	11.89	CC
	ATOM	1807	O	GLY	D	13	-0.260	25.078	34.538	1.00	8.83	CC
	ATOM	1808	N	PRO	D	14	-0.947	26.016	36.464	1.00	12.32	CC
45	ATOM	1809	CD	PRO	D	14	-1.005	27.064	37.497	1.00	11.59	CC
	ATOM	1810	CA	PRO	D	14	-1.890	24.933	36.764	1.00	12.45	CC
	ATOM	1811	CB	PRO	D	14	-2.364	25.275	38.174	1.00	13.04	CC
	ATOM	1812	CG	PRO	D	14	-2.319	26.762	38.187	1.00	11.93	CC
	ATOM	1813	C	PRO	D	14	-3.039	24.923	35.755	1.00	12.89	CC
50	ATOM	1814	O	PRO	D	14	-3.289	25.928	35.082	1.00	12.39	CC
	ATOM	1815	N	HYP	D	15	-3.748	23.789	35.632	1.00	13.51	CC
	ATOM	1816	CD	HYP	D	15	-3.595	22.531	36.385	1.00	14.38	CC
	ATOM	1817	CA	HYP	D	15	-4.868	23.708	34.684	1.00	13.05	CC
	ATOM	1818	CB	HYP	D	15	-5.454	22.315	34.942	1.00	14.65	CC
55	ATOM	1819	CG	HYP	D	15	-4.292	21.541	35.488	1.00	13.87	CC
	ATOM	1820	C	HYP	D	15	-5.877	24.811	34.990	1.00	12.80	CC

81

	ATOM	1821	O	HYP	D	15	-5.971	25.268	36.130	1.00	12.18	CC
	ATOM	1822	OD	HYP	D	15	-3.452	20.982	34.490	1.00	15.74	CC
	ATOM	1823	N	GLY	D	16	-6.623	25.237	33.973	1.00	13.68	CC
	ATOM	1824	CA	GLY	D	16	-7.619	26.277	34.165	1.00	13.35	CC
5	ATOM	1825	C	GLY	D	16	-8.887	25.737	34.808	1.00	15.22	CC
	ATOM	1826	O	GLY	D	16	-9.015	24.529	35.002	1.00	14.14	CC
	ATOM	1827	N	PRO	D	17	-9.858	26.604	35.130	1.00	16.78	CC
	ATOM	1828	CD	PRO	D	17	-9.857	28.062	34.923	1.00	15.74	CC
	ATOM	1829	CA	PRO	D	17	-11.110	26.166	35.760	1.00	17.75	CC
10	ATOM	1830	CB	PRO	D	17	-11.840	27.484	36.045	1.00	17.60	CC
	ATOM	1831	CG	PRO	D	17	-10.729	28.522	36.051	1.00	17.99	CC
	ATOM	1832	C	PRO	D	17	-11.945	25.237	34.884	1.00	18.61	CC
	ATOM	1833	O	PRO	D	17	-11.758	25.172	33.667	1.00	18.40	CC
	ATOM	1834	N	HYP	D	18	-12.876	24.489	35.498	1.00	19.66	CC
15	ATOM	1835	CD	HYP	D	18	-13.157	24.363	36.939	1.00	19.82	CC
	ATOM	1836	CA	HYP	D	18	-13.720	23.580	34.715	1.00	19.63	CC
	ATOM	1837	CB	HYP	D	18	-14.608	22.924	35.778	1.00	21.13	CC
	ATOM	1838	CG	HYP	D	18	-13.760	22.991	37.010	1.00	20.32	CC
	ATOM	1839	C	HYP	D	18	-14.529	24.432	33.746	1.00	18.79	CC
20	ATOM	1840	O	HYP	D	18	-14.809	25.592	34.033	1.00	18.95	CC
	ATOM	1841	OD	HYP	D	18	-12.787	21.962	37.083	1.00	23.21	CC
	ATOM	1842	N	GLY	D	19	-14.893	23.863	32.602	1.00	18.88	CC
	ATOM	1843	CA	GLY	D	19	-15.668	24.613	31.631	1.00	18.26	CC
	ATOM	1844	C	GLY	D	19	-17.104	24.824	32.078	1.00	18.68	CC
25	ATOM	1845	O	GLY	D	19	-17.477	24.399	33.174	1.00	16.61	CC
	ATOM	1846	N	PRO	D	20	-17.938	25.502	31.265	1.00	19.16	CC
	ATOM	1847	CD	PRO	D	20	-17.561	26.245	30.055	1.00	19.89	CC
	ATOM	1848	CA	PRO	D	20	-19.342	25.752	31.604	1.00	20.26	CC
	ATOM	1849	CB	PRO	D	20	-19.732	26.886	30.660	1.00	20.83	CC
30	ATOM	1850	CG	PRO	D	20	-18.412	27.463	30.179	1.00	20.62	CC
	ATOM	1851	C	PRO	D	20	-20.162	24.491	31.300	1.00	21.06	CC
	ATOM	1852	O	PRO	D	20	-19.697	23.616	30.577	1.00	20.72	CC
	ATOM	1853	N	HYP	D	21	-21.378	24.377	31.859	1.00	21.33	CC
	ATOM	1854	CD	HYP	D	21	-21.927	25.146	32.992	1.00	21.67	CC
35	ATOM	1855	CA	HYP	D	21	-22.215	23.189	31.590	1.00	21.74	CC
	ATOM	1856	CB	HYP	D	21	-23.468	23.451	32.440	1.00	22.13	CC
	ATOM	1857	CG	HYP	D	21	-22.878	24.155	33.631	1.00	21.33	CC
	ATOM	1858	C	HYP	D	21	-22.551	23.036	30.094	1.00	21.48	CC
	ATOM	1859	O	HYP	D	21	-22.726	24.026	29.378	1.00	22.03	CC
40	ATOM	1860	OD	HYP	D	21	-22.228	23.265	34.516	1.00	23.21	CC
	ATOM	1861	N	NHH	D	22	-22.657	21.806	29.613	1.00	20.91	CC
	TER											
	ATOM	1862	O	HOH	E	401	16.330	14.217	61.265	1.00	7.27	W
	ATOM	1863	O	HOH	E	402	19.752	18.951	37.584	1.00	15.74	W
45	ATOM	1864	O	HOH	E	403	2.016	10.266	32.905	1.00	23.77	W
	ATOM	1865	O	HOH	E	404	4.266	11.763	34.068	1.00	9.44	W
	ATOM	1866	O	HOH	E	405	10.519	11.274	32.006	1.00	21.51	W
	ATOM	1867	O	HOH	E	406	1.504	12.266	29.042	1.00	21.77	W
	ATOM	1868	O	HOH	E	407	20.908	16.308	36.153	1.00	17.64	W
50	ATOM	1869	O	HOH	E	408	17.091	20.929	39.613	1.00	12.14	W
	ATOM	1870	O	HOH	E	409	8.326	-0.946	34.265	1.00	26.84	W
	ATOM	1871	O	HOH	E	410	10.585	22.363	46.723	1.00	11.87	W
	ATOM	1872	O	HOH	E	411	25.378	10.794	55.016	1.00	24.26	W
	ATOM	1873	O	HOH	E	412	20.406	16.105	51.398	1.00	11.61	W
55	ATOM	1874	O	HOH	E	413	16.878	25.139	38.620	1.00	14.37	W
	ATOM	1875	O	HOH	E	414	-0.842	16.913	58.285	1.00	16.87	W

	ATOM	1876	O	HOH	E	415	10.411	24.807	49.914	1.00	52.97	W
	ATOM	1877	O	HOH	E	416	13.368	22.460	47.864	1.00	18.07	W
	ATOM	1878	O	HOH	E	417	13.150	11.289	62.240	1.00	47.74	W
	ATOM	1879	O	HOH	E	418	1.303	-6.147	47.976	1.00	16.49	W
5	ATOM	1880	O	HOH	E	419	8.599	13.854	30.673	1.00	18.89	W
	ATOM	1881	O	HOH	E	420	10.232	-2.382	37.701	1.00	14.49	W
	ATOM	1882	O	HOH	E	421	-3.601	4.030	52.968	1.00	15.10	W
	ATOM	1883	O	HOH	E	422	5.410	-7.210	42.591	1.00	21.64	W
	ATOM	1884	O	HOH	E	423	3.279	-9.212	44.213	1.00	29.74	W
10	ATOM	1885	O	HOH	E	424	-16.951	19.401	35.082	1.00	34.19	W
	ATOM	1886	O	HOH	E	425	-1.522	17.595	32.378	1.00	24.97	W
	ATOM	1887	O	HOH	E	426	8.884	13.210	58.870	1.00	25.98	W
	ATOM	1888	O	HOH	E	427	11.250	14.511	57.508	1.00	10.37	W
	ATOM	1889	O	HOH	E	428	-2.929	10.128	32.874	1.00	37.15	W
15	ATOM	1890	O	HOH	E	429	-2.009	12.948	33.369	1.00	17.55	W
	ATOM	1891	O	HOH	E	430	-5.571	16.309	35.097	1.00	32.24	W
	ATOM	1892	O	HOH	E	431	-4.389	33.187	33.783	1.00	18.95	W
	ATOM	1893	O	HOH	E	432	15.969	10.887	53.476	1.00	32.71	W
	ATOM	1894	O	HOH	E	433	14.711	22.985	29.797	1.00	54.65	W
20	ATOM	1895	O	HOH	E	434	4.779	-4.755	31.380	1.00	28.71	W
	ATOM	1896	O	HOH	E	435	-5.058	10.030	50.214	1.00	28.66	W
	ATOM	1897	O	HOH	E	436	-16.040	29.691	30.628	1.00	30.05	W
	ATOM	1898	O	HOH	E	437	-7.659	20.017	35.921	1.00	29.62	W
	ATOM	1899	O	HOH	E	438	7.624	5.929	62.247	1.00	18.95	W
25	ATOM	1900	O	HOH	E	439	5.101	33.897	32.954	1.00	15.88	W
	ATOM	1901	O	HOH	E	440	20.979	6.175	33.371	1.00	32.22	W
	ATOM	1902	O	HOH	E	441	-6.393	32.120	30.613	1.00	29.97	W
	ATOM	1903	O	HOH	E	442	23.467	19.968	39.168	1.00	40.58	W
	ATOM	1904	O	HOH	E	443	15.123	6.339	30.675	1.00	22.32	W
30	ATOM	1905	O	HOH	E	444	-2.185	1.475	51.922	1.00	30.14	W
	ATOM	1906	O	HOH	E	445	16.868	-11.187	38.112	1.00	33.83	W
	ATOM	1907	O	HOH	E	446	9.709	29.020	43.378	1.00	47.17	W
	ATOM	1908	O	HOH	E	447	9.022	20.434	54.535	1.00	39.15	W
	ATOM	1909	O	HOH	E	448	18.161	0.376	56.588	1.00	41.53	W
35	ATOM	1910	O	HOH	E	449	1.292	37.093	34.663	1.00	39.13	W
	ATOM	1911	O	HOH	E	450	-5.218	28.339	39.373	1.00	20.28	W
	ATOM	1912	O	HOH	E	451	-18.990	23.798	35.404	1.00	22.93	W
	ATOM	1913	O	HOH	E	452	15.022	35.511	35.405	1.00	34.37	W
	ATOM	1914	O	HOH	E	453	11.191	32.962	36.498	1.00	14.69	W
40	ATOM	1915	O	HOH	E	454	15.768	-4.887	52.120	1.00	22.65	W
	ATOM	1916	O	HOH	E	455	1.460	-6.101	37.435	1.00	20.27	W
	ATOM	1917	O	HOH	E	456	2.850	-3.540	37.375	1.00	21.11	W
	ATOM	1918	O	HOH	E	457	-0.387	-3.197	40.345	1.00	22.30	W
	ATOM	1919	O	HOH	E	458	17.628	33.001	33.070	1.00	28.12	W
45	ATOM	1920	O	HOH	E	459	20.718	33.705	32.843	1.00	47.02	W
	ATOM	1921	O	HOH	E	460	12.058	-13.328	39.611	1.00	28.23	W
	ATOM	1922	O	HOH	E	461	19.085	-13.047	45.158	1.00	36.96	W
	ATOM	1923	O	HOH	E	462	25.263	12.268	35.569	1.00	33.88	W
	ATOM	1924	O	HOH	E	463	1.677	-5.057	32.759	1.00	35.05	W
50	ATOM	1925	O	HOH	E	464	13.210	-5.412	32.844	1.00	19.95	W
	ATOM	1926	O	HOH	E	465	20.199	2.558	34.558	1.00	23.92	W
	ATOM	1927	O	HOH	E	466	10.903	11.186	29.019	1.00	22.99	W
	ATOM	1928	O	HOH	E	467	12.411	31.695	40.333	1.00	18.47	W
	ATOM	1929	O	HOH	E	468	18.494	31.420	41.330	1.00	36.00	W
55	ATOM	1930	O	HOH	E	469	0.713	30.644	38.709	1.00	32.15	W
	ATOM	1931	O	HOH	E	470	4.495	-7.749	54.370	1.00	27.53	W

	ATOM	1932	O	HOH	E	471	4.455	16.672	59.168	1.00	33.94	W
	ATOM	1933	O	HOH	E	472	-7.327	18.714	30.650	1.00	75.20	W
	ATOM	1934	O	HOH	E	473	-15.390	28.107	33.235	1.00	23.19	W
	ATOM	1935	O	HOH	E	474	-25.202	16.177	24.609	1.00	30.95	W
5	ATOM	1936	O	HOH	E	475	7.128	18.700	40.698	1.00	16.55	W
	ATOM	1937	O	HOH	E	476	23.267	16.273	48.985	1.00	56.29	W
	ATOM	1938	O	HOH	E	477	28.423	-0.449	48.099	1.00	28.46	W
	ATOM	1939	O	HOH	E	478	18.290	5.977	30.269	1.00	35.16	W
	ATOM	1940	O	HOH	E	479	-2.932	19.947	46.633	1.00	37.58	W
10	ATOM	1941	O	HOH	E	480	-6.995	14.103	33.192	1.00	41.98	W
	ATOM	1942	O	HOH	E	481	19.155	28.681	30.733	1.00	41.30	W
	ATOM	1943	O	HOH	E	482	8.752	19.818	28.348	1.00	18.61	W
	ATOM	1944	O	HOH	E	483	13.768	-10.940	38.730	1.00	25.60	W
	ATOM	1945	O	HOH	E	484	-9.232	12.028	47.636	1.00	29.15	W
15	ATOM	1946	O	HOH	E	485	25.768	-2.672	34.238	1.00	19.91	W
	ATOM	1947	O	HOH	E	486	-9.793	8.985	29.027	1.00	47.04	W
	ATOM	1948	O	HOH	E	487	36.629	34.002	46.802	1.00	36.63	W
	ATOM	1949	O	HOH	E	488	-10.031	3.831	41.340	1.00	23.32	W
	ATOM	1950	O	HOH	E	489	3.698	-8.671	31.566	1.00	26.69	W
20	ATOM	1951	O	HOH	E	490	16.860	-15.407	49.734	1.00	42.23	W
	ATOM	1952	O	HOH	E	491	-1.973	-11.244	43.332	1.00	54.06	W
	ATOM	1953	O	HOH	E	492	2.252	-3.277	56.623	1.00	59.17	W
	ATOM	1954	O	HOH	E	493	-0.813	20.662	43.718	1.00	29.10	W
	ATOM	1955	O	HOH	E	494	27.179	32.232	34.060	1.00	33.41	W
25	ATOM	1956	O	HOH	E	495	9.702	16.259	28.490	1.00	30.80	W
	ATOM	1957	O	HOH	E	496	-5.273	5.984	51.412	1.00	26.74	W
	ATOM	1958	O	HOH	E	497	12.811	20.705	25.466	1.00	36.98	W
	ATOM	1959	O	HOH	E	498	4.397	-2.916	59.475	1.00	45.37	W
	ATOM	1960	O	HOH	E	499	21.810	20.049	42.888	1.00	25.48	W
30	ATOM	1961	O	HOH	E	500	29.335	-5.682	39.527	1.00	29.98	W
	ATOM	1962	O	HOH	E	501	-4.035	1.559	59.722	1.00	48.77	W
	ATOM	1963	O	HOH	E	502	24.853	-4.028	51.970	1.00	29.73	W
	ATOM	1964	O	HOH	E	503	8.735	12.981	27.657	1.00	25.99	W
	ATOM	1965	O	HOH	E	504	4.608	5.432	66.221	1.00	39.32	W
35	ATOM	1966	O	HOH	E	505	8.157	26.632	37.716	1.00	19.09	W
	ATOM	1967	O	HOH	E	506	19.925	21.667	40.974	1.00	30.96	W
	ATOM	1968	O	HOH	E	507	21.123	21.624	38.019	1.00	57.54	W
	ATOM	1969	O	HOH	E	508	19.670	4.586	54.357	1.00	18.45	W
	ATOM	1970	O	HOH	E	509	16.405	2.164	52.694	1.00	15.67	W
40	ATOM	1971	O	HOH	E	510	17.181	3.240	55.387	1.00	20.43	W
	ATOM	1972	O	HOH	E	511	10.379	22.476	43.820	1.00	10.33	W
	ATOM	1973	O	HOH	E	512	-5.658	18.433	37.515	1.00	9.41	W
	ATOM	1974	O	HOH	E	513	-0.352	11.410	31.231	1.00	22.75	W
	ATOM	1975	O	HOH	E	514	-1.032	-6.393	39.369	1.00	71.81	W
45	ATOM	1976	O	HOH	E	515	12.801	14.283	61.993	1.00	43.75	W
	ATOM	1977	O	HOH	E	516	0.335	-7.160	34.633	1.00	43.12	W
	ATOM	1978	O	HOH	E	517	18.740	9.195	34.517	1.00	21.42	W
	ATOM	1979	O	HOH	E	518	21.092	26.747	46.523	1.00	37.98	W
	ATOM	1980	O	HOH	E	519	-0.634	-5.353	30.779	1.00	31.44	W
50	ATOM	1981	O	HOH	E	520	9.702	29.614	29.819	1.00	39.63	W
	ATOM	1982	O	HOH	E	521	2.103	31.457	25.374	1.00	60.68	W
	ATOM	1983	O	HOH	E	522	21.839	23.414	46.265	1.00	27.45	W
	ATOM	1984	O	HOH	E	523	-1.829	-6.665	43.612	1.00	38.69	W
	ATOM	1985	O	HOH	E	524	-16.318	15.309	29.036	1.00	29.84	W
55	ATOM	1986	O	HOH	E	525	12.381	9.143	26.968	1.00	35.75	W
	ATOM	1987	O	HOH	E	526	-9.464	13.244	43.157	1.00	15.14	W

	ATOM	1988	O	HOH E 527	1.957	19.483	58.941	1.00	44.43	W
	ATOM	1989	O	HOH E 528	-7.641	5.258	33.722	1.00	42.72	W
	ATOM	1990	O	HOH E 529	9.446	17.350	65.141	1.00	58.61	W
	ATOM	1991	O	HOH E 530	26.874	39.005	45.593	1.00	38.89	W
5	ATOM	1992	O	HOH E 531	21.700	9.818	32.431	1.00	29.79	W
	ATOM	1993	O	HOH E 532	19.909	37.845	37.897	1.00	45.65	W
	ATOM	1994	O	HOH E 533	-4.483	18.944	32.657	1.00	29.09	W
	ATOM	1995	O	HOH E 534	5.879	18.842	61.111	1.00	25.87	W
	ATOM	1996	O	HOH E 535	14.645	-14.638	53.958	1.00	34.91	W
10	ATOM	1997	O	HOH E 536	10.758	23.693	29.607	1.00	39.53	W
	ATOM	1998	O	HOH E 537	14.338	29.236	52.072	1.00	23.79	W
	ATOM	1999	O	HOH E 538	-1.741	9.523	54.031	1.00	15.67	W
	ATOM	2000	O	HOH E 539	37.974	28.457	47.538	1.00	37.53	W
	ATOM	2001	O	HOH E 540	-4.043	22.878	40.941	1.00	24.51	W
15	ATOM	2002	O	HOH E 541	-10.067	3.093	33.051	1.00	39.04	W
	ATOM	2003	O	HOH E 542	23.692	16.947	40.249	1.00	37.69	W
	ATOM	2004	O	HOH E 543	-14.538	18.262	36.711	1.00	25.98	W
	ATOM	2005	O	HOH E 544	-21.782	25.567	27.128	1.00	22.21	W
	ATOM	2006	O	HOH E 545	-6.512	24.664	43.761	1.00	24.02	W
20	ATOM	2007	O	HOH E 546	0.663	-12.626	51.997	1.00	21.29	W
	ATOM	2008	O	HOH E 547	5.183	-4.422	55.353	1.00	28.59	W
	ATOM	2009	O	HOH E 548	15.427	-11.562	53.600	1.00	41.82	W
	ATOM	2010	O	HOH E 549	-6.105	0.971	34.469	1.00	33.69	W
	ATOM	2011	O	HOH E 550	24.009	14.010	45.618	1.00	31.33	W
25	ATOM	2012	O	HOH E 551	28.845	1.189	53.843	1.00	25.92	W
	ATOM	2013	O	HOH E 552	22.693	-2.757	30.748	1.00	39.50	W
	ATOM	2014	O	HOH E 553	14.366	8.993	63.904	1.00	27.99	W
	ATOM	2015	O	HOH E 554	-2.851	7.676	50.104	1.00	6.24	W
	ATOM	2016	O	HOH E 555	-21.496	18.740	25.299	1.00	37.92	W
30	ATOM	2017	O	HOH E 556	-4.586	-0.965	54.920	1.00	32.72	W
	ATOM	2018	O	HOH E 557	28.684	7.487	39.407	1.00	38.90	W
	ATOM	2019	O	HOH E 558	-4.261	27.809	42.326	1.00	38.34	W
	ATOM	2020	O	HOH E 559	27.593	12.602	39.403	1.00	33.36	W
	ATOM	2021	O	HOH E 560	5.408	21.728	39.073	1.00	18.41	W
35	ATOM	2022	O	HOH E 561	4.934	33.417	35.974	1.00	41.20	W
	ATOM	2023	O	HOH E 562	20.940	-9.117	33.600	1.00	37.49	W
	ATOM	2024	O	HOH E 563	25.023	4.235	34.909	1.00	32.12	W
	ATOM	2025	O	HOH E 564	-7.915	31.142	34.213	1.00	20.84	W
	ATOM	2026	O	HOH E 565	25.443	21.564	41.029	1.00	29.81	W
40	ATOM	2027	O	HOH E 566	7.224	3.183	57.981	1.00	18.29	W
	ATOM	2028	O	HOH E 567	-11.011	17.891	38.676	1.00	54.99	W
	ATOM	2029	O	HOH E 568	27.552	-6.668	34.568	1.00	57.12	W
	ATOM	2030	O	HOH E 569	-9.431	19.864	28.498	1.00	33.60	W
	ATOM	2031	O	HOH E 570	-9.953	33.734	35.439	1.00	38.58	W
45	ATOM	2032	O	HOH E 571	15.884	-3.180	55.349	1.00	42.47	W
	ATOM	2033	O	HOH E 572	9.077	20.453	25.079	1.00	34.23	W
	ATOM	2034	O	HOH E 573	27.196	8.842	33.494	1.00	28.68	W
	ATOM	2035	O	HOH E 574	3.622	-14.068	39.777	1.00	40.01	W
	ATOM	2036	O	HOH E 575	22.780	-6.705	48.821	1.00	35.65	W
50	ATOM	2037	O	HOH E 576	20.461	14.459	53.991	1.00	7.42	W
	ATOM	2038	O	HOH E 577	27.952	24.030	44.546	1.00	49.20	W
	ATOM	2039	O	HOH E 578	2.048	26.398	43.059	1.00	38.93	W
	ATOM	2040	O	HOH E 579	18.772	13.735	50.322	1.00	14.30	W
	ATOM	2041	O	HOH E 580	28.890	4.103	47.890	1.00	39.36	W
55	ATOM	2042	O	HOH E 581	16.438	0.081	60.966	1.00	45.15	W
	ATOM	2043	O	HOH E 582	6.734	26.793	26.473	1.00	55.90	W

85

	ATOM	2044	O	HOH	E	583	1.207	4.137	65.627	1.00	45.41	W
	ATOM	2045	O	HOH	E	584	7.326	-9.176	55.828	1.00	55.37	W
	ATOM	2046	O	HOH	E	585	-5.971	-6.427	38.603	1.00	31.68	W
	ATOM	2047	O	HOH	E	586	3.834	-8.745	40.456	1.00	20.37	W
5	ATOM	2048	O	HOH	E	587	18.895	-15.206	53.910	1.00	36.75	W
	ATOM	2049	O	HOH	E	588	10.278	12.294	61.398	1.00	49.20	W
	ATOM	2050	O	HOH	E	589	23.956	15.507	34.852	1.00	41.12	W
	ATOM	2051	O	HOH	E	590	-0.393	16.534	29.704	1.00	50.39	W
	ATOM	2052	O	HOH	E	591	28.619	-2.738	54.840	1.00	60.38	W
10	ATOM	2053	O	HOH	E	592	16.294	-17.370	59.916	1.00	37.59	W
	ATOM	2054	O	HOH	E	593	26.970	17.196	40.746	1.00	51.31	W
	ATOM	2055	O	HOH	E	594	19.730	-17.598	48.544	1.00	40.50	W
	ATOM	2056	O	HOH	E	595	1.326	0.954	59.482	1.00	34.91	W
	ATOM	2057	O	HOH	E	596	-9.799	9.892	37.138	1.00	33.55	W
15	ATOM	2058	O	HOH	E	597	-0.061	-9.253	45.965	1.00	50.81	W
	ATOM	2059	O	HOH	E	598	-9.383	16.434	31.738	1.00	80.11	W
	ATOM	2060	O	HOH	E	599	28.769	8.640	42.670	1.00	43.27	W
	ATOM	2061	O	HOH	E	600	-0.063	-14.933	49.352	1.00	49.59	W
	ATOM	2062	O	HOH	E	601	-3.092	19.360	39.749	1.00	10.48	W
20	ATOM	2063	O	HOH	E	602	2.098	30.090	44.138	1.00	33.04	W
	ATOM	2064	O	HOH	E	603	16.517	-5.223	41.821	1.00	13.16	W
	ATOM	2065	O	HOH	E	604	13.725	-15.908	43.046	1.00	50.39	W
	ATOM	2066	O	HOH	E	605	-8.398	-0.815	36.648	1.00	44.78	W
	ATOM	2067	O	HOH	E	606	-11.723	16.827	35.869	1.00	45.21	W
25	ATOM	2068	O	HOH	E	607	21.277	-5.651	56.343	1.00	29.34	W
	ATOM	2069	O	HOH	E	608	0.385	28.090	25.264	1.00	30.39	W
	ATOM	2070	O	HOH	E	609	22.972	36.785	37.710	1.00	61.85	W
	ATOM	2071	O	HOH	E	610	-22.932	23.819	37.010	1.00	35.16	W
	ATOM	2072	O	HOH	E	611	-0.053	32.476	43.573	1.00	47.38	W
30	ATOM	2073	O	HOH	E	612	16.349	-4.295	32.442	1.00	11.94	W
	ATOM	2074	O	HOH	E	613	8.944	17.294	55.291	1.00	38.30	W
	ATOM	2075	O	HOH	E	614	-12.696	5.454	42.347	1.00	24.01	W
	ATOM	2076	O	HOH	E	615	9.177	8.214	28.044	1.00	14.97	W
	ATOM	2077	O	HOH	E	616	0.445	33.900	38.846	1.00	49.81	W
35	ATOM	2078	O	HOH	E	617	21.274	-2.650	56.811	1.00	51.42	W
	ATOM	2079	O	HOH	E	618	-10.014	10.985	40.675	1.00	19.46	W
	ATOM	2080	O	HOH	E	619	-0.454	23.829	44.924	1.00	45.60	W
	ATOM	2081	O	HOH	E	620	11.214	19.178	21.651	1.00	43.14	W
	ATOM	2082	O	HOH	E	621	0.405	-9.345	49.102	1.00	29.74	W
40	ATOM	2083	O	HOH	E	622	12.410	20.925	30.282	1.00	32.22	W
	ATOM	2084	O	HOH	E	623	1.346	-7.579	51.489	1.00	37.32	W
	ATOM	2085	O	HOH	E	624	0.952	-1.848	62.790	1.00	40.55	W
	ATOM	2086	O	HOH	E	625	25.065	35.727	35.689	1.00	49.74	W
	ATOM	2087	O	HOH	E	626	-0.370	-8.630	31.015	1.00	29.03	W
45	ATOM	2088	O	HOH	E	627	-16.728	15.876	25.532	1.00	30.88	W
	ATOM	2089	O	HOH	E	628	6.938	-5.411	53.020	1.00	42.93	W
	ATOM	2090	O	HOH	E	629	24.380	1.854	32.909	1.00	47.21	W
	ATOM	2091	O	HOH	E	630	-8.097	-0.898	58.999	1.00	26.17	W
	ATOM	2092	O	HOH	E	631	6.349	26.620	30.559	1.00	19.66	W
50	ATOM	2093	O	HOH	E	632	-2.843	-4.402	37.498	1.00	36.21	W
	ATOM	2094	O	HOH	E	633	-11.910	13.215	48.308	1.00	38.00	W
	ATOM	2095	O	HOH	E	634	-3.324	-7.892	37.394	1.00	38.68	W
	ATOM	2096	O	HOH	E	635	24.398	-13.158	48.927	1.00	43.76	W
	ATOM	2097	O	HOH	E	636	-8.198	-5.459	47.003	1.00	27.11	W
55	ATOM	2098	O	HOH	E	637	-8.309	2.465	36.126	1.00	41.61	W
	ATOM	2099	O	HOH	E	638	11.803	20.581	62.626	1.00	35.46	W

	ATOM	2100	O	HOH	E	639	10.945	19.084	58.586	1.00	45.01	W
	ATOM	2101	O	HOH	E	640	24.849	29.419	47.628	1.00	43.17	W
	ATOM	2102	O	HOH	E	641	29.935	-2.937	50.468	1.00	46.17	W
	ATOM	2103	O	HOH	E	642	-13.168	15.458	33.377	1.00	44.29	W
5	ATOM	2104	O	HOH	E	643	30.171	-8.396	50.663	1.00	44.09	W
	ATOM	2105	O	HOH	E	644	-3.800	-10.918	49.026	1.00	42.03	W
	ATOM	2106	O	HOH	E	645	-11.802	13.503	31.227	1.00	32.17	W
	ATOM	2107	O	HOH	E	646	25.724	15.828	32.256	1.00	47.08	W
	ATOM	2108	O	HOH	E	647	23.197	36.930	41.760	1.00	59.31	W
10	ATOM	2109	O	HOH	E	648	6.297	13.476	62.219	1.00	20.21	W
	ATOM	2110	O	HOH	E	649	26.923	39.279	48.907	1.00	38.82	W
	ATOM	2111	O	HOH	E	650	-11.912	28.753	27.748	1.00	15.52	W
	ATOM	2112	O	HOH	E	651	-1.841	0.730	55.015	1.00	34.19	W
	ATOM	2113	O	HOH	E	652	27.087	19.363	43.124	1.00	35.99	W
15	ATOM	2114	O	HOH	E	653	-5.759	32.720	51.478	1.00	42.93	W
	ATOM	2115	O	HOH	E	654	2.519	-7.426	58.675	1.00	44.06	W
	ATOM	2116	O	HOH	E	655	19.199	36.052	31.423	1.00	50.09	W
	ATOM	2117	O	HOH	E	656	36.482	33.963	37.970	1.00	29.85	W
	ATOM	2118	O	HOH	E	657	17.605	38.239	35.191	1.00	49.64	W
20	ATOM	2119	O	HOH	E	658	-6.132	-1.762	40.679	1.00	58.90	W
	ATOM	2120	O	HOH	E	659	16.738	-12.983	56.218	1.00	26.39	W
	ATOM	2121	O	HOH	E	660	30.120	2.212	50.795	1.00	47.95	W
	ATOM	2122	O	HOH	E	661	-2.330	32.018	54.211	1.00	22.05	W
	ATOM	2123	O	HOH	E	662	26.040	10.878	43.103	1.00	58.31	W
25	ATOM	2124	O	HOH	E	663	12.297	13.980	28.533	1.00	28.23	W
	ATOM	2125	O	HOH	E	664	29.821	12.619	35.702	1.00	36.51	W
	ATOM	2126	O	HOH	E	665	-4.617	-1.126	50.876	1.00	38.50	W
	ATOM	2127	O	HOH	E	666	24.545	-0.669	55.100	1.00	32.21	W
	ATOM	2128	O	HOH	E	667	-7.088	31.748	54.539	1.00	38.30	W
30	ATOM	2129	O	HOH	E	668	28.885	15.172	42.351	1.00	38.33	W
	ATOM	2130	O	HOH	E	669	-10.569	21.693	38.518	1.00	38.74	W
	ATOM	2131	O	HOH	E	670	21.244	5.913	29.116	1.00	61.57	W
	ATOM	2132	O	HOH	E	671	-5.925	23.682	38.495	1.00	35.75	W
	ATOM	2133	O	HOH	E	672	-5.893	25.939	47.728	1.00	31.91	W
35	ATOM	2134	O	HOH	E	673	4.714	-10.124	59.049	1.00	47.84	W
	ATOM	2135	O	HOH	E	674	-7.727	-4.136	55.451	1.00	24.28	W
	ATOM	2136	O	HOH	E	675	8.051	-12.031	31.037	1.00	26.07	W
	ATOM	2137	O	HOH	E	676	6.482	12.323	23.254	1.00	41.15	W
	ATOM	2138	O	HOH	E	677	28.692	38.404	43.002	1.00	53.47	W
40	ATOM	2139	O	HOH	E	678	8.274	3.989	68.327	1.00	29.04	W
	ATOM	2140	O	HOH	E	679	14.925	-15.917	62.867	1.00	30.26	W
	ATOM	2141	O	HOH	E	680	25.612	12.902	48.272	1.00	68.00	W
	ATOM	2142	O	HOH	E	681	12.405	4.058	68.632	1.00	29.34	W
	ATOM	2143	O	HOH	E	682	16.645	26.144	28.767	1.00	37.16	W
45	ATOM	2144	O	HOH	E	683	4.557	0.245	60.083	1.00	46.50	W
	ATOM	2145	O	HOH	E	684	23.005	-9.610	47.006	1.00	39.61	W
	ATOM	2146	O	HOH	E	685	-15.268	27.535	28.052	1.00	56.53	W
	ATOM	2147	O	HOH	E	686	-3.271	32.616	30.463	1.00	32.99	W
	ATOM	2148	O	HOH	E	687	-1.210	-0.738	58.568	1.00	67.47	W
50	ATOM	2149	O	HOH	E	688	27.788	35.525	47.975	1.00	40.99	W
	ATOM	2150	O	HOH	E	689	2.086	34.462	35.942	1.00	27.35	W
	ATOM	2151	O	HOH	E	690	10.069	2.633	70.673	1.00	49.43	W
	ATOM	2152	O	HOH	E	691	21.297	-14.655	49.191	1.00	49.35	W
	ATOM	2153	O	HOH	E	692	19.982	-16.815	59.582	1.00	56.16	W
55	ATOM	2154	O	HOH	E	693	20.800	35.579	40.253	1.00	48.20	W
	ATOM	2155	O	HOH	E	694	24.030	6.818	32.263	1.00	50.91	W

87

	ATOM	2156	O	HOH	E	695	-1.111	27.060	46.541	1.00	17.67	W
	ATOM	2157	O	HOH	E	696	-27.078	18.341	26.678	1.00	55.01	W
	ATOM	2158	O	HOH	E	697	-10.231	0.457	56.323	1.00	33.31	W
	ATOM	2159	O	HOH	E	698	4.275	-2.353	63.270	1.00	40.77	W
5	ATOM	2160	O	HOH	E	699	28.449	24.425	47.948	1.00	32.19	W
	ATOM	2161	O	HOH	E	700	30.889	38.367	39.277	1.00	54.24	W
	ATOM	2162	O	HOH	E	701	6.516	33.704	54.312	1.00	24.50	W
	ATOM	2163	O	HOH	E	702	9.479	32.909	53.611	1.00	53.53	W
	ATOM	2164	O	HOH	E	703	9.352	29.832	54.842	1.00	34.81	W
10	ATOM	2165	O	HOH	E	704	26.759	36.138	40.043	1.00	30.98	W
	ATOM	2166	O	HOH	E	705	29.458	-6.695	53.369	1.00	47.75	W
	ATOM	2167	O	HOH	E	706	5.033	-10.973	29.828	1.00	27.71	W
	ATOM	2168	O	HOH	E	707	27.793	-9.749	35.681	1.00	31.20	W
	ATOM	2169	O	HOH	E	708	31.071	-1.537	53.144	1.00	32.97	W
15	ATOM	2170	O	HOH	E	709	-3.807	22.472	44.590	1.00	46.35	W
	ATOM	2171	O	HOH	E	710	-4.795	-7.128	44.799	1.00	28.48	W
	ATOM	2172	O	HOH	E	711	-12.586	1.440	45.045	1.00	36.39	W
	ATOM	2173	O	HOH	E	712	-5.260	3.802	61.612	1.00	40.65	W
	ATOM	2174	O	HOH	E	713	29.964	1.189	35.812	1.00	34.49	W
20	ATOM	2175	O	HOH	E	714	-2.343	-12.035	40.222	1.00	69.00	W
	ATOM	2176	O	HOH	E	715	9.302	23.483	53.331	1.00	44.74	W
	ATOM	2177	O	HOH	E	716	-2.242	-2.626	62.126	1.00	38.70	W
	ATOM	2178	O	HOH	E	717	-7.275	0.894	52.443	1.00	54.44	W
	ATOM	2179	O	HOH	E	718	-8.110	15.858	43.753	1.00	42.70	W
25	ATOM	2180	O	HOH	E	719	26.788	-8.036	52.120	1.00	40.32	W
	ATOM	2181	O	HOH	E	720	6.407	3.434	64.438	1.00	28.31	W
	ATOM	2182	O	HOH	E	721	-5.768	15.496	29.504	1.00	39.40	W
	ATOM	2183	O	HOH	E	722	31.860	30.480	48.051	1.00	35.91	W
	ATOM	2184	O	HOH	E	723	-2.018	-11.813	46.456	1.00	40.13	W
30	ATOM	2185	O	HOH	E	724	-14.067	13.952	45.904	1.00	30.17	W
	ATOM	2186	O	HOH	E	725	11.597	22.036	22.756	1.00	43.20	W
	ATOM	2187	O	HOH	E	726	12.253	25.948	27.576	1.00	42.36	W
	ATOM	2188	O	HOH	E	727	0.693	-4.936	60.187	1.00	55.60	W
	ATOM	2189	O	HOH	E	728	3.595	14.524	25.741	1.00	30.29	W
35	ATOM	2190	O	HOH	E	729	29.954	37.854	47.035	1.00	52.60	W
	ATOM	2191	O	HOH	E	730	-2.366	30.916	41.868	1.00	55.38	W
	ATOM	2192	O	HOH	E	731	8.713	-11.641	36.683	1.00	30.73	W
	ATOM	2193	O	HOH	E	732	0.761	-5.195	53.384	1.00	38.64	W
	ATOM	2194	O	HOH	E	733	31.365	26.739	47.933	1.00	31.61	W
40	ATOM	2195	O	HOH	E	734	7.345	16.504	26.173	1.00	64.82	W
	ATOM	2196	O	HOH	E	735	10.677	0.163	68.748	1.00	36.34	W
	ATOM	2197	O	HOH	E	736	27.161	35.880	32.022	1.00	33.61	W
	ATOM	2198	O	HOH	E	737	-13.094	10.266	30.707	1.00	43.14	W
	ATOM	2199	O	HOH	E	738	-10.853	17.032	27.531	1.00	38.09	W
45	ATOM	2200	O	HOH	E	739	3.458	16.325	42.437	1.00	7.40	W
	ATOM	2201	O	HOH	E	740	1.544	-12.771	41.970	1.00	43.59	W
	ATOM	2202	O	HOH	E	741	-1.559	2.106	29.784	1.00	31.14	W
	ATOM	2203	O	HOH	E	742	12.165	-12.601	53.138	1.00	28.68	W
	ATOM	2204	O	HOH	E	743	-7.457	9.069	33.302	1.00	55.50	W
50	ATOM	2205	O	HOH	E	744	38.921	31.695	46.548	1.00	26.37	W
	ATOM	2206	O	HOH	E	745	10.857	-10.683	32.696	1.00	39.32	W
	ATOM	2207	O	HOH	E	746	22.495	18.359	51.539	1.00	63.86	W
	ATOM	2208	O	HOH	E	747	-2.309	34.601	37.405	1.00	44.56	W
	ATOM	2209	O	HOH	E	748	27.912	17.187	45.245	1.00	46.22	W
55	ATOM	2210	O	HOH	E	749	-5.769	11.268	31.499	1.00	57.12	W
	ATOM	2211	O	HOH	E	750	-9.792	14.584	34.747	1.00	49.85	W

88

	ATOM	2212	O	HOH	E	751	-11.874	-1.486	58.793	1.00	44.85	W
	ATOM	2213	O	HOH	E	752	27.694	25.282	40.488	1.00	33.06	W
	ATOM	2214	O	HOH	E	753	-4.429	3.543	33.226	1.00	55.03	W
	ATOM	2215	O	HOH	E	754	9.486	26.613	30.244	1.00	28.82	W
5	ATOM	2216	O	HOH	E	755	16.245	21.348	27.760	1.00	49.05	W
	ATOM	2217	O	HOH	E	756	5.957	-12.920	38.184	1.00	55.64	W
	ATOM	2218	O	HOH	E	757	-1.395	-3.051	52.384	1.00	36.76	W
	ATOM	2219	O	HOH	E	758	-23.397	28.050	27.312	1.00	49.99	W
	ATOM	2220	O	HOH	E	759	-3.913	17.130	47.667	1.00	40.93	W
10	ATOM	2221	O	HOH	E	760	8.477	-3.858	56.162	1.00	32.91	W
	ATOM	2222	O	HOH	E	762	26.500	-4.882	49.324	1.00	61.66	W
	ATOM	2223	O	HOH	E	763	3.962	17.618	26.722	1.00	44.99	W
	ATOM	2224	O	HOH	E	764	-7.442	30.127	37.158	1.00	47.35	W
	ATOM	2225	O	HOH	E	765	-9.170	1.976	59.674	1.00	40.00	W
15	ATOM	2226	O	HOH	E	766	1.556	-9.249	54.896	1.00	46.10	W
	ATOM	2227	O	HOH	E	767	23.553	11.164	30.150	1.00	57.11	W
	ATOM	2228	O	HOH	E	768	-6.304	-9.029	42.535	1.00	34.59	W
	ATOM	2229	O	HOH	E	769	12.201	26.847	52.874	1.00	44.51	W
	ATOM	2230	O	HOH	E	770	8.167	36.689	53.755	1.00	42.84	W
20	ATOM	2231	O	HOH	E	771	7.844	25.653	40.709	1.00	11.73	W
	ATOM	2232	O	HOH	E	772	10.893	-0.048	52.560	1.00	29.20	W
	ATOM	2233	O	HOH	E	773	5.664	0.278	57.220	1.00	21.93	W
	ATOM	2234	O	HOH	E	774	5.263	27.600	45.159	1.00	20.60	W
	ATOM	2235	O	HOH	E	775	17.170	-3.453	39.193	1.00	18.37	W
25	ATOM	2236	O	HOH	E	776	-2.126	-9.071	34.451	1.00	27.96	W
	ATOM	2237	O	HOH	E	777	26.372	-0.053	36.568	1.00	32.03	W
	ATOM	2238	O	HOH	E	778	11.643	-4.518	55.330	1.00	27.32	W
	ATOM	2239	O	HOH	E	779	-7.701	28.135	54.948	1.00	37.66	W
	ATOM	2240	O	HOH	E	780	7.009	19.440	56.694	1.00	45.06	W
30	ATOM	2241	O	HOH	E	781	-2.535	-3.002	65.200	1.00	44.49	W
	ATOM	2242	O	HOH	E	782	29.850	-8.720	55.997	1.00	33.80	W
	ATOM	2243	O	HOH	E	783	29.002	-1.110	38.096	1.00	49.80	W
	ATOM	2244	O	HOH	E	784	2.629	-11.502	38.153	1.00	20.48	W
	ATOM	2245	O	HOH	E	785	8.170	-2.889	59.317	1.00	55.76	W
35	ATOM	2246	O	HOH	E	786	-7.757	7.231	36.343	1.00	44.27	W
	ATOM	2247	O	HOH	E	787	29.509	41.574	42.391	1.00	30.71	W
	ATOM	2248	O	HOH	E	788	12.321	5.000	73.438	1.00	39.23	W
	ATOM	2249	O	HOH	E	789	9.077	-0.805	56.886	1.00	49.68	W
	ATOM	2250	O	HOH	E	790	20.165	3.781	31.501	1.00	56.66	W
40	ATOM	2251	O	HOH	E	791	9.932	0.809	61.593	1.00	51.39	W
	ATOM	2252	O	HOH	E	792	-5.760	35.496	52.936	1.00	48.89	W
	ATOM	2253	O	HOH	E	793	6.379	23.275	56.289	1.00	34.66	W
	ATOM	2254	O	HOH	E	794	-8.872	27.821	51.823	1.00	45.23	W
	ATOM	2255	O	HOH	E	795	12.375	13.901	24.850	1.00	36.05	W
45	ATOM	2256	O	HOH	E	796	8.356	10.904	25.421	1.00	36.51	W
	ATOM	2257	O	HOH	E	797	24.045	36.583	31.107	1.00	27.65	W
	ATOM	2258	O	HOH	E	798	16.372	-13.823	59.823	1.00	36.61	W
	ATOM	2259	O	HOH	E	799	3.373	-1.958	66.429	1.00	34.14	W
	ATOM	2260	O	HOH	E	800	28.182	27.903	50.321	1.00	38.54	W
50	ATOM	2261	O	HOH	E	801	25.336	2.496	55.259	1.00	49.82	W
	TER											
	HETATM	2262	CO	CO	F	400	7.161	20.051	38.857	1.00	17.95	M
	TER											
	END											

55

Table 2 - Interactions between the $\alpha 2$ I-domain surface and the triple-helical peptide.

The table shows the co-ordinates of both the receptor and ligand surfaces, defined by identifiable interactions between the two. The interacting residue is indicated as (A) or (M), according to Table 1, representing I-domain or metal ion, respectively, or as (D) or (C), according to Table 1, representing middle or trailing strand, respectively, of the triple-helical peptide. Interacting atoms within the amino acid residue are identified according to Table 1. Hydrophobic interactions, more diffuse in nature are identified by residue number and chain only, not by co-ordinates.

Integrin $\alpha 2$ -I domain Co-ordinates (Å)				GFOGER peptide Co-ordinates (Å)			
Residue (chain) Atom	x	y	z	Residue (chain) Atom	x	y	z
Electrostatic Interactions:							
D219 (A) OD1	6.287	22.858	28.292	R12 (D) NH1	1.806	21.563	27.940
D219 (A) OD2	6.053	20.992	29.406	R12 (D) NH2	3.954	21.199	27.207
Co ²⁺ (M)	7.161	20.051	38.857	E11 (D) OE1	7.903	21.213	37.093
Hydrogen bonds:							
N154 (A) ND2	11.262	23.084	32.568	O9 (D) OH	14.095	26.856	29.776
N154 (A) C=O	12.723	22.629	37.870	O9 (C) OH	14.426	24.210	39.593
N154 (A) N	10.976	20.327	35.801	E11 (D) OE2	5.884	21.318	36.268
Y157 (A) OH	20.258	25.725	43.687	O6 (C) C=O	24.272	24.224	38.878
D219 (A) C=O	5.110	22.362	32.522	R12 (D) N	4.615	25.188	33.098
T221 (A) OH	5.695	19.117	37.506	E11 (D) OE1	7.903	21.213	37.093
H258 (A) NE2	2.099	22.463	35.236	R12 (D) C=O	2.670	25.239	34.916
H258 (A) C=O	-3.002	18.940	36.428	O15 (D) OH	-3.452	20.982	34.490
Hydrophobic Contacts:							
Y157 (A)				F9 (C)			
Q215 (A)				F9 (D)			
N154 (A)				F9 (D)			
L286 (A)				F9 (C)			

Residues E318 (A) and D292 (A) become more exposed upon ligand binding.

Residues L286 (A) and Co²⁺ (M) become exposed and contact ligand.

Claims

1. A method of identifying a potential inhibitor of an I-domain-containing polypeptide, the method comprising the step
5 of employing a three-dimensional structure of the Integrin $\alpha 2$ I-domain as shown in Table 1 to design or select a potential inhibitor.
2. A method of identifying a potential inhibitor according
10 to claim 1, wherein the potential inhibitor is designed or selected to inhibit conformational changes to the C-helix and/or Helix $\alpha 7$ of the Integrin $\alpha 2$ I-domain.
3. A method of identifying a potential inhibitor of an I-
15 domain-containing polypeptide, the method comprising the step of designing or selecting a potential inhibitor that interacts with one or more points in the I-domain crystal structure shown for the I-domain in Table 2.
- 20 4. A method of identifying a potential inhibitor of an I-domain-containing polypeptide, the method comprising the step of designing or selecting a potential inhibitor that mimics one or more points in the peptide structure shown for the
25 peptide structure in Table 2.
5. A method of identifying a potential inhibitor according to any one of claims 1 to 4, the method comprising the further steps of:
synthesizing or providing said potential inhibitor; and
30 testing said potential inhibitor for ability to interact with an I-domain-containing polypeptide.
6. A method of identifying a potential inhibitor according

to claim 5, wherein the testing step includes bringing said potential inhibitor into contact with an I-domain-containing polypeptide to determine the ability of said potential inhibitor to inhibit (i) the ability of the I-domain to
5 interact with collagen or a collagen peptide or other ligand which binds the I-domain, and/or (ii) I-domain or I-domain-containing polypeptide function.

7. A method of identifying a potential inhibitor according to
10 claim 5, wherein testing step includes the sub-steps of:

(i) forming a complex of the I-domain-containing polypeptide and said potential inhibitor ; and

(ii) analysing said complex by X-ray crystallography or NMR
15 spectroscopy to determine the ability of said potential inhibitor to interact with the I-domain-containing polypeptide.

8. A method of identifying a potential inhibitor according to any one of claims 1 to 7, wherein the I-domain-containing polypeptide is an integrin.
20

9. A method of obtaining a potential inhibitor of an integrin, the method comprising the steps of:

(a) providing a peptide fragment of integrin $\alpha 2$ I-domain, which peptide fragment contains the E318 residue, the D292
25 residue, or the residues 284-288;

(b) bringing the peptide fragment into contact with a test substance ; and

(c) determining the ability of the peptide fragment to bind with the test substance.

30

10. A method of obtaining a potential inhibitor according to claim 9, wherein the test substance is an antibody molecule.

11. A method of analysing an I-domain-containing polypeptide complex comprising employing (i) X-ray crystallographic diffraction data from the I-domain-containing polypeptide complex and (ii) atomic coordinate data according to Table 1 to generate a difference Fourier electron density map of the complex.
12. A crystal of $\alpha 2$ I-domain complex having a space group $P2_12_12_1$, and unit cell dimensions of $a = 42.0 \text{ \AA}$, $b = 48.4 \text{ \AA}$, and $c = 114.5 \text{ \AA}$.
13. A crystal of $\alpha 2$ I-domain complex having the three dimensional atomic coordinates of Table 1.
14. A computer system, intended to generate structures and/or perform rational drug design for I-domain-containing polypeptides or I-domain-containing polypeptide complexes, the system containing atomic coordinate data according to Table 1 or Table 2.
15. Computer readable media for use in the computer system of claim 14, having atomic coordinate data according to Table 1 or Table 2 recorded thereon.
16. An inhibitor of an I-domain-containing polypeptide which is identified or obtained by any one of methods 1 to 10.
17. The inhibitor of claim 16 for treatment of a disorder or disease.
18. Use of the inhibitor of claim 16 in the manufacture of a pharmaceutical composition for the treatment of a disorder or disease.

19. A method of making a pharmaceutical composition comprising admixing the inhibitor of claim 16 with a pharmaceutically acceptable excipient, vehicle or carrier.

5

20. A method of treating a disease or disorder in which an I-domain-containing polypeptide has a role, comprising administering an effective amount of an inhibitor of the I-domain-containing polypeptide to an individual, the inhibitor

10 being identified or obtained by any one of methods 1 to 10.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

